16. Literaturverzeichnis – Soft Tissue Sarcoma
1. Balshem, H., Helfand, M., Schunemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., et.al. GRADE guidelines: 3. Rating the quality of evidence, J Clin Epidemiol, 2011. 64(4): p. 401-6., https://www.ncbi.nlm.nih.gov/pubmed/21208779
2. Guyatt, G. H., Oxman, A. D., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., et.al. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias), J Clin Epidemiol, 2011. 64(4): p. 407-15., https://www.ncbi.nlm.nih.gov/pubmed/21247734
3. Guyatt, G. H., Oxman, A. D., Kunz, R., Woodcock, J., Brozek, J., Helfand, M., et.al. GRADE guidelines: 7. Rating the quality of evidence--inconsistency, J Clin Epidemiol, 2011. 64(12): p. 1294-302., https://www.ncbi.nlm.nih.gov/pubmed/21803546
4. Guyatt, G. H., Oxman, A. D., Kunz, R., Woodcock, J., Brozek, J., Helfand, M., et.al. GRADE guidelines: 8. Rating the quality of evidence--indirectness, J Clin Epidemiol, 2011. 64(12): p. 1303-10., https://www.ncbi.nlm.nih.gov/pubmed/21802903
5. Guyatt, G. H., Oxman, A. D., Kunz, R., Brozek, J., Alonso-Coello, P., Rind, D., et.al. GRADE guidelines 6. Rating the quality of evidence--imprecision, J Clin Epidemiol, 2011. 64(12): p. 1283-93., https://www.ncbi.nlm.nih.gov/pubmed/21839614
6. Guyatt, G. H., Oxman, A. D., Montori, V., Vist, G., Kunz, R., Brozek, J., et.al. GRADE guidelines: 5. Rating the quality of evidence--publication bias, J Clin Epidemiol, 2011. 64(12): p. 1277-82., https://www.ncbi.nlm.nih.gov/pubmed/21802904
7. Guyatt, G. H., Oxman, A. D., Sultan, S., Glasziou, P., Akl, E. A., Alonso-Coello, P., et.al. GRADE guidelines: 9. Rating up the quality of evidence, J Clin Epidemiol, 2011. 64(12): p. 1311-6., https://www.ncbi.nlm.nih.gov/pubmed/21802902
8. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften - Ständige Kommission, Leitlinien, AWMF-Regelwerk "Leitlinien", 1. Auflage 2012. 09.12.2013:, http://www.awmf.org/leitlinien/awmf-regelwerk/awmf-regelwerk.html
9. Lahat, G., Lazar, A., Lev, D., Sarcoma epidemiology and etiology: potential environmental and genetic factors, Surg Clin North Am, 2008. 88(3): p. 451-81, v., https://www.ncbi.nlm.nih.gov/pubmed/18514694
10. Burningham, Z., Hashibe, M., Spector, L., Schiffman, J. D., The epidemiology of sarcoma, Clin Sarcoma Res, 2012. 2(1): p. 14., https://www.ncbi.nlm.nih.gov/pubmed/23036164
11. Toro, J. R., Travis, L. B., Wu, H. J., Zhu, K., Fletcher, C. D., Devesa, S. S., Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: An analysis of 26,758 cases, Int J Cancer, 2006. 119(12): p. 2922-30., https://www.ncbi.nlm.nih.gov/pubmed/17013893
12. Stiller, C. A., Trama, A., Serraino, D., Rossi, S., Navarro, C., Chirlaque, M. D., et.al. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project, Eur J Cancer, 2013. 49(3): p. 684-95., https://www.ncbi.nlm.nih.gov/pubmed/23079473
13. Krebs in Deutschland 2013/2014Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg), 2017, 11 Ausgabe.
14. Ressing, M., Wardelmann, E., Hohenberger, P., Jakob, J., Kasper, B., Emrich, K., et.al. Strengthening health data on a rare and heterogeneous disease: sarcoma incidence and histological subtypes in Germany, BMC Public Health, 2018. 18(1): p. 235., https://www.ncbi.nlm.nih.gov/pubmed/29433465
15. Herzog, C. E., Overview of sarcomas in the adolescent and young adult population, J Pediatr Hematol Oncol, 2005. 27(4): p. 215-8., https://www.ncbi.nlm.nih.gov/pubmed/15838394
16. Wibmer, C., Leithner, A., Zielonke, N., Sperl, M., Windhager, R., Increasing incidence rates of soft tissue sarcomas? A population-based epidemiologic study and literature review, Ann Oncol, 2010. 21(5): p. 1106-11., https://www.ncbi.nlm.nih.gov/pubmed/19858086
17. Gage, M. M., Nagarajan, N., Ruck, J. M., Canner, J. K., Khan, S., Giuliano, K., et.al. Sarcomas in the United States: Recent trends and a call for improved staging, Oncotarget, 2019. 10(25): p. 2462-2474., https://www.ncbi.nlm.nih.gov/pubmed/31069009
18. Bahl, S., Theis, B., Nishri, D., Marrett, L. D., Changing incidence of AIDS-related Kaposi sarcoma and non-Hodgkin lymphoma in Ontario, Canada, Cancer Causes Control, 2008. 19(10): p. 1251-8., https://www.ncbi.nlm.nih.gov/pubmed/18618279
19. Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., et.al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors, Science, 1998. 279(5350): p. 577-80., https://www.ncbi.nlm.nih.gov/pubmed/9438854
20. Ma, G. L., Murphy, J. D., Martinez, M. E., Sicklick, J. K., Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study, Cancer Epidemiol Biomarkers Prev, 2015. 24(1): p. 298-302., https://www.ncbi.nlm.nih.gov/pubmed/25277795
21. Lv, M., Wu, C., Zheng, Y., Zhao, N., Incidence and survival analysis of gastrointestinal stromal tumors in shanghai: a population-based study from 2001 to 2010, Gastroenterol Res Pract, 2014. 2014: p. 834136., https://www.ncbi.nlm.nih.gov/pubmed/24864136
22. Maretty-Nielsen, K., Aggerholm-Pedersen, N., Keller, J., Safwat, A., Baerentzen, S., Pedersen, A. B., Relative mortality in soft tissue sarcoma patients: a Danish population-based cohort study, BMC Cancer, 2014. 14: p. 682., https://www.ncbi.nlm.nih.gov/pubmed/25239186
23. Selik, R. M., Starcher, E. T., Curran, J. W., Opportunistic diseases reported in AIDS patients: frequencies, associations, and trends, AIDS, 1987. 1(3): p. 175-82., https://www.ncbi.nlm.nih.gov/pubmed/2831912
24. Bhatia, K., Shiels, M. S., Berg, A., Engels, E. A., Sarcomas other than Kaposi sarcoma occurring in immunodeficiency: interpretations from a systematic literature review, Curr Opin Oncol, 2012. 24(5): p. 537-46., https://www.ncbi.nlm.nih.gov/pubmed/22729152
25. Chang, Y., Cesarman, E., Pessin, M. S., Lee, F., Culpepper, J., Knowles, D. M., et.al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma, Science, 1994. 266(5192): p. 1865-9., https://www.ncbi.nlm.nih.gov/pubmed/7997879
26. Moore, P. S., Chang, Y., Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection, N Engl J Med, 1995. 332(18): p. 1181-5., https://www.ncbi.nlm.nih.gov/pubmed/7700310
27. Hatano, M., Takada, H., Nomura, A., Ohga, S., Ohshima, K., Saeki, I., et.al. Epstein-Barr virus-associated bronchial leiomyoma in a boy with cellular immunodeficiency, Pediatr Pulmonol, 2006. 41(4): p. 371-3., https://www.ncbi.nlm.nih.gov/pubmed/16429426
28. Fernandez, M. P., Krejci-Manwaring, J., Davis, T. L., Epstein-Barr virus is not associated with angioleiomyomas, or other cutaneous smooth muscle tumors in immunocompetent individuals, J Cutan Pathol, 2010. 37(4): p. 507-10., https://www.ncbi.nlm.nih.gov/pubmed/19615017
29. Stubbins, R. J., Alami Laroussi, N., Peters, A. C., Urschel, S., Dicke, F., Lai, R. L., et.al. Epstein-Barr virus associated smooth muscle tumors in solid organ transplant recipients: Incidence over 31 years at a single institution and review of the literature, Transpl Infect Dis, 2019. 21(1): p. e13010., https://www.ncbi.nlm.nih.gov/pubmed/30298678
30. Cohen, J. I., Dropulic, L., Hsu, A. P., Zerbe, C. S., Krogmann, T., Dowdell, K., et.al. Association of GATA2 Deficiency With Severe Primary Epstein-Barr Virus (EBV) Infection and EBV-associated Cancers, Clin Infect Dis, 2016. 63(1): p. 41-7., https://www.ncbi.nlm.nih.gov/pubmed/27169477
31. Monforte-Munoz, H., Kapoor, N., Saavedra, J. A., Epstein-Barr virus-associated leiomyomatosis and posttransplant lymphoproliferative disorder in a child with severe combined immunodeficiency: case report and review of the literature, Pediatr Dev Pathol, 2003. 6(5): p. 449-57., https://www.ncbi.nlm.nih.gov/pubmed/14708738
32. Rubino, C., Shamsaldin, A., Le, M. G., Labbe, M., Guinebretiere, J. M., Chavaudra, J., et.al. Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment, Breast Cancer Res Treat, 2005. 89(3): p. 277-88., https://www.ncbi.nlm.nih.gov/pubmed/15754127
33. Virtanen, A., Pukkala, E., Auvinen, A., Incidence of bone and soft tissue sarcoma after radiotherapy: a cohort study of 295,712 Finnish cancer patients, Int J Cancer, 2006. 118(4): p. 1017-21., https://www.ncbi.nlm.nih.gov/pubmed/16152578
34. Menu-Branthomme, A., Rubino, C., Shamsaldin, A., Hawkins, M. M., Grimaud, E., Dondon, M. G., et.al. Radiation dose, chemotherapy and risk of soft tissue sarcoma after solid tumours during childhood, Int J Cancer, 2004. 110(1): p. 87-93., https://www.ncbi.nlm.nih.gov/pubmed/15054872
35. Jenkinson, H. C., Winter, D. L., Marsden, H. B., Stovall, M. A., Stevens, M. C., Stiller, C. A., et.al. A study of soft tissue sarcomas after childhood cancer in Britain, Br J Cancer, 2007. 97(5): p. 695-9., https://www.ncbi.nlm.nih.gov/pubmed/17653071
36. MacCarthy, A., Bayne, A. M., Brownbill, P. A., Bunch, K. J., Diggens, N. L., Draper, G. J., et.al. Second and subsequent tumours among 1927 retinoblastoma patients diagnosed in Britain 1951-2004, Br J Cancer, 2013. 108(12): p. 2455-63., https://www.ncbi.nlm.nih.gov/pubmed/23674091
37. Farzaliyev, F., Hamacher, R., Steinau Professor, H. U., Bertram, S., Podleska, L. E., Secondary angiosarcoma: A fatal complication of chronic lymphedema, J Surg Oncol, 2020. 121(1): p. 85-90., https://www.ncbi.nlm.nih.gov/pubmed/31236970
38. Shavit, E., Alavi, A., Limacher, J. J., Sibbald, R. G., Angiosarcoma complicating lower leg elephantiasis in a male patient: An unusual clinical complication, case report and literature review, SAGE Open Med Case Rep, 2018. 6: p. 2050313X18796343., https://www.ncbi.nlm.nih.gov/pubmed/30397474
39. Lipshutz, G. S., Brennan, T. V., Warren, R. S., Thorotrast-induced liver neoplasia: a collective review, J Am Coll Surg, 2002. 195(5): p. 713-8., https://www.ncbi.nlm.nih.gov/pubmed/12437262
40. Coulier, B., Pierard, F., Gielen, I., Maldague, P., Hepatic angiosarcoma occurring 65 years after thorium dioxide (Thorotrast) exposure: imaging, surgical and histo- pathologic findings of a historical case, JBR-BTR, 2014. 97(4): p. 254-8., https://www.ncbi.nlm.nih.gov/pubmed/25603638
41. Pukkala, E., Martinsen, J. I., Lynge, E., Gunnarsdottir, H. K., Sparen, P., Tryggvadottir, L., et.al. Occupation and cancer - follow-up of 15 million people in five Nordic countries, Acta Oncol, 2009. 48(5): p. 646-790., https://www.ncbi.nlm.nih.gov/pubmed/19925375
42. Hoppin, J. A., Tolbert, P. E., Flanders, W. D., Zhang, R. H., Daniels, D. S., Ragsdale, B. D., et.al. Occupational risk factors for sarcoma subtypes, Epidemiology, 1999. 10(3): p. 300-6., https://www.ncbi.nlm.nih.gov/pubmed/10230842
43. Mundt, K. A., Dell, L. D., Crawford, L., Gallagher, A. E., Quantitative estimated exposure to vinyl chloride and risk of angiosarcoma of the liver and hepatocellular cancer in the US industry-wide vinyl chloride cohort: mortality update through 2013, Occup Environ Med, 2017. 74(10): p. 709-716., https://www.ncbi.nlm.nih.gov/pubmed/28490663
44. Zahm, S. H., Blair, A., Holmes, F. F., Boysen, C. D., Robel, R. J., Fraumeni, J. F., Jr., A case-control study of soft-tissue sarcoma, Am J Epidemiol, 1989. 130(4): p. 665-74., https://www.ncbi.nlm.nih.gov/pubmed/2773915
45. Serraino, D., Franceschi, S., Talamini, R., Frustaci, S., La Vecchia, C., Non-occupational risk factors for adult soft-tissue sarcoma in northern Italy, Cancer Causes Control, 1991. 2(3): p. 157-64., https://www.ncbi.nlm.nih.gov/pubmed/1873445
46. Jouenne, F., Chauvot de Beauchene, I., Bollaert, E., Avril, M. F., Caron, O., Ingster, O., et.al. Germline CDKN2A/P16INK4A mutations contribute to genetic determinism of sarcoma, J Med Genet, 2017. 54(9): p. 607-612., https://www.ncbi.nlm.nih.gov/pubmed/28592523
47. Schneider, K., Zelley, K., Nichols, K. E., Garber, J., Li-Fraumeni Syndrome, in GeneReviews((R)), Adam, M. P.Ardinger, H. H.Pagon, R. A.Wallace, S. E.Bean, L. J. H.Mirzaa, G. and Amemiya, A., Editors. 1993: Seattle (WA)., https://www.ncbi.nlm.nih.gov/pubmed/20301488
48. von Mehren, M., Randall, R. L., Benjamin, R. S., Boles, S., Bui, M. M., Casper, E. S., et.al. Soft tissue sarcoma, version 2.2014, J Natl Compr Canc Netw, 2014. 12(4): p. 473-83., https://www.ncbi.nlm.nih.gov/pubmed/24717567
49. Ognjanovic, S., Olivier, M., Bergemann, T. L., Hainaut, P., Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database, Cancer, 2012. 118(5): p. 1387-96., https://www.ncbi.nlm.nih.gov/pubmed/21837677
50. Mai, P. L., Best, A. F., Peters, J. A., DeCastro, R. M., Khincha, P. P., Loud, J. T., et.al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort, Cancer, 2016. 122(23): p. 3673-3681., https://www.ncbi.nlm.nih.gov/pubmed/27496084
51. Kleihues, P., Schauble, B., zur Hausen, A., Esteve, J., Ohgaki, H., Tumors associated with p53 germline mutations: a synopsis of 91 families, Am J Pathol, 1997. 150(1): p. 1-13., https://www.ncbi.nlm.nih.gov/pubmed/9006316
52. Ognjanovic, S., Martel, G., Manivel, C., Olivier, M., Langer, E., Hainaut, P., Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma, Sarcoma, 2012. 2012: p. 492086., https://www.ncbi.nlm.nih.gov/pubmed/22550420
53. Doros, L., Yang, J., Dehner, L., Rossi, C. T., Skiver, K., Jarzembowski, J. A., et.al. DICER1 mutations in embryonal rhabdomyosarcomas from children with and without familial PPB-tumor predisposition syndrome, Pediatr Blood Cancer, 2012. 59(3): p. 558-60., https://www.ncbi.nlm.nih.gov/pubmed/22180160
54. Diller, L., Sexsmith, E., Gottlieb, A., Li, F. P., Malkin, D., Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma, J Clin Invest, 1995. 95(4): p. 1606-11., https://www.ncbi.nlm.nih.gov/pubmed/7706467
55. Hettmer, S., Archer, N. M., Somers, G. R., Novokmet, A., Wagers, A. J., Diller, L., et.al. Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers, Cancer, 2014. 120(7): p. 1068-75., https://www.ncbi.nlm.nih.gov/pubmed/24382691
56. Wang, W. L., Nero, C., Pappo, A., Lev, D., Lazar, A. J., Lopez-Terrada, D., CTNNB1 genotyping and APC screening in pediatric desmoid tumors: a proposed algorithm, Pediatr Dev Pathol, 2012. 15(5): p. 361-7., https://www.ncbi.nlm.nih.gov/pubmed/22372443
57. Kattentidt Mouravieva, A. A., Geurts-Giele, I. R., de Krijger, R. R., van Noesel, M. M., van de Ven, C. P., van den Ouweland, A. M., et.al. Identification of Familial Adenomatous Polyposis carriers among children with desmoid tumours, Eur J Cancer, 2012. 48(12): p. 1867-74., https://www.ncbi.nlm.nih.gov/pubmed/22305464
58. Brueckl, W. M., Ballhausen, W. G., Fortsch, T., Gunther, K., Fiedler, W., Gentner, B., et.al. Genetic testing for germline mutations of the APC gene in patients with apparently sporadic desmoid tumors but a family history of colorectal carcinoma, Dis Colon Rectum, 2005. 48(6): p. 1275-81., https://www.ncbi.nlm.nih.gov/pubmed/15793634
59. Farid, M., Ngeow, J., Sarcomas Associated With Genetic Cancer Predisposition Syndromes: A Review, Oncologist, 2016. 21(8): p. 1002-13., https://www.ncbi.nlm.nih.gov/pubmed/27401891
60. Bottillo, I., Ahlquist, T., Brekke, H., Danielsen, S. A., van den Berg, E., Mertens, F., et.al. Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours, J Pathol, 2009. 217(5): p. 693-701., https://www.ncbi.nlm.nih.gov/pubmed/19142971
61. Upadhyaya, M., Spurlock, G., Monem, B., Thomas, N., Friedrich, R. E., Kluwe, L., et.al. Germline and somatic NF1 gene mutations in plexiform neurofibromas, Hum Mutat, 2008. 29(8): p. E103-11., https://www.ncbi.nlm.nih.gov/pubmed/18484666
62. Crucis, A., Richer, W., Brugieres, L., Bergeron, C., Marie-Cardine, A., Stephan, J. L., et.al. Rhabdomyosarcomas in children with neurofibromatosis type I: A national historical cohort, Pediatr Blood Cancer, 2015. 62(10): p. 1733-8., https://www.ncbi.nlm.nih.gov/pubmed/25893277
63. Postow, M. A., Robson, M. E., Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications, Clin Sarcoma Res, 2012. 2(1): p. 16., https://www.ncbi.nlm.nih.gov/pubmed/23036227
64. Pantaleo, M. A., Astolfi, A., Urbini, M., Nannini, M., Paterini, P., Indio, V., et.al. Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFRA wild-type GIST, Eur J Hum Genet, 2014. 22(1): p. 32-9., https://www.ncbi.nlm.nih.gov/pubmed/23612575
65. Boikos, S. A., Pappo, A. S., Killian, J. K., LaQuaglia, M. P., Weldon, C. B., George, S., et.al. Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic, JAMA Oncol, 2016. 2(7): p. 922-8., https://www.ncbi.nlm.nih.gov/pubmed/27011036
66. Bachet, J. B., Emile, J. F., Diagnostic criteria, specific mutations, and genetic predisposition in gastrointestinal stromal tumors, Appl Clin Genet, 2010. 3: p. 85-101., https://www.ncbi.nlm.nih.gov/pubmed/23776354
67. Kleinerman, R. A., Schonfeld, S. J., Tucker, M. A., Sarcomas in hereditary retinoblastoma, Clin Sarcoma Res, 2012. 2(1): p. 15., https://www.ncbi.nlm.nih.gov/pubmed/23036192
68. Francis, J. H., Kleinerman, R. A., Seddon, J. M., Abramson, D. H., Increased risk of secondary uterine leiomyosarcoma in hereditary retinoblastoma, Gynecol Oncol, 2012. 124(2): p. 254-9., https://www.ncbi.nlm.nih.gov/pubmed/22027510
69. Wu, M. K., Vujanic, G. M., Fahiminiya, S., Watanabe, N., Thorner, P. S., O'Sullivan, M. J., et.al. Anaplastic sarcomas of the kidney are characterized by DICER1 mutations, Mod Pathol, 2018. 31(1): p. 169-178., https://www.ncbi.nlm.nih.gov/pubmed/28862265
70. Dehner, L. P., Jarzembowski, J. A., Hill, D. A., Embryonal rhabdomyosarcoma of the uterine cervix: a report of 14 cases and a discussion of its unusual clinicopathological associations, Mod Pathol, 2012. 25(4): p. 602-14., https://www.ncbi.nlm.nih.gov/pubmed/22157934
71. Yang, X. R., Ng, D., Alcorta, D. A., Liebsch, N. J., Sheridan, E., Li, S., et.al. T (brachyury) gene duplication confers major susceptibility to familial chordoma, Nat Genet, 2009. 41(11): p. 1176-8., https://www.ncbi.nlm.nih.gov/pubmed/19801981
72. Urso, E., Agostini, M., Pucciarelli, S., Bedin, C., D'Angelo, E., Mescoli, C., et.al. Soft tissue sarcoma and the hereditary non-polyposis colorectal cancer (HNPCC) syndrome: formulation of an hypothesis, Mol Biol Rep, 2012. 39(10): p. 9307-10., https://www.ncbi.nlm.nih.gov/pubmed/22782591
73. Hettmer, S., Teot, L. A., Kozakewich, H., Werger, A. M., Davies, K. J., Fletcher, C. D., et.al. Myogenic tumors in nevoid Basal cell carcinoma syndrome, J Pediatr Hematol Oncol, 2015. 37(2): p. 147-9., https://www.ncbi.nlm.nih.gov/pubmed/24517962
74. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.4, 2021 AWMF Registernummer: 032-045OL, 2021., https://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/
75. Young, M. A., Herlihy, A., Mitchell, G., Thomas, D. M., Ballinger, M., Tucker, K., et.al. The attitudes of people with sarcoma and their family towards genomics and incidental information arising from genetic research, Clin Sarcoma Res, 2013. 3(1): p. 11., https://www.ncbi.nlm.nih.gov/pubmed/23898988
76. Ballinger, M. L., Goode, D. L., Ray-Coquard, I., James, P. A., Mitchell, G., Niedermayr, E., et.al. Monogenic and polygenic determinants of sarcoma risk: an international genetic study, Lancet Oncol, 2016. 17(9): p. 1261-71., https://www.ncbi.nlm.nih.gov/pubmed/27498913
77. Villani, A., Shore, A., Wasserman, J. D., Stephens, D., Kim, R. H., Druker, H., et.al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study, Lancet Oncol, 2016. 17(9): p. 1295-305., https://www.ncbi.nlm.nih.gov/pubmed/27501770
78. Villani, A., Tabori, U., Schiffman, J., Shlien, A., Beyene, J., Druker, H., et.al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study, Lancet Oncol, 2011. 12(6): p. 559-67., https://www.ncbi.nlm.nih.gov/pubmed/21601526
79. Ballinger, M. L., Best, A., Mai, P. L., Khincha, P. P., Loud, J. T., Peters, J. A., et.al. Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis, JAMA Oncol, 2017. 3(12): p. 1634-1639., https://www.ncbi.nlm.nih.gov/pubmed/28772291
80. Stacchiotti, S., Frezza, A. M., Blay, J. Y., Baldini, E. H., Bonvalot, S., Bovee, Jvmg, et.al. Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities, Cancer, 2021., https://www.ncbi.nlm.nih.gov/pubmed/33910263
81. Lahat, G., Madewell, J. E., Anaya, D. A., Qiao, W., Tuvin, D., Benjamin, R. S., et.al. Computed tomography scan-driven selection of treatment for retroperitoneal liposarcoma histologic subtypes, Cancer, 2009. 115(5): p. 1081-90., https://www.ncbi.nlm.nih.gov/pubmed/19156920
82. Holzapfel, K, Regler, J, Baum, T, Rechl, H, Specht, K, Haller, B, et.al. Local Staging of Soft-Tissue Sarcoma: Emphasis on Assessment of Neurovascular Encasement-Value of MR Imaging in 174 Confirmed Cases., Radiology, 2015. 275 (2)(2): p. 501-9., https://pubmed.ncbi.nlm.nih.gov/25584707/
83. Elias, DA, White, LM, Simpson, DJ, Kandel, RA, Tomlinson, G, Bell, RS, et.al. Osseous invasion by soft-tissue sarcoma: assessment with MR imaging., Radiology, 2003. 229 (1)(1): p. 145-52., https://pubmed.ncbi.nlm.nih.gov/14519874/
84. Panicek, DM, Go, SD, Healey, JH, Leung, DH, Brennan, MF, Lewis, JJ, Soft-tissue sarcoma involving bone or neurovascular structures: MR imaging prognostic factors., Radiology, 1997. 205 (3)(3): p. 871-5., https://pubmed.ncbi.nlm.nih.gov/9393550/
85. Casali, P. G., Abecassis, N., Aro, H. T., Bauer, S., Biagini, R., Bielack, S., et.al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 2018. 29(Suppl 4): p. iv51-iv67., https://www.ncbi.nlm.nih.gov/pubmed/29846498
86. Dangoor, A., Seddon, B., Gerrand, C., Grimer, R., Whelan, J., Judson, I., UK guidelines for the management of soft tissue sarcomas, Clin Sarcoma Res, 2016. 6: p. 20., https://www.ncbi.nlm.nih.gov/pubmed/27891213
87. Rastrelli, M., Tropea, S., Basso, U., Roma, A., Maruzzo, M., Rossi, C. R., Soft tissue limb and trunk sarcomas: diagnosis, treatment and follow-up, Anticancer Res, 2014. 34(10): p. 5251-62., https://www.ncbi.nlm.nih.gov/pubmed/25275017
88. Singh, H. K., Kilpatrick, S. E., Silverman, J. F., Fine needle aspiration biopsy of soft tissue sarcomas: utility and diagnostic challenges, Adv Anat Pathol, 2004. 11(1): p. 24-37., https://www.ncbi.nlm.nih.gov/pubmed/14676638
89. Fleshman, R., Mayerson, J., Wakely, P. E., Jr., Fine-needle aspiration biopsy of high-grade sarcoma: a report of 107 cases, Cancer, 2007. 111(6): p. 491-8., https://www.ncbi.nlm.nih.gov/pubmed/17941014
90. Jakowski, J. D., Mayerson, J., Wakely, P. E., Jr., Fine-needle aspiration biopsy of the distal extremities: a study of 141 cases, Am J Clin Pathol, 2010. 133(2): p. 224-31., https://www.ncbi.nlm.nih.gov/pubmed/20093231
91. Heslin, M. J., Lewis, J. J., Woodruff, J. M., Brennan, M. F., Core needle biopsy for diagnosis of extremity soft tissue sarcoma, Ann Surg Oncol, 1997. 4(5): p. 425-31., https://www.ncbi.nlm.nih.gov/pubmed/9259971
92. Pohlig, F., Kirchhoff, C., Lenze, U., Schauwecker, J., Burgkart, R., Rechl, H., et.al. Percutaneous core needle biopsy versus open biopsy in diagnostics of bone and soft tissue sarcoma: a retrospective study, Eur J Med Res, 2012. 17: p. 29., https://www.ncbi.nlm.nih.gov/pubmed/23114293
93. Fraser-Hill, M. A., Renfrew, D. L., Hilsenrath, P. E., Percutaneous needle biopsy of musculoskeletal lesions. 2. Cost-effectiveness, AJR Am J Roentgenol, 1992. 158(4): p. 813-8., https://www.ncbi.nlm.nih.gov/pubmed/1546598
94. Welker, J. A., Henshaw, R. M., Jelinek, J., Shmookler, B. M., Malawer, M. M., The percutaneous needle biopsy is safe and recommended in the diagnosis of musculoskeletal masses, Cancer, 2000. 89(12): p. 2677-86., https://www.ncbi.nlm.nih.gov/pubmed/11135231
95. Strauss, D. C., Qureshi, Y. A., Hayes, A. J., Thway, K., Fisher, C., Thomas, J. M., The role of core needle biopsy in the diagnosis of suspected soft tissue tumours, J Surg Oncol, 2010. 102(5): p. 523-9., https://www.ncbi.nlm.nih.gov/pubmed/20872955
96. Barrientos-Ruiz, I., Ortiz-Cruz, E. J., Serrano-Montilla, J., Bernabeu-Taboada, D., Pozo-Kreilinger, J. J., Are Biopsy Tracts a Concern for Seeding and Local Recurrence in Sarcomas?, Clin Orthop Relat Res, 2017. 475(2): p. 511-518., https://www.ncbi.nlm.nih.gov/pubmed/27655183
97. Serpell, J. W., Pitcher, M. E., Pre-operative core biopsy of soft-tissue tumours facilitates their surgical management, Aust N Z J Surg, 1998. 68(5): p. 345-9., https://www.ncbi.nlm.nih.gov/pubmed/9631907
98. Ray-Coquard, I., Ranchere-Vince, D., Thiesse, P., Ghesquieres, H., Biron, P., Sunyach, M. P., et.al. Evaluation of core needle biopsy as a substitute to open biopsy in the diagnosis of soft-tissue masses, Eur J Cancer, 2003. 39(14): p. 2021-5., https://www.ncbi.nlm.nih.gov/pubmed/12957456
99. Birgin, E., Yang, C., Hetjens, S., Reissfelder, C., Hohenberger, P., Rahbari, N. N., Core needle biopsy versus incisional biopsy for differentiation of soft-tissue sarcomas: A systematic review and meta-analysis, Cancer, 2020. 126(9): p. 1917-1928., https://www.ncbi.nlm.nih.gov/pubmed/32022262
100. Kim, S. Y., Chung, H. W., Small Musculoskeletal Soft-Tissue Lesions: US-guided Core Needle Biopsy--Comparative Study of Diagnostic Yields according to Lesion Size, Radiology, 2016. 278(1): p. 156-63., https://www.ncbi.nlm.nih.gov/pubmed/26162027
101. Wu, J. S., Goldsmith, J. D., Horwich, P. J., Shetty, S. K., Hochman, M. G., Bone and soft-tissue lesions: what factors affect diagnostic yield of image-guided core-needle biopsy?, Radiology, 2008. 248(3): p. 962-70., https://www.ncbi.nlm.nih.gov/pubmed/18710986
102. Nandra, R., Forsberg, J., Grimer, R., If your lump is bigger than a golf ball and growing, think Sarcoma, Eur J Surg Oncol, 2015. 41(10): p. 1400-5., https://www.ncbi.nlm.nih.gov/pubmed/26163048
103. Wardelmann, E., Haas, R. L., Bovee, J. V., Terrier, P., Lazar, A., Messiou, C., et.al. Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) recommendations for pathological examination and reporting, Eur J Cancer, 2016. 53: p. 84-95., https://www.ncbi.nlm.nih.gov/pubmed/26700077
104. Harati, K., Goertz, O., Pieper, A., Daigeler, A., Joneidi-Jafari, H., Niggemann, H., et.al. Soft Tissue Sarcomas of the Extremities: Surgical Margins Can Be Close as Long as the Resected Tumor Has No Ink on It, Oncologist, 2017. 22(11): p. 1400-1410., https://www.ncbi.nlm.nih.gov/pubmed/28739867
105. Gundle, K. R., Kafchinski, L., Gupta, S., Griffin, A. M., Dickson, B. C., Chung, P. W., et.al. Analysis of Margin Classification Systems for Assessing the Risk of Local Recurrence After Soft Tissue Sarcoma Resection, J Clin Oncol, 2018. 36(7): p. 704-709., https://www.ncbi.nlm.nih.gov/pubmed/29346043
106. Sbaraglia, M., Dei Tos, A. P., The pathology of soft tissue sarcomas, Radiol Med, 2019. 124(4): p. 266-281., https://www.ncbi.nlm.nih.gov/pubmed/29948548
107. Anderson, W. J., Hornick, J. L., Immunohistochemical correlates of recurrent genetic alterations in sarcomas, Genes Chromosomes Cancer, 2019. 58(2): p. 111-123., https://www.ncbi.nlm.nih.gov/pubmed/30382607
108. Hornick, J. L., Limited biopsies of soft tissue tumors: the contemporary role of immunohistochemistry and molecular diagnostics, Mod Pathol, 2019. 32(Suppl 1): p. 27-37., https://www.ncbi.nlm.nih.gov/pubmed/30600320
109. Machado, I., Yoshida, A., Morales, M. G. N., Abrahao-Machado, L. F., Navarro, S., Cruz, J., et.al. Review with novel markers facilitates precise categorization of 41 cases of diagnostically challenging, "undifferentiated small round cell tumors". A clinicopathologic, immunophenotypic and molecular analysis, Ann Diagn Pathol, 2018. 34: p. 1-12., https://www.ncbi.nlm.nih.gov/pubmed/29661713
110. Fletcher, C. D. M., Bridge, J. A., Hogendoorn, P., Mertens, F., WHO Classification of Tumours of Soft Tissue and BoneIARC Press, 2013.
111. Deyrup, A. T., Weiss, S. W., Grading of soft tissue sarcomas: the challenge of providing precise information in an imprecise world, Histopathology, 2006. 48(1): p. 42-50., https://www.ncbi.nlm.nih.gov/pubmed/16359536
112. Coindre, J. M., Grading of soft tissue sarcomas: review and update, Arch Pathol Lab Med, 2006. 130(10): p. 1448-53., https://www.ncbi.nlm.nih.gov/pubmed/17090186
113. Trojani, M., Contesso, G., Coindre, J. M., Rouesse, J., Bui, N. B., de Mascarel, A., et.al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system, Int J Cancer, 1984. 33(1): p. 37-42., https://www.ncbi.nlm.nih.gov/pubmed/6693192
114. Guillou, L., Coindre, J. M., Bonichon, F., Nguyen, B. B., Terrier, P., Collin, F., et.al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma, J Clin Oncol, 1997. 15(1): p. 350-62., https://www.ncbi.nlm.nih.gov/pubmed/8996162
115. Miettinen, M., Lasota, J., Gastrointestinal stromal tumors: pathology and prognosis at different sites, Semin Diagn Pathol, 2006. 23(2): p. 70-83., https://www.ncbi.nlm.nih.gov/pubmed/17193820
116. Joensuu, H., Vehtari, A., Riihimaki, J., Nishida, T., Steigen, S. E., Brabec, P., et.al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts, Lancet Oncol, 2012. 13(3): p. 265-74., https://www.ncbi.nlm.nih.gov/pubmed/22153892
117. Folpe, A. L., Mentzel, T., Lehr, H. A., Fisher, C., Balzer, B. L., Weiss, S. W., Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature, Am J Surg Pathol, 2005. 29(12): p. 1558-75., https://www.ncbi.nlm.nih.gov/pubmed/16327428
118. Doyle, L. A., Hornick, J. L., Fletcher, C. D., PEComa of the gastrointestinal tract: clinicopathologic study of 35 cases with evaluation of prognostic parameters, Am J Surg Pathol, 2013. 37(12): p. 1769-82., https://www.ncbi.nlm.nih.gov/pubmed/24061520
119. Mertens, F., Antonescu, C. R., Mitelman, F., Gene fusions in soft tissue tumors: Recurrent and overlapping pathogenetic themes, Genes Chromosomes Cancer, 2016. 55(4): p. 291-310., https://www.ncbi.nlm.nih.gov/pubmed/26684580
120. Nakano, K., Takahashi, S., Translocation-Related Sarcomas, Int J Mol Sci, 2018. 19(12):, https://www.ncbi.nlm.nih.gov/pubmed/30487384
121. Xiao, X., Garbutt, C. C., Hornicek, F., Guo, Z., Duan, Z., Advances in chromosomal translocations and fusion genes in sarcomas and potential therapeutic applications, Cancer Treat Rev, 2018. 63: p. 61-70., https://www.ncbi.nlm.nih.gov/pubmed/29247978
122. Schaefer, I. M., Cote, G. M., Hornick, J. L., Contemporary Sarcoma Diagnosis, Genetics, and Genomics, J Clin Oncol, 2018. 36(2): p. 101-110., https://www.ncbi.nlm.nih.gov/pubmed/29220288
123. Schmitz, K., Schildhaus, H. U., [Molecular pathology of soft tissue tumors: Contribution to diagnosis and therapy prediction], Pathologe, 2015. 36(2): p. 126-36., https://www.ncbi.nlm.nih.gov/pubmed/25822596
124. Italiano, A., Di Mauro, I., Rapp, J., Pierron, G., Auger, N., Alberti, L., et.al. Clinical effect of molecular methods in sarcoma diagnosis (GENSARC): a prospective, multicentre, observational study, Lancet Oncol, 2016. 17(4): p. 532-538., https://www.ncbi.nlm.nih.gov/pubmed/26970672
125. Mitelman, F., Johansson, B, Mertens, F., Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer, 2019., https://mitelmandatabase.isb-cgc.org/, [abgerufen, am, 26.11.2019]
126. COSMIC, Fusions, 2019., https://cancer.sanger.ac.uk/cosmic/fusion, [abgerufen, am, 28.08.2019]
127. Forsythe, A., Zhang, W., Phillip Strauss, U., Fellous, M., Korei, M., Keating, K., A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors, Ther Adv Med Oncol, 2020. 12: p. 1758835920975613., https://www.ncbi.nlm.nih.gov/pubmed/33425024
128. Demetri, G. D., Antonescu, C. R., Bjerkehagen, B., Bovee, Jvmg, Boye, K., Chacon, M., et.al. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network, Ann Oncol, 2020. 31(11): p. 1506-1517., https://www.ncbi.nlm.nih.gov/pubmed/32891793
129. Groisberg, R., Roszik, J., Conley, A., Patel, S. R., Subbiah, V., The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope, Curr Oncol Rep, 2017. 19(12): p. 78., https://www.ncbi.nlm.nih.gov/pubmed/29030741
130. Szurian, K., Kashofer, K., Liegl-Atzwanger, B., Role of Next-Generation Sequencing as a Diagnostic Tool for the Evaluation of Bone and Soft-Tissue Tumors, Pathobiology, 2017. 84(6): p. 323-338., https://www.ncbi.nlm.nih.gov/pubmed/28817827
131. Lurkin, A., Ducimetiere, F., Vince, D. R., Decouvelaere, A. V., Cellier, D., Gilly, F. N., et.al. Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region, BMC Cancer, 2010. 10: p. 150., https://www.ncbi.nlm.nih.gov/pubmed/20403160
132. Al-Ibraheemi, A., Folpe, A. L., Voluntary Second Opinions in Pediatric Bone and Soft Tissue Pathology: A Retrospective Review of 1601 Cases From a Single Mesenchymal Tumor Consultation Service, Int J Surg Pathol, 2016. 24(8): p. 685-691., https://www.ncbi.nlm.nih.gov/pubmed/27363432
133. Ray-Coquard, I., Montesco, M. C., Coindre, J. M., Dei Tos, A. P., Lurkin, A., Ranchere-Vince, D., et.al. Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions, Ann Oncol, 2012. 23(9): p. 2442-2449., https://www.ncbi.nlm.nih.gov/pubmed/22331640
134. Pisters, P. W., Leung, D. H., Woodruff, J., Shi, W., Brennan, M. F., Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities, J Clin Oncol, 1996. 14(5): p. 1679-89., https://www.ncbi.nlm.nih.gov/pubmed/8622088
135. Lahat, G., Tuvin, D., Wei, C., Anaya, D. A., Bekele, B. N., Lazar, A. J., et.al. New perspectives for staging and prognosis in soft tissue sarcoma, Ann Surg Oncol, 2008. 15(10): p. 2739-48., https://www.ncbi.nlm.nih.gov/pubmed/18521685
136. Wankhede, D., Evaluation of Eighth AJCC TNM Sage for Lung Cancer NSCLC: A Meta-analysis, Ann Surg Oncol, 2021. 28(1): p. 142-147., https://www.ncbi.nlm.nih.gov/pubmed/32951092
137. Le Cesne, A., Ouali, M., Leahy, M. G., Santoro, A., Hoekstra, H. J., Hohenberger, P., et.al. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials, Ann Oncol, 2014. 25(12): p. 2425-2432., https://www.ncbi.nlm.nih.gov/pubmed/25294887
138. Kattan, M. W., Leung, D. H., Brennan, M. F., Postoperative nomogram for 12-year sarcoma-specific death, J Clin Oncol, 2002. 20(3): p. 791-6., https://www.ncbi.nlm.nih.gov/pubmed/11821462
139. Dalal, K. M., Kattan, M. W., Antonescu, C. R., Brennan, M. F., Singer, S., Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk, Ann Surg, 2006. 244(3): p. 381-91., https://www.ncbi.nlm.nih.gov/pubmed/16926564
140. Canter, R. J., Qin, L. X., Maki, R. G., Brennan, M. F., Ladanyi, M., Singer, S., A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients, Clin Cancer Res, 2008. 14(24): p. 8191-7., https://www.ncbi.nlm.nih.gov/pubmed/19088035
141. Gronchi, A., Miceli, R., Shurell, E., Eilber, F. C., Eilber, F. R., Anaya, D. A., et.al. Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets, J Clin Oncol, 2013. 31(13): p. 1649-55., https://www.ncbi.nlm.nih.gov/pubmed/23530096
142. Callegaro, D., Miceli, R., Bonvalot, S., Ferguson, P., Strauss, D. C., Levy, A., et.al. Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis, Lancet Oncol, 2016. 17(5): p. 671-80., https://www.ncbi.nlm.nih.gov/pubmed/27068860
143. Callegaro, D., Miceli, R., Bonvalot, S., Ferguson, P. C., Strauss, D. C., van Praag, V. V. M., et.al. Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors, EClinicalMedicine, 2019. 17: p. 100215., https://www.ncbi.nlm.nih.gov/pubmed/31891146
144. Gross, J. L., Younes, R. N., Haddad, F. J., Deheinzelin, D., Pinto, C. A., Costa, M. L., Soft-tissue sarcomas of the chest wall: prognostic factors, Chest, 2005. 127(3): p. 902-8., https://www.ncbi.nlm.nih.gov/pubmed/15764774
145. Enneking, W. F., Spanier, S. S., Goodman, M. A., A system for the surgical staging of musculoskeletal sarcoma, Clin Orthop Relat Res, 1980. p. 106-20., https://www.ncbi.nlm.nih.gov/pubmed/7449206
146. Steinau, H. U., Homann, H. H., Drucke, D., Torres, A., Soimaru, D., Vogt, P., [Resection method and functional restoration in soft tissue sarcomas of the extremities], Chirurg, 2001. 72(5): p. 501-13., https://www.ncbi.nlm.nih.gov/pubmed/11383061
147. Kawaguchi, N., Ahmed, A. R., Matsumoto, S., Manabe, J., Matsushita, Y., The concept of curative margin in surgery for bone and soft tissue sarcoma, Clin Orthop Relat Res, 2004. p. 165-72., https://www.ncbi.nlm.nih.gov/pubmed/15021149
148. Shiu, M. H., Castro, E. B., Hajdu, S. I., Fortner, J. G., Surgical treatment of 297 soft tissue sarcomas of the lower extremity, Ann Surg, 1975. 182(5): p. 597-602., https://www.ncbi.nlm.nih.gov/pubmed/1190864
149. Rosenberg, S. A., Tepper, J., Glatstein, E., Costa, J., Baker, A., Brennan, M., et.al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy, Ann Surg, 1982. 196(3): p. 305-15., https://www.ncbi.nlm.nih.gov/pubmed/7114936
150. Daigeler, A., Lehnhardt, M., Khadra, A., Hauser, J., Steinstraesser, L., Langer, S., et.al. Proximal major limb amputations--a retrospective analysis of 45 oncological cases, World J Surg Oncol, 2009. 7: p. 15., https://www.ncbi.nlm.nih.gov/pubmed/19203359
151. Ghert, M. A., Abudu, A., Driver, N., Davis, A. M., Griffin, A. M., Pearce, D., et.al. The indications for and the prognostic significance of amputation as the primary surgical procedure for localized soft tissue sarcoma of the extremity, Ann Surg Oncol, 2005. 12(1): p. 10-7., https://www.ncbi.nlm.nih.gov/pubmed/15827772
152. Catena, F., Di Battista, M., Ansaloni, L., Pantaleo, M., Fusaroli, P., Di Scioscio, V., et.al. Microscopic margins of resection influence primary gastrointestinal stromal tumor survival, Onkologie, 2012. 35(11): p. 645-8., https://www.ncbi.nlm.nih.gov/pubmed/23147540
153. Engstrom, K., Bergh, P., Gustafson, P., Hultborn, R., Johansson, H., Lofvenberg, R., et.al. Liposarcoma: outcome based on the Scandinavian Sarcoma Group register, Cancer, 2008. 113(7): p. 1649-56., https://www.ncbi.nlm.nih.gov/pubmed/18720363
154. Gingrich, A. A., Bateni, S. B., Monjazeb, A. M., Darrow, M. A., Thorpe, S. W., Kirane, A. R., et.al. Neoadjuvant Radiotherapy is Associated with R0 Resection and Improved Survival for Patients with Extremity Soft Tissue Sarcoma Undergoing Surgery: A National Cancer Database Analysis, Ann Surg Oncol, 2017. 24(11): p. 3252-3263., https://www.ncbi.nlm.nih.gov/pubmed/28741123
155. Jebsen, N. L., Trovik, C. S., Bauer, H. C., Rydholm, A., Monge, O. R., Hall, K. S., et.al. Radiotherapy to improve local control regardless of surgical margin and malignancy grade in extremity and trunk wall soft tissue sarcoma: a Scandinavian sarcoma group study, Int J Radiat Oncol Biol Phys, 2008. 71(4): p. 1196-203., https://www.ncbi.nlm.nih.gov/pubmed/18207661
156. Jebsen, N. L., Engellau, J., Engstrom, K., Bauer, H. C., Monge, O. R., Muren, L. P., et.al. Patterns of local recurrence and dose fractionation of adjuvant radiation therapy in 462 patients with soft tissue sarcoma of extremity and trunk wall, Int J Radiat Oncol Biol Phys, 2013. 86(5): p. 949-55., https://www.ncbi.nlm.nih.gov/pubmed/23725998
157. Li, B., Luo, C. H., Zheng, W., Risk factors for recurrence and survival in patients with primary retroperitoneal tumors, J BUON, 2013. 18(3): p. 782-7., https://www.ncbi.nlm.nih.gov/pubmed/24065499
158. Seagle, B. L., Shilpi, A., Buchanan, S., Goodman, C., Shahabi, S., Low-grade and high-grade endometrial stromal sarcoma: A National Cancer Database study, Gynecol Oncol, 2017. 146(2): p. 254-262., https://www.ncbi.nlm.nih.gov/pubmed/28596015
159. Sinnamon, A. J., Neuwirth, M. G., McMillan, M. T., Ecker, B. L., Bartlett, E. K., Zhang, P. J., et.al. A prognostic model for resectable soft tissue and cutaneous angiosarcoma, J Surg Oncol, 2016. 114(5): p. 557-563., https://www.ncbi.nlm.nih.gov/pubmed/27378102
160. Stahl, J. M., Corso, C. D., Park, H. S., An, Y., Rutter, C. E., Han, D., et.al. The effect of microscopic margin status on survival in adult retroperitoneal soft tissue sarcomas, Eur J Surg Oncol, 2017. 43(1): p. 168-174., https://www.ncbi.nlm.nih.gov/pubmed/27335080
161. Trovik, C. S., Bauer, H. C., Alvegard, T. A., Anderson, H., Blomqvist, C., Berlin, O., et.al. Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian Sarcoma Group Register, Eur J Cancer, 2000. 36(6): p. 710-6., https://www.ncbi.nlm.nih.gov/pubmed/10762742
162. Trovik, L. H., Ovrebo, K., Almquist, M., Haugland, H. K., Rissler, P., Eide, J., et.al. Adjuvant radiotherapy in retroperitoneal sarcomas. A Scandinavian Sarcoma Group study of 97 patients, Acta Oncol, 2014. 53(9): p. 1165-72., https://www.ncbi.nlm.nih.gov/pubmed/25000415
163. Chang, H. R., Gaynor, J., Tan, C., Hajdu, S. I., Brennan, M. F., Multifactorial analysis of survival in primary extremity liposarcoma, World J Surg, 1990. 14(5): p. 610-8., https://www.ncbi.nlm.nih.gov/pubmed/2238661
164. Alamanda, V. K., Delisca, G. O., Mathis, S. L., Archer, K. R., Ehrenfeld, J. M., Miller, M. W., et.al. The financial burden of reexcising incompletely excised soft tissue sarcomas: a cost analysis, Ann Surg Oncol, 2013. 20(9): p. 2808-14., https://www.ncbi.nlm.nih.gov/pubmed/23636515
165. Willeumier, J. J., Rueten-Budde, A. J., Jeys, L. M., Laitinen, M., Pollock, R., Aston, W., et.al. Individualised risk assessment for local recurrence and distant metastases in a retrospective transatlantic cohort of 687 patients with high-grade soft tissue sarcomas of the extremities: a multistate model, BMJ Open, 2017. 7(2): p. e012930., https://www.ncbi.nlm.nih.gov/pubmed/28196946
166. Rauh, J., Klein, A., Baur-Melnyk, A., Knosel, T., Lindner, L., Roeder, F., et.al. The role of surgical margins in atypical Lipomatous Tumours of the extremities, BMC Musculoskelet Disord, 2018. 19(1): p. 152., https://www.ncbi.nlm.nih.gov/pubmed/29776450
167. Braun, K. F., Pohlig, F., Lenze, U., Netter, C., Hadjamu, M., Rechl, H., et.al. [Insufficiency fractures after irradiation therapy - case series], MMW Fortschr Med, 2015. 157 Suppl 5: p. 1-4., https://www.ncbi.nlm.nih.gov/pubmed/26168741
168. Blaes, A. H., Lindgren, B., Mulrooney, D. A., Willson, L., Cho, L. C., Pathologic femur fractures after limb-sparing treatment of soft-tissue sarcomas, J Cancer Surviv, 2010. 4(4): p. 399-404., https://www.ncbi.nlm.nih.gov/pubmed/20827514
169. Seinen, J. M., Jutte, P. C., Been, L. B., Pras, E., Hoekstra, H. J., Fractures after multimodality treatment of soft tissue sarcomas with isolated limb perfusion and radiation; likely to occur and hard to heal, Eur J Surg Oncol, 2018. 44(9): p. 1398-1405., https://www.ncbi.nlm.nih.gov/pubmed/29789188
170. Lin, P. P., Pino, E. D., Normand, A. N., Deavers, M. T., Cannon, C. P., Ballo, M. T., et.al. Periosteal margin in soft-tissue sarcoma, Cancer, 2007. 109(3): p. 598-602., https://www.ncbi.nlm.nih.gov/pubmed/17183556
171. Schwarzbach, M. H., Hohenberger, P., Current concepts in the management of retroperitoneal soft tissue sarcoma, Recent Results Cancer Res, 2009. 179: p. 301-19., https://www.ncbi.nlm.nih.gov/pubmed/19230548
172. Hohenberger, P., Allenberg, J. R., Schlag, P. M., Reichardt, P., Results of surgery and multimodal therapy for patients with soft tissue sarcoma invading to vascular structures, Cancer, 1999. 85(2): p. 396-408., https://www.ncbi.nlm.nih.gov/pubmed/10023708
173. Poultsides, G. A., Tran, T. B., Zambrano, E., Janson, L., Mohler, D. G., Mell, M. W., et.al. Sarcoma Resection With and Without Vascular Reconstruction: A Matched Case-control Study, Ann Surg, 2015. 262(4): p. 632-40., https://www.ncbi.nlm.nih.gov/pubmed/26366542
174. Wortmann, M., Alldinger, I., Bockler, D., Ulrich, A., Hyhlik-Durr, A., Vascular reconstruction after retroperitoneal and lower extremity sarcoma resection, Eur J Surg Oncol, 2017. 43(2): p. 407-415., https://www.ncbi.nlm.nih.gov/pubmed/27914772
175. Sweiti, H., Tamimi, N., Bormann, F., Divo, M., Schulz-Ertner, D., Ahrens, M., et.al. Limb-Salvage Surgery of Soft Tissue Sarcoma with Sciatic Nerve Involvement, Sarcoma, 2018. 2018: p. 6483579., https://www.ncbi.nlm.nih.gov/pubmed/29692655
176. Fuchs, B., Davis, A. M., Wunder, J. S., Bell, R. S., Masri, B. A., Isler, M., et.al. Sciatic nerve resection in the thigh: a functional evaluation, Clin Orthop Relat Res, 2001. p. 34-41., https://www.ncbi.nlm.nih.gov/pubmed/11154002
177. Bickels, J., Wittig, J. C., Kollender, Y., Kellar-Graney, K., Malawer, M. M., Meller, I., Sciatic nerve resection: is that truly an indication for amputation?, Clin Orthop Relat Res, 2002. p. 201-4., https://www.ncbi.nlm.nih.gov/pubmed/12011710
178. McKee, M. D., Liu, D. F., Brooks, J. J., Gibbs, J. F., Driscoll, D. L., Kraybill, W. G., The prognostic significance of margin width for extremity and trunk sarcoma, J Surg Oncol, 2004. 85(2): p. 68-76., https://www.ncbi.nlm.nih.gov/pubmed/14755506
179. Biau, D. J., Ferguson, P. C., Chung, P., Griffin, A. M., Catton, C. N., O'Sullivan, B., et.al. Local recurrence of localized soft tissue sarcoma: a new look at old predictors, Cancer, 2012. 118(23): p. 5867-77., https://www.ncbi.nlm.nih.gov/pubmed/22648518
180. Agulnik, M., Yarber, J. L., Okuno, S. H., von Mehren, M., Jovanovic, B. D., Brockstein, B. E., et.al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas, Ann Oncol, 2013. 24(1): p. 257-63., https://www.ncbi.nlm.nih.gov/pubmed/22910841
181. Gerrand, C. H., Wunder, J. S., Kandel, R. A., O'Sullivan, B., Catton, C. N., Bell, R. S., et.al. Classification of positive margins after resection of soft-tissue sarcoma of the limb predicts the risk of local recurrence, J Bone Joint Surg Br, 2001. 83(8): p. 1149-55., https://www.ncbi.nlm.nih.gov/pubmed/11764430
182. Geer, R. J., Woodruff, J., Casper, E. S., Brennan, M. F., Management of small soft-tissue sarcoma of the extremity in adults, Arch Surg, 1992. 127(11): p. 1285-9., https://www.ncbi.nlm.nih.gov/pubmed/1444788
183. Cahlon, O., Spierer, M., Brennan, M. F., Singer, S., Alektiar, K. M., Long-term outcomes in extremity soft tissue sarcoma after a pathologically negative re-resection and without radiotherapy, Cancer, 2008. 112(12): p. 2774-9., https://www.ncbi.nlm.nih.gov/pubmed/18429001
184. Billing, V., Mertens, F., Domanski, H. A., Rydholm, A., Deep-seated ordinary and atypical lipomas: histopathology, cytogenetics, clinical features, and outcome in 215 tumours of the extremity and trunk wall, J Bone Joint Surg Br, 2008. 90(7): p. 929-33., https://www.ncbi.nlm.nih.gov/pubmed/18591605
185. Kraybill, W. G., Harris, J., Spiro, I. J., Ettinger, D. S., DeLaney, T. F., Blum, R. H., et.al. Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514, Cancer, 2010. 116(19): p. 4613-21., https://www.ncbi.nlm.nih.gov/pubmed/20572040
186. Gortzak, E., Azzarelli, A., Buesa, J., Bramwell, V. H., van Coevorden, F., van Geel, A. N., et.al. A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma, Eur J Cancer, 2001. 37(9): p. 1096-103., https://www.ncbi.nlm.nih.gov/pubmed/11378339
187. Pisters, P. W., Pollock, R. E., Lewis, V. O., Yasko, A. W., Cormier, J. N., Respondek, P. M., et.al. Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas, Ann Surg, 2007. 246(4): p. 675-81; discussion 681-2., https://www.ncbi.nlm.nih.gov/pubmed/17893504
188. Baldini, E. H., Goldberg, J., Jenner, C., Manola, J. B., Demetri, G. D., Fletcher, C. D., et.al. Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk, J Clin Oncol, 1999. 17(10): p. 3252-9., https://www.ncbi.nlm.nih.gov/pubmed/10506627
189. Yang, J. C., Chang, A. E., Baker, A. R., Sindelar, W. F., Danforth, D. N., Topalian, S. L., et.al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity, J Clin Oncol, 1998. 16(1): p. 197-203., https://www.ncbi.nlm.nih.gov/pubmed/9440743
190. Amin, M.B., Edge, S. B., Greene, F. L., Byrd, D. R., Brookland, R. K., Washington, M. K., et.al. AJCC Cancer Staging ManualSpringer International Publishing, 2017.
191. Keung, E. Z., Chiang, Y. J., Voss, R. K., Cormier, J. N., Torres, K. E., Hunt, K. K., et.al. Defining the incidence and clinical significance of lymph node metastasis in soft tissue sarcoma, Eur J Surg Oncol, 2018. 44(1): p. 170-177., https://www.ncbi.nlm.nih.gov/pubmed/29208319
192. Daigeler, A., Kuhnen, C., Moritz, R., Stricker, I., Goertz, O., Tilkorn, D., et.al. Lymph node metastases in soft tissue sarcomas: a single center analysis of 1,597 patients, Langenbecks Arch Surg, 2009. 394(2): p. 321-9., https://www.ncbi.nlm.nih.gov/pubmed/18594854
193. Jacobs, A. J., Morris, C. D., Levin, A. S., Synovial Sarcoma Is Not Associated With a Higher Risk of Lymph Node Metastasis Compared With Other Soft Tissue Sarcomas, Clin Orthop Relat Res, 2018. 476(3): p. 589-598., https://www.ncbi.nlm.nih.gov/pubmed/29529647
194. Fong, Y., Coit, D. G., Woodruff, J. M., Brennan, M. F., Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients, Ann Surg, 1993. 217(1): p. 72-7., https://www.ncbi.nlm.nih.gov/pubmed/8424704
195. Andreou, D., Boldt, H., Werner, M., Hamann, C., Pink, D., Tunn, P. U., Sentinel node biopsy in soft tissue sarcoma subtypes with a high propensity for regional lymphatic spread--results of a large prospective trial, Ann Oncol, 2013. 24(5): p. 1400-5., https://www.ncbi.nlm.nih.gov/pubmed/23372051
196. Alektiar, K. M., Velasco, J., Zelefsky, M. J., Woodruff, J. M., Lewis, J. J., Brennan, M. F., Adjuvant radiotherapy for margin-positive high-grade soft tissue sarcoma of the extremity, Int J Radiat Oncol Biol Phys, 2000. 48(4): p. 1051-8., https://www.ncbi.nlm.nih.gov/pubmed/11072162
197. Zagars, G. K., Ballo, M. T., Pisters, P. W., Pollock, R. E., Patel, S. R., Benjamin, R. S., Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy, Cancer, 2003. 97(10): p. 2544-53., https://www.ncbi.nlm.nih.gov/pubmed/12733154
198. le Grange, F., Cassoni, A. M., Seddon, B. M., Tumour volume changes following pre-operative radiotherapy in borderline resectable limb and trunk soft tissue sarcoma, Eur J Surg Oncol, 2014. 40(4): p. 394-401., https://www.ncbi.nlm.nih.gov/pubmed/24534361
199. Liuzzi, J. F., Da Cunha, M., Salas, D., Siso, S., Garriga, E., Soft-tissue sarcomas in the head and neck: 25 years of experience, Ecancermedicalscience, 2017. 11: p. 740., https://www.ncbi.nlm.nih.gov/pubmed/28626490
200. Breakey, R. W., Crowley, T. P., Anderson, I. B., Milner, R. H., Ragbir, M., The surgical management of head and neck sarcoma: The Newcastle experience, J Plast Reconstr Aesthet Surg, 2017. 70(1): p. 78-84., https://www.ncbi.nlm.nih.gov/pubmed/27836568
201. Shin, J. Y., Roh, S. G., Lee, N. H., Yang, K. M., Predisposing factors for poor prognosis of angiosarcoma of the scalp and face: Systematic review and meta-analysis, Head Neck, 2017. 39(2): p. 380-386., https://www.ncbi.nlm.nih.gov/pubmed/27507124
202. Mallen-St Clair, J., Arshi, A., Abemayor, E., St John, M., Factors Associated With Survival in Patients With Synovial Cell Sarcoma of the Head and Neck: An Analysis of 167 Cases Using the SEER (Surveillance, Epidemiology, and End Results) Database, JAMA Otolaryngol Head Neck Surg, 2016. 142(6): p. 576-83., https://www.ncbi.nlm.nih.gov/pubmed/27100936
203. Park, J. T., Roh, J. L., Kim, S. O., Cho, K. J., Choi, S. H., Nam, S. Y., et.al. Prognostic factors and oncological outcomes of 122 head and neck soft tissue sarcoma patients treated at a single institution, Ann Surg Oncol, 2015. 22(1): p. 248-55., https://www.ncbi.nlm.nih.gov/pubmed/25001093
204. Mattavelli, D., Miceli, R., Radaelli, S., Mattavelli, F., Cantu, G., Barisella, M., et.al. Head and neck soft tissue sarcomas: prognostic factors and outcome in a series of patients treated at a single institution, Ann Oncol, 2013. 24(8): p. 2181-9., https://www.ncbi.nlm.nih.gov/pubmed/23562930
205. Kraus, D. H., Dubner, S., Harrison, L. B., Strong, E. W., Hajdu, S. I., Kher, U., et.al. Prognostic factors for recurrence and survival in head and neck soft tissue sarcomas, Cancer, 1994. 74(2): p. 697-702., https://www.ncbi.nlm.nih.gov/pubmed/8033050
206. Wanebo, H. J., Koness, R. J., MacFarlane, J. K., Eilber, F. R., Byers, R. M., Elias, E. G., et.al. Head and neck sarcoma: report of the Head and Neck Sarcoma Registry. Society of Head and Neck Surgeons Committee on Research, Head Neck, 1992. 14(1): p. 1-7., https://www.ncbi.nlm.nih.gov/pubmed/1624288
207. Wang, L., Lao, I. W., Yu, L., Wang, J., Clinicopathological features and prognostic factors in angiosarcoma: A retrospective analysis of 200 patients from a single Chinese medical institute, Oncol Lett, 2017. 14(5): p. 5370-5378., https://www.ncbi.nlm.nih.gov/pubmed/29113171
208. Shuman, A. G., Brennan, M. F., Palmer, F. L., Kuk, D., Moraco, N., Singer, S., et.al. Soft tissue sarcoma of the head & neck: nomogram validation and analysis of staging systems, J Surg Oncol, 2015. 111(6): p. 690-5., https://www.ncbi.nlm.nih.gov/pubmed/25711850
209. Perez, M. C., Padhya, T. A., Messina, J. L., Jackson, R. S., Gonzalez, R. J., Bui, M. M., et.al. Cutaneous angiosarcoma: a single-institution experience, Ann Surg Oncol, 2013. 20(11): p. 3391-7., https://www.ncbi.nlm.nih.gov/pubmed/23835652
210. Gonzalez-Gonzalez, R., Bologna-Molina, R., Molina-Frechero, N., Dominguez-Malagon, H. R., Prognostic factors and treatment strategies for adult head and neck soft tissue sarcoma, Int J Oral Maxillofac Surg, 2012. 41(5): p. 569-75., https://www.ncbi.nlm.nih.gov/pubmed/22398019
211. Le Vay, J., O'Sullivan, B., Catton, C., Cummings, B., Fornasier, V., Gullane, P., et.al. An assessment of prognostic factors in soft-tissue sarcoma of the head and neck, Arch Otolaryngol Head Neck Surg, 1994. 120(9): p. 981-6., https://www.ncbi.nlm.nih.gov/pubmed/8074826
212. Makary, R. F., Gopinath, A., Markiewicz, M. R., Fernandes, R., Margin Analysis: Sarcoma of the Head and Neck, Oral Maxillofac Surg Clin North Am, 2017. 29(3): p. 355-366., https://www.ncbi.nlm.nih.gov/pubmed/28709534
213. Rosko, A. J., Birkeland, A. C., Chinn, S. B., Shuman, A. G., Prince, M. E., Patel, R. M., et.al. Survival and Margin Status in Head and Neck Radiation-Induced Sarcomas and De Novo Sarcomas, Otolaryngol Head Neck Surg, 2017. 157(2): p. 252-259., https://www.ncbi.nlm.nih.gov/pubmed/28397585
214. Tajudeen, B. A., Fuller, J., Lai, C., Grogan, T., Elashoff, D., Abemayor, E., et.al. Head and neck sarcomas: the UCLA experience, Am J Otolaryngol, 2014. 35(4): p. 476-81., https://www.ncbi.nlm.nih.gov/pubmed/24721744
215. Colville, R. J., Charlton, F., Kelly, C. G., Nicoll, J. J., McLean, N. R., Multidisciplinary management of head and neck sarcomas, Head Neck, 2005. 27(9): p. 814-24., https://www.ncbi.nlm.nih.gov/pubmed/16086411
216. Borucki, R. B., Neskey, D. M., Lentsch, E. J., Malignant fibrous histiocytoma: Database review suggests a favorable prognosis in the head and neck, Laryngoscope, 2018. 128(4): p. 885-888., https://www.ncbi.nlm.nih.gov/pubmed/28988458
217. Chang, A. E., Chai, X., Pollack, S. M., Loggers, E., Rodler, E., Dillon, J., et.al. Analysis of clinical prognostic factors for adult patients with head and neck sarcomas, Otolaryngol Head Neck Surg, 2014. 151(6): p. 976-83., https://www.ncbi.nlm.nih.gov/pubmed/25257906
218. Mucke, T., Mitchell, D. A., Tannapfel, A., Holzle, F., Kesting, M. R., Wolff, K. D., et.al. Outcome in adult patients with head and neck sarcomas--a 10-year analysis, J Surg Oncol, 2010. 102(2): p. 170-4., https://www.ncbi.nlm.nih.gov/pubmed/20648589
219. Fayda, M., Aksu, G., Yaman Agaoglu, F., Karadeniz, A., Darendeliler, E., Altun, M., et.al. The role of surgery and radiotherapy in treatment of soft tissue sarcomas of the head and neck region: review of 30 cases, J Craniomaxillofac Surg, 2009. 37(1): p. 42-8., https://www.ncbi.nlm.nih.gov/pubmed/18804382
220. Lindford, A., McIntyre, B., Marsh, R., MacKinnon, C. A., Davis, C., Tan, S. T., Outcomes of the treatment of head and neck sarcomas in a tertiary referral center, Front Surg, 2015. 2: p. 19., https://www.ncbi.nlm.nih.gov/pubmed/26042220
221. Dietz, A., Frerich, B., [Current opinion in treatment of soft tissue sarcoma], Laryngorhinootologie, 2009. 88(5): p. 293-302., https://www.ncbi.nlm.nih.gov/pubmed/19391071
222. Chen, H., Zhou, N., Huang, X., Song, S., Comparison of morbidity after reconstruction of tongue defects with an anterolateral thigh cutaneous flap compared with a radial forearm free-flap: a meta-analysis, Br J Oral Maxillofac Surg, 2016. 54(10): p. 1095-1101., https://www.ncbi.nlm.nih.gov/pubmed/27516163
223. Saito, N., Tsutsumida, A., Furukawa, H., Sekido, M., Oyama, A., Funayama, E., et.al. Reconstructive considerations in the treatment of soft tissue sarcomas of the cheek, Acta Otorhinolaryngol Ital, 2010. 30(2): p. 103-6., https://www.ncbi.nlm.nih.gov/pubmed/20559481
224. Huang, C. H., Chen, H. C., Huang, Y. L., Mardini, S., Feng, G. M., Comparison of the radial forearm flap and the thinned anterolateral thigh cutaneous flap for reconstruction of tongue defects: an evaluation of donor-site morbidity, Plast Reconstr Surg, 2004. 114(7): p. 1704-10., https://www.ncbi.nlm.nih.gov/pubmed/15577337
225. Lonie, S., Herle, P., Paddle, A., Pradhan, N., Birch, T., Shayan, R., Mandibular reconstruction: meta-analysis of iliac- versus fibula-free flaps, ANZ J Surg, 2016. 86(5): p. 337-42., https://www.ncbi.nlm.nih.gov/pubmed/26331293
226. Mueller, S., Hohlweg-Majert, B., Buergers, R., Steiner, T., Reichert, T. E., Wolff, K. D., et.al. The functional and aesthetic reconstruction of midfacial and orbital defects by combining free flap transfer and craniofacial prosthesis, Clin Oral Investig, 2015. 19(2): p. 413-9., https://www.ncbi.nlm.nih.gov/pubmed/24771201
227. Federspil, P. A., Implant-retained craniofacial prostheses for facial defects, GMS Curr Top Otorhinolaryngol Head Neck Surg, 2009. 8: p. Doc03., https://www.ncbi.nlm.nih.gov/pubmed/22073096
228. Ugurel, S., Kortmann, R. D., Mohr, P., Mentzel, T., Garbe, C., Breuninger, H., et.al. S1-Leitlinie Dermatofibrosarcoma protuberans (DFSP) - Update 2018, J Dtsch Dermatol Ges, 2019. 17(6): p. 663-668., https://www.ncbi.nlm.nih.gov/pubmed/31241846
229. Vogt, T., Brockmeyer, N., Kutzner, H., Schofer, H., Brief S1 guidelines--Cutaneous angiosarcoma and Kaposi sarcoma, J Dtsch Dermatol Ges, 2013. 11 Suppl 3: p. 2-9, 2-10., https://www.ncbi.nlm.nih.gov/pubmed/23734888
230. Miller, K., Goodlad, J. R., Brenn, T., Pleomorphic dermal sarcoma: adverse histologic features predict aggressive behavior and allow distinction from atypical fibroxanthoma, Am J Surg Pathol, 2012. 36(9): p. 1317-26., https://www.ncbi.nlm.nih.gov/pubmed/22510760
231. Kohlmeyer, J., Steimle-Grauer, S. A., Hein, R., Cutaneous sarcomas, J Dtsch Dermatol Ges, 2017. 15(6): p. 630-648., https://www.ncbi.nlm.nih.gov/pubmed/28591457
232. Foroozan, M., Sei, J. F., Amini, M., Beauchet, A., Saiag, P., Efficacy of Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans: systematic review, Arch Dermatol, 2012. 148(9): p. 1055-63., https://www.ncbi.nlm.nih.gov/pubmed/22986859
233. Trofymenko, O., Bordeaux, J. S., Zeitouni, N. C., Survival in patients with primary dermatofibrosarcoma protuberans: National Cancer Database analysis, J Am Acad Dermatol, 2018. 78(6): p. 1125-1134., https://www.ncbi.nlm.nih.gov/pubmed/29175214
234. Hafner, H. M., Moehrle, M., Eder, S., Trilling, B., Rocken, M., Breuninger, H., 3D-Histological evaluation of surgery in dermatofibrosarcoma protuberans and malignant fibrous histiocytoma: differences in growth patterns and outcome, Eur J Surg Oncol, 2008. 34(6): p. 680-6., https://www.ncbi.nlm.nih.gov/pubmed/17716851
235. Lopez, L. V., Yatsenko, S. A., Burgess, M., Schoedel, K., Rao, U. N. M., Dermatofibrosarcoma protuberans with fibrosarcomatous transformation: our experience, molecular evaluation of selected cases, and short literature review, Int J Dermatol, 2019. 58(11): p. 1246-1252., https://www.ncbi.nlm.nih.gov/pubmed/30968395
236. Persa, O. D., Loquai, C., Wobser, M., Baltaci, M., Dengler, S., Kreuter, A., et.al. Extended surgical safety margins and ulceration are associated with an improved prognosis in pleomorphic dermal sarcomas, J Eur Acad Dermatol Venereol, 2019. 33(8): p. 1577-1580., https://www.ncbi.nlm.nih.gov/pubmed/30767327
237. Tolkachjov, S. N., Kelley, B. F., Alahdab, F., Erwin, P. J., Brewer, J. D., Atypical fibroxanthoma: Systematic review and meta-analysis of treatment with Mohs micrographic surgery or excision, J Am Acad Dermatol, 2018. 79(5): p. 929-934 e6., https://www.ncbi.nlm.nih.gov/pubmed/29981390
238. Soleymani, T., Aasi, S. Z., Novoa, R., Hollmig, S. T., Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma: Updates on Classification and Management, Dermatol Clin, 2019. 37(3): p. 253-259., https://www.ncbi.nlm.nih.gov/pubmed/31084719
239. Lonie, S., Yau, B., Henderson, M., Gyorki, D., Angel, C., Webb, A., Management of pleomorphic dermal sarcoma, ANZ J Surg, 2020. 90(11): p. 2322-2324., https://www.ncbi.nlm.nih.gov/pubmed/32338819
240. Ang, G. C., Roenigk, R. K., Otley, C. C., Kim Phillips, P., Weaver, A. L., More than 2 decades of treating atypical fibroxanthoma at mayo clinic: what have we learned from 91 patients?, Dermatol Surg, 2009. 35(5): p. 765-72., https://www.ncbi.nlm.nih.gov/pubmed/19389106
241. Winchester, D. S., Hocker, T. L., Brewer, J. D., Baum, C. L., Hochwalt, P. C., Arpey, C. J., et.al. Leiomyosarcoma of the skin: clinical, histopathologic, and prognostic factors that influence outcomes, J Am Acad Dermatol, 2014. 71(5): p. 919-25., https://www.ncbi.nlm.nih.gov/pubmed/25174541
242. Aneiros-Fernandez, J., Antonio Retamero, J., Husein-Elahmed, H., Ovalle, F., Aneiros-Cachaza, J., Primary cutaneous and subcutaneous leiomyosarcomas: evolution and prognostic factors, Eur J Dermatol, 2016. 26(1): p. 9-12., https://www.ncbi.nlm.nih.gov/pubmed/26678649
243. Young, R. J., Brown, N. J., Reed, M. W., Hughes, D., Woll, P. J., Angiosarcoma, Lancet Oncol, 2010. 11(10): p. 983-91., https://www.ncbi.nlm.nih.gov/pubmed/20537949
244. Cohen-Hallaleh, R. B., Smith, H. G., Smith, R. C., Stamp, G. F., Al-Muderis, O., Thway, K., et.al. Radiation induced angiosarcoma of the breast: outcomes from a retrospective case series, Clin Sarcoma Res, 2017. 7: p. 15., https://www.ncbi.nlm.nih.gov/pubmed/28794852
245. Porter, G. A., Baxter, N. N., Pisters, P. W., Retroperitoneal sarcoma: a population-based analysis of epidemiology, surgery, and radiotherapy, Cancer, 2006. 106(7): p. 1610-6., https://www.ncbi.nlm.nih.gov/pubmed/16518798
246. Bonvalot, S., Raut, C. P., Pollock, R. E., Rutkowski, P., Strauss, D. C., Hayes, A. J., et.al. Technical considerations in surgery for retroperitoneal sarcomas: position paper from E-Surge, a master class in sarcoma surgery, and EORTC-STBSG, Ann Surg Oncol, 2012. 19(9): p. 2981-91., https://www.ncbi.nlm.nih.gov/pubmed/22476756
247. Trans-Atlantic, R. P. S. Working Group, Management of primary retroperitoneal sarcoma (RPS) in the adult: a consensus approach from the Trans-Atlantic RPS Working Group, Ann Surg Oncol, 2015. 22(1): p. 256-63., https://www.ncbi.nlm.nih.gov/pubmed/25316486
248. Raut, C. P., Miceli, R., Strauss, D. C., Swallow, C. J., Hohenberger, P., van Coevorden, F., et.al. External validation of a multi-institutional retroperitoneal sarcoma nomogram, Cancer, 2016. 122(9): p. 1417-24., https://www.ncbi.nlm.nih.gov/pubmed/26916507
249. Haas, R. L. M., Bonvalot, S., Miceli, R., Strauss, D. C., Swallow, C. J., Hohenberger, P., et.al. Radiotherapy for retroperitoneal liposarcoma: A report from the Transatlantic Retroperitoneal Sarcoma Working Group, Cancer, 2019. 125(8): p. 1290-1300., https://www.ncbi.nlm.nih.gov/pubmed/30602058
250. Jakob, J., Gerres, A., Ronellenfitsch, U., Pilz, L., Wartenberg, M., Kasper, B., et.al. [Treatment of retroperitoneal sarcoma in Germany : Results of a survey of the German Society of General and Visceral Surgery, the German Interdisciplinary Sarcoma Study Group and the advocacy group Das Lebenshaus], Chirurg, 2018. 89(1): p. 50-55., https://www.ncbi.nlm.nih.gov/pubmed/28905080
251. Gronchi, A., Strauss, D. C., Miceli, R., Bonvalot, S., Swallow, C. J., Hohenberger, P., et.al. Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group, Ann Surg, 2016. 263(5): p. 1002-9., https://www.ncbi.nlm.nih.gov/pubmed/26727100
252. Hohenberger, P., Dinter, D., Stroebel, P., Kasper, B., Wenz, F., [Principles of surgery for retroperitoneal sarcoma], Zentralbl Chir, 2014. 139 Suppl 2: p. e72-8., https://www.ncbi.nlm.nih.gov/pubmed/23115028
253. Toulmonde, M., Bonvalot, S., Meeus, P., Stoeckle, E., Riou, O., Isambert, N., et.al. Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group, Ann Oncol, 2014. 25(3): p. 735-742., https://www.ncbi.nlm.nih.gov/pubmed/24567518
254. Berger-Richardson, D., Swallow, C. J., Needle tract seeding after percutaneous biopsy of sarcoma: Risk/benefit considerations, Cancer, 2017. 123(4): p. 560-567., https://www.ncbi.nlm.nih.gov/pubmed/27859013
255. Wilkinson, M. J., Martin, J. L., Khan, A. A., Hayes, A. J., Thomas, J. M., Strauss, D. C., Percutaneous core needle biopsy in retroperitoneal sarcomas does not influence local recurrence or overall survival, Ann Surg Oncol, 2015. 22(3): p. 853-8., https://www.ncbi.nlm.nih.gov/pubmed/25190132
256. Stojadinovic, A., Yeh, A., Brennan, M. F., Completely resected recurrent soft tissue sarcoma: primary anatomic site governs outcomes, J Am Coll Surg, 2002. 194(4): p. 436-47., https://www.ncbi.nlm.nih.gov/pubmed/11949749
257. Herman, K., Kusy, T., Retroperitoneal sarcoma--the continued challenge for surgery and oncology, Surg Oncol, 1998. 7(1-2): p. 77-81., https://www.ncbi.nlm.nih.gov/pubmed/10421510
258. Gronchi, A., Miceli, R., Colombo, C., Stacchiotti, S., Collini, P., Mariani, L., et.al. Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas, Ann Oncol, 2012. 23(4): p. 1067-73., https://www.ncbi.nlm.nih.gov/pubmed/21765179
259. Bonvalot, S., Rivoire, M., Castaing, M., Stoeckle, E., Le Cesne, A., Blay, J. Y., et.al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control, J Clin Oncol, 2009. 27(1): p. 31-7., https://www.ncbi.nlm.nih.gov/pubmed/19047280
260. Trans-Atlantic Retroperitoneal Sarcoma Working Group . Electronic address, andrea macneill bccancer bc ca, Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG), Ann Oncol, 2018. 29(4): p. 857-871., https://www.ncbi.nlm.nih.gov/pubmed/29432564
261. Callegaro, D., Raut, C. P., Ng, D., Strauss, D. C., Honore, C., Stoeckle, E., et.al. Has the Outcome for Patients Who Undergo Resection of Primary Retroperitoneal Sarcoma Changed Over Time? A Study of Time Trends During the Past 15 years, Ann Surg Oncol, 2021. 28(3): p. 1700-1709., https://www.ncbi.nlm.nih.gov/pubmed/33073340
262. MacNeill, A. J., Gronchi, A., Miceli, R., Bonvalot, S., Swallow, C. J., Hohenberger, P., et.al. Postoperative Morbidity After Radical Resection of Primary Retroperitoneal Sarcoma: A Report From the Transatlantic RPS Working Group, Ann Surg, 2018. 267(5): p. 959-964., https://www.ncbi.nlm.nih.gov/pubmed/28394870
263. Peacock, O., Patel, S., Simpson, J. A., Walter, C. J., Humes, D. J., A systematic review of population-based studies examining outcomes in primary retroperitoneal sarcoma surgery, Surg Oncol, 2019. 29: p. 53-63., https://www.ncbi.nlm.nih.gov/pubmed/31196494
264. Bonvalot, S., Gronchi, A., Le Pechoux, C., Swallow, C. J., Strauss, D., Meeus, P., et.al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial, Lancet Oncol, 2020. 21(10): p. 1366-1377., https://www.ncbi.nlm.nih.gov/pubmed/32941794
265. Jakob, J., Simeonova, A., Kasper, B., Ronellenfitsch, U., Wenz, F., Hohenberger, P., Combined radiation therapy and sunitinib for preoperative treatment of soft tissue sarcoma, Ann Surg Oncol, 2015. 22(9): p. 2839-45., https://www.ncbi.nlm.nih.gov/pubmed/26085221
266. McBride, S. M., Raut, C. P., Lapidus, M., Devlin, P. M., Marcus, K. J., Bertagnolli, M., et.al. Locoregional recurrence after preoperative radiation therapy for retroperitoneal sarcoma: adverse impact of multifocal disease and potential implications of dose escalation, Ann Surg Oncol, 2013. 20(7): p. 2140-7., https://www.ncbi.nlm.nih.gov/pubmed/23392853
267. Yoon, S. S., Chen, Y. L., Kirsch, D. G., Maduekwe, U. N., Rosenberg, A. E., Nielsen, G. P., et.al. Proton-beam, intensity-modulated, and/or intraoperative electron radiation therapy combined with aggressive anterior surgical resection for retroperitoneal sarcomas, Ann Surg Oncol, 2010. 17(6): p. 1515-29., https://www.ncbi.nlm.nih.gov/pubmed/20151216
268. Bossi, A., De Wever, I., Van Limbergen, E., Vanstraelen, B., Intensity modulated radiation-therapy for preoperative posterior abdominal wall irradiation of retroperitoneal liposarcomas, Int J Radiat Oncol Biol Phys, 2007. 67(1): p. 164-70., https://www.ncbi.nlm.nih.gov/pubmed/17084556
269. Angele, M. K., Albertsmeier, M., Prix, N. J., Hohenberger, P., Abdel-Rahman, S., Dieterle, N., et.al. Effectiveness of regional hyperthermia with chemotherapy for high-risk retroperitoneal and abdominal soft-tissue sarcoma after complete surgical resection: a subgroup analysis of a randomized phase-III multicenter study, Ann Surg, 2014. 260(5): p. 749-54; discussion 754-6., https://www.ncbi.nlm.nih.gov/pubmed/25379845
270. Robert Koch Institut, Impfungen bei Asplenie (Entfernung der Milz oder Ausfall der Organfunktion), 2019., https://www.rki.de/SharedDocs/FAQ/Impfen/AllgFr_Grunderkrankungen/FAQ01.html, [abgerufen, am, 03.06.2019]
271. Issels, R. D., Lindner, L. H., Verweij, J., Wessalowski, R., Reichardt, P., Wust, P., et.al. Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial, JAMA Oncol, 2018. 4(4): p. 483-492., https://www.ncbi.nlm.nih.gov/pubmed/29450452
272. Pervaiz, N., Colterjohn, N., Farrokhyar, F., Tozer, R., Figueredo, A., Ghert, M., A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma, Cancer, 2008. 113(3): p. 573-81., https://www.ncbi.nlm.nih.gov/pubmed/18521899
273. Guideline of the DGGG and OEGGG (S2k-Level, AWMF Registry No.015/074, April 2021), Uterine sarcoma, 2021., https://www.awmf.org/leitlinien/detail/ll/015-074.html, [abgerufen, am, 25.05.2021]
274. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientinnen mit Endometriumkarzinom, 2018., https://www.leitlinienprogramm-onkologie.de/leitlinien/endometriumkarzinom/, [abgerufen, am, 24.06.2021]
275. Brooks, S. E., Zhan, M., Cote, T., Baquet, C. R., Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999, Gynecol Oncol, 2004. 93(1): p. 204-8., https://www.ncbi.nlm.nih.gov/pubmed/15047237
276. Wittekind, C., TNM Klassifikation maligner TumorenWiley-VCH Verlag, 2020.
277. Conklin, C. M., Longacre, T. A., Endometrial stromal tumors: the new WHO classification, Adv Anat Pathol, 2014. 21(6): p. 383-93., https://www.ncbi.nlm.nih.gov/pubmed/25299308
278. Oliva E., Carcangiu ML., Carinelli SG., Ip P., Loening T., Longacre TA., et.al. Mesenchymal Tumors of the Uterus, in WHO Classification of Tumours of Female Reproductive Tract, Kurman RJ.Carcangiu ML.Herrington CS. and Young RH., Editors. 2014, IARC Press: Lyon. p. 135-147.
279. Kapp, D. S., Shin, J. Y., Chan, J. K., Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy, Cancer, 2008. 112(4): p. 820-30., https://www.ncbi.nlm.nih.gov/pubmed/18189292
280. Garg, G., Shah, J. P., Liu, J. R., Bryant, C. S., Kumar, S., Munkarah, A., et.al. Validation of tumor size as staging variable in the revised International Federation of Gynecology and Obstetrics stage I leiomyosarcoma: a population-based study, Int J Gynecol Cancer, 2010. 20(7): p. 1201-6., https://www.ncbi.nlm.nih.gov/pubmed/20940535
281. Zaloudek CJ., Hendrickson MR., Soslow, RA., Mesenchymal Tumors of the Uterus, in Blaustein's Pathology of the Female Genital Tract, Kurman RJ.Hedrick Ellenson, L. and Ronnett, BM., Editors. 2011, Springer: New York, Dodrecht, Heidelberg, London.
282. Perri, T., Korach, J., Sadetzki, S., Oberman, B., Fridman, E., Ben-Baruch, G., Uterine leiomyosarcoma: does the primary surgical procedure matter?, Int J Gynecol Cancer, 2009. 19(2): p. 257-60., https://www.ncbi.nlm.nih.gov/pubmed/19396005
283. Park, J. Y., Park, S. K., Kim, D. Y., Kim, J. H., Kim, Y. M., Kim, Y. T., et.al. The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma, Gynecol Oncol, 2011. 122(2): p. 255-9., https://www.ncbi.nlm.nih.gov/pubmed/21565389
284. Leitao, M. M., Sonoda, Y., Brennan, M. F., Barakat, R. R., Chi, D. S., Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus, Gynecol Oncol, 2003. 91(1): p. 209-12., https://www.ncbi.nlm.nih.gov/pubmed/14529683
285. Einstein, M. H., Barakat, R. R., Chi, D. S., Sonoda, Y., Alektiar, K. M., Hensley, M. L., et.al. Management of uterine malignancy found incidentally after supracervical hysterectomy or uterine morcellation for presumed benign disease, Int J Gynecol Cancer, 2008. 18(5): p. 1065-70., https://www.ncbi.nlm.nih.gov/pubmed/17986239
286. Chan, J. K., Kawar, N. M., Shin, J. Y., Osann, K., Chen, L. M., Powell, C. B., et.al. Endometrial stromal sarcoma: a population-based analysis, Br J Cancer, 2008. 99(8): p. 1210-5., https://www.ncbi.nlm.nih.gov/pubmed/18813312
287. Bai, H., Yang, J., Cao, D., Huang, H., Xiang, Y., Wu, M., et.al. Ovary and uterus-sparing procedures for low-grade endometrial stromal sarcoma: a retrospective study of 153 cases, Gynecol Oncol, 2014. 132(3): p. 654-60., https://www.ncbi.nlm.nih.gov/pubmed/24412112
288. Amant, F., De Knijf, A., Van Calster, B., Leunen, K., Neven, P., Berteloot, P., et.al. Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma, Br J Cancer, 2007. 97(9): p. 1194-9., https://www.ncbi.nlm.nih.gov/pubmed/17895898
289. Shah, J. P., Bryant, C. S., Kumar, S., Ali-Fehmi, R., Malone, J. M., Jr., Morris, R. T., Lymphadenectomy and ovarian preservation in low-grade endometrial stromal sarcoma, Obstet Gynecol, 2008. 112(5): p. 1102-8., https://www.ncbi.nlm.nih.gov/pubmed/18978112
290. Beck, T. L., Singhal, P. K., Ehrenberg, H. M., Rose, P. G., Lele, S. B., Krivak, T. C., et.al. Endometrial stromal sarcoma: analysis of recurrence following adjuvant treatment, Gynecol Oncol, 2012. 125(1): p. 141-4., https://www.ncbi.nlm.nih.gov/pubmed/22119993
291. Amant, F., Coosemans, A., Debiec-Rychter, M., Timmerman, D., Vergote, I., Clinical management of uterine sarcomas, Lancet Oncol, 2009. 10(12): p. 1188-98., https://www.ncbi.nlm.nih.gov/pubmed/19959075
292. Barney, B., Tward, J. D., Skidmore, T., Gaffney, D. K., Does radiotherapy or lymphadenectomy improve survival in endometrial stromal sarcoma?, Int J Gynecol Cancer, 2009. 19(7): p. 1232-8., https://www.ncbi.nlm.nih.gov/pubmed/19823060
293. Leath, C. A., 3rd, Huh, W. K., Hyde, J., Jr., Cohn, D. E., Resnick, K. E., Taylor, N. P., et.al. A multi-institutional review of outcomes of endometrial stromal sarcoma, Gynecol Oncol, 2007. 105(3): p. 630-4., https://www.ncbi.nlm.nih.gov/pubmed/17320937
294. Hendrickson, MA., Tavassoli, FA., Kempson, RL., McCluggage, WG., Haller, U., Kubik-Huch, RA., Mesenchymal tumors and related lesions, in Pathology and Genetics of Tumours of the Breast and Female Genital Organs. World Health Organization Classification of Tumours, Tavassoli, FA. and Devilee, P., Editors. 2003, IARC Press. p. 233-249.
295. D'Angelo, E., Prat, J., Uterine sarcomas: a review, Gynecol Oncol, 2010. 116(1): p. 131-9., https://www.ncbi.nlm.nih.gov/pubmed/19853898
296. Schick, U., Bolukbasi, Y., Thariat, J., Abdah-Bortnyak, R., Kuten, A., Igdem, S., et.al. Outcome and prognostic factors in endometrial stromal tumors: a Rare Cancer Network study, Int J Radiat Oncol Biol Phys, 2012. 82(5): p. e757-63., https://www.ncbi.nlm.nih.gov/pubmed/22300565
297. Wu, T. I., Chou, H. H., Yeh, C. J., Hsueh, S., Yang, J. E., Jao, M. S., et.al. Clinicopathologic parameters and immunohistochemical study of endometrial stromal sarcomas, Int J Gynecol Pathol, 2013. 32(5): p. 482-92., https://www.ncbi.nlm.nih.gov/pubmed/23896713
298. Pautier, P., Nam, E. J., Provencher, D. M., Hamilton, A. L., Mangili, G., Siddiqui, N. A., et.al. Gynecologic Cancer InterGroup (GCIG) consensus review for high-grade undifferentiated sarcomas of the uterus, Int J Gynecol Cancer, 2014. 24(9 Suppl 3): p. S73-7., https://www.ncbi.nlm.nih.gov/pubmed/25341584
299. Yoon, A., Park, J. Y., Park, J. Y., Lee, Y. Y., Kim, T. J., Choi, C. H., et.al. Prognostic factors and outcomes in endometrial stromal sarcoma with the 2009 FIGO staging system: a multicenter review of 114 cases, Gynecol Oncol, 2014. 132(1): p. 70-5., https://www.ncbi.nlm.nih.gov/pubmed/24184602
300. Ring, A., Kirchhoff, P., Goertz, O., Behr, B., Daigeler, A., Lehnhardt, M., et.al. Reconstruction of Soft-Tissue Defects at the Foot and Ankle after Oncological Resection, Front Surg, 2016. 3: p. 15., https://www.ncbi.nlm.nih.gov/pubmed/27014697
301. Misra, A., Mistry, N., Grimer, R., Peart, F., The management of soft tissue sarcoma, J Plast Reconstr Aesthet Surg, 2009. 62(2): p. 161-74., https://www.ncbi.nlm.nih.gov/pubmed/19036655
302. Arbeit, J. M., Hilaris, B. S., Brennan, M. F., Wound complications in the multimodality treatment of extremity and superficial truncal sarcomas, J Clin Oncol, 1987. 5(3): p. 480-8., https://www.ncbi.nlm.nih.gov/pubmed/3819810
303. Kapalschinski, N., Goertz, O., Harati, K., Kueckelhaus, M., Kolbenschlag, J., Lehnhardt, M., et.al. Plastic Surgery in the Multimodal Treatment Concept of Soft Tissue Sarcoma: Influence of Radiation, Chemotherapy, and Isolated Limb Perfusion on Plastic Surgery Techniques, Front Oncol, 2015. 5: p. 268., https://www.ncbi.nlm.nih.gov/pubmed/26649280
304. Bannasch, H., Haivas, I., Momeni, A., Stark, G. B., Oncosurgical and reconstructive concepts in the treatment of soft tissue sarcomas: a retrospective analysis, Arch Orthop Trauma Surg, 2009. 129(1): p. 43-9., https://www.ncbi.nlm.nih.gov/pubmed/18210141
305. Odom, E. B., Qureshi, A. A., Mull, A. B., Rao, Y. J., Min, C., Hunter, D., et.al. The Impact of Radiation and Its Timing on Donor Internal Mammary Vessel Histopathology at the Time of Autologous Microvascular Breast Reconstruction, J Reconstr Microsurg, 2017. 33(7): p. 509-517., https://www.ncbi.nlm.nih.gov/pubmed/28493235
306. Penna, V., Iblher, N., Momeni, A., Stark, G. B., Bannasch, H., Free tissue transfer in reconstruction following soft tissue sarcoma resection, Microsurgery, 2011. 31(6): p. 434-40., https://www.ncbi.nlm.nih.gov/pubmed/21630335
307. Salzer-Kuntschik, M., Brand, G., Delling, G., [Determination of the degree of morphological regression following chemotherapy in malignant bone tumors], Pathologe, 1983. 4(3): p. 135-41., https://www.ncbi.nlm.nih.gov/pubmed/6576329
308. Weichselbaum, R. R., Beckett, M. A., Vijayakumar, S., Simon, M. A., Awan, A. M., Nachman, J., et.al. Radiobiological characterization of head and neck and sarcoma cells derived from patients prior to radiotherapy, Int J Radiat Oncol Biol Phys, 1990. 19(2): p. 313-9., https://www.ncbi.nlm.nih.gov/pubmed/2394610
309. Budach, W., Paulsen, F., Welz, S., Classen, J., Scheithauer, H., Marini, P., et.al. Mitomycin C in combination with radiotherapy as a potent inhibitor of tumour cell repopulation in a human squamous cell carcinoma, Br J Cancer, 2002. 86(3): p. 470-6., https://www.ncbi.nlm.nih.gov/pubmed/11875717
310. Budach, W., Budach, V., Dinges, S., Stuschke, M., Sack, H., Correlation between primary chemo- and radiation sensitivity in a panel of highly malignant human soft tissue sarcoma xenografts, Radiother Oncol, 1997. 42(2): p. 181-7., https://www.ncbi.nlm.nih.gov/pubmed/9106928
311. Kepka, L., DeLaney, T. F., Suit, H. D., Goldberg, S. I., Results of radiation therapy for unresected soft-tissue sarcomas, Int J Radiat Oncol Biol Phys, 2005. 63(3): p. 852-9., https://www.ncbi.nlm.nih.gov/pubmed/16199316
312. Pisters, P. W., Patel, S. R., Prieto, V. G., Thall, P. F., Lewis, V. O., Feig, B. W., et.al. Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas, J Clin Oncol, 2004. 22(16): p. 3375-80., https://www.ncbi.nlm.nih.gov/pubmed/15310783
313. MacDermed, D. M., Miller, L. L., Peabody, T. D., Simon, M. A., Luu, H. H., Haydon, R. C., et.al. Primary tumor necrosis predicts distant control in locally advanced soft-tissue sarcomas after preoperative concurrent chemoradiotherapy, Int J Radiat Oncol Biol Phys, 2010. 76(4): p. 1147-53., https://www.ncbi.nlm.nih.gov/pubmed/19577863
314. de Vreeze, R. S., de Jong, D., Haas, R. L., Stewart, F., van Coevorden, F., Effectiveness of radiotherapy in myxoid sarcomas is associated with a dense vascular pattern, Int J Radiat Oncol Biol Phys, 2008. 72(5): p. 1480-7., https://www.ncbi.nlm.nih.gov/pubmed/18448271
315. Beane, J. D., Yang, J. C., White, D., Steinberg, S. M., Rosenberg, S. A., Rudloff, U., Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial, Ann Surg Oncol, 2014. 21(8): p. 2484-9., https://www.ncbi.nlm.nih.gov/pubmed/24756814
316. Pisters, P. W., Harrison, L. B., Leung, D. H., Woodruff, J. M., Casper, E. S., Brennan, M. F., Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma, J Clin Oncol, 1996. 14(3): p. 859-68., https://www.ncbi.nlm.nih.gov/pubmed/8622034
317. Pisters, P. W., Harrison, L. B., Woodruff, J. M., Gaynor, J. J., Brennan, M. F., A prospective randomized trial of adjuvant brachytherapy in the management of low-grade soft tissue sarcomas of the extremity and superficial trunk, J Clin Oncol, 1994. 12(6): p. 1150-5., https://www.ncbi.nlm.nih.gov/pubmed/8201376
318. Brennan, M. F., Hilaris, B., Shiu, M. H., Lane, J., Magill, G., Friedrich, C., et.al. Local recurrence in adult soft-tissue sarcoma. A randomized trial of brachytherapy, Arch Surg, 1987. 122(11): p. 1289-93., https://www.ncbi.nlm.nih.gov/pubmed/3314794
319. Albertsmeier, M., Rauch, A., Roeder, F., Hasenhutl, S., Pratschke, S., Kirschneck, M., et.al. External Beam Radiation Therapy for Resectable Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis, Ann Surg Oncol, 2018. 25(3): p. 754-767., https://www.ncbi.nlm.nih.gov/pubmed/28895107
320. Qu, X., Lubitz, C. C., Rickard, J., Bergeron, S. G., Wasif, N., A Meta-Analysis of the Association Between Radiation Therapy and Survival for Surgically Resected Soft-Tissue Sarcoma, Am J Clin Oncol, 2018. 41(4): p. 348-356., https://www.ncbi.nlm.nih.gov/pubmed/26886948
321. Delaney, T. F., Kepka, L., Goldberg, S. I., Hornicek, F. J., Gebhardt, M. C., Yoon, S. S., et.al. Radiation therapy for control of soft-tissue sarcomas resected with positive margins, Int J Radiat Oncol Biol Phys, 2007. 67(5): p. 1460-9., https://www.ncbi.nlm.nih.gov/pubmed/17394945
322. Cassier, P. A., Kantor, G., Bonvalot, S., Lavergne, E., Stoeckle, E., Le Pechoux, C., et.al. Adjuvant radiotherapy for extremity and trunk wall atypical lipomatous tumor/well-differentiated LPS (ALT/WD-LPS): a French Sarcoma Group (GSF-GETO) study, Ann Oncol, 2014. 25(9): p. 1854-1860., https://www.ncbi.nlm.nih.gov/pubmed/24914041
323. Huang, J., Barbera, L., Brouwers, M., Browman, G., Mackillop, W. J., Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review, J Clin Oncol, 2003. 21(3): p. 555-63., https://www.ncbi.nlm.nih.gov/pubmed/12560449
324. Suwinski, R., Sowa, A., Rutkowski, T., Wydmanski, J., Tarnawski, R., Maciejewski, B., Time factor in postoperative radiotherapy: a multivariate locoregional control analysis in 868 patients, Int J Radiat Oncol Biol Phys, 2003. 56(2): p. 399-412., https://www.ncbi.nlm.nih.gov/pubmed/12738315
325. Ballo, M. T., Zagars, G. K., Cormier, J. N., Hunt, K. K., Feig, B. W., Patel, S. R., et.al. Interval between surgery and radiotherapy: effect on local control of soft tissue sarcoma, Int J Radiat Oncol Biol Phys, 2004. 58(5): p. 1461-7., https://www.ncbi.nlm.nih.gov/pubmed/15050324
326. Schwartz, D. L., Einck, J., Hunt, K., Bruckner, J., Conrad, E., Koh, W. J., et.al. The effect of delayed postoperative irradiation on local control of soft tissue sarcomas of the extremity and torso, Int J Radiat Oncol Biol Phys, 2002. 52(5): p. 1352-9., https://www.ncbi.nlm.nih.gov/pubmed/11955749
327. Fein, D. A., Lee, W. R., Lanciano, R. M., Corn, B. W., Herbert, S. H., Hanlon, A. L., et.al. Management of extremity soft tissue sarcomas with limb-sparing surgery and postoperative irradiation: do total dose, overall treatment time, and the surgery-radiotherapy interval impact on local control?, Int J Radiat Oncol Biol Phys, 1995. 32(4): p. 969-76., https://www.ncbi.nlm.nih.gov/pubmed/7607971
328. O'Sullivan, B., Davis, A. M., Turcotte, R., Bell, R., Catton, C., Chabot, P., et.al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial, Lancet, 2002. 359(9325): p. 2235-41., https://www.ncbi.nlm.nih.gov/pubmed/12103287
329. Pawlik, T. M., Pisters, P. W., Mikula, L., Feig, B. W., Hunt, K. K., Cormier, J. N., et.al. Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma, Ann Surg Oncol, 2006. 13(4): p. 508-17., https://www.ncbi.nlm.nih.gov/pubmed/16491338
330. Davis, A. M., O'Sullivan, B., Turcotte, R., Bell, R., Catton, C., Chabot, P., et.al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma, Radiother Oncol, 2005. 75(1): p. 48-53., https://www.ncbi.nlm.nih.gov/pubmed/15948265
331. Sampath, S., Schultheiss, T. E., Hitchcock, Y. J., Randall, R. L., Shrieve, D. C., Wong, J. Y., Preoperative versus postoperative radiotherapy in soft-tissue sarcoma: multi-institutional analysis of 821 patients, Int J Radiat Oncol Biol Phys, 2011. 81(2): p. 498-505., https://www.ncbi.nlm.nih.gov/pubmed/20888702
332. Dagan, R., Indelicato, D. J., McGee, L., Morris, C. G., Kirwan, J. M., Knapik, J., et.al. The significance of a marginal excision after preoperative radiation therapy for soft tissue sarcoma of the extremity, Cancer, 2012. 118(12): p. 3199-207., https://www.ncbi.nlm.nih.gov/pubmed/22020375
333. Al Yami, A., Griffin, A. M., Ferguson, P. C., Catton, C. N., Chung, P. W., Bell, R. S., et.al. Positive surgical margins in soft tissue sarcoma treated with preoperative radiation: is a postoperative boost necessary?, Int J Radiat Oncol Biol Phys, 2010. 77(4): p. 1191-7., https://www.ncbi.nlm.nih.gov/pubmed/20056340
334. Jones, J. J., Catton, C. N., O'Sullivan, B., Couture, J., Heisler, R. L., Kandel, R. A., et.al. Initial results of a trial of preoperative external-beam radiation therapy and postoperative brachytherapy for retroperitoneal sarcoma, Ann Surg Oncol, 2002. 9(4): p. 346-54., https://www.ncbi.nlm.nih.gov/pubmed/11986186
335. Karthik, N., Ward, M. C., Juloori, A., Scott, J., Mesko, N., Shah, C., Factors Associated With Acute and Chronic Wound Complications in Patients With Soft Tissue Sarcoma With Long-term Follow-up, Am J Clin Oncol, 2018. 41(10): p. 1019-1023., https://www.ncbi.nlm.nih.gov/pubmed/29315173
336. Eckert, F., Braun, L. H., Traub, F., Kopp, H. G., Sipos, B., Lamprecht, U., et.al. Radiotherapy and hyperthermia with curative intent in recurrent high risk soft tissue sarcomas, Int J Hyperthermia, 2018. 34(7): p. 980-987., https://www.ncbi.nlm.nih.gov/pubmed/28826283
337. Eckert, F., Matuschek, C., Mueller, A. C., Weinmann, M., Hartmann, J. T., Belka, C., et.al. Definitive radiotherapy and single-agent radiosensitizing ifosfamide in patients with localized, irresectable soft tissue sarcoma: a retrospective analysis, Radiat Oncol, 2010. 5: p. 55., https://www.ncbi.nlm.nih.gov/pubmed/20553599
338. Aiba, H., Yamada, S., Mizutani, J., Yamamoto, N., Okamoto, H., Hayashi, K., et.al. Efficacy of radio-hyperthermo-chemotherapy as salvage therapy for recurrent or residual malignant soft tissue tumors, Int J Hyperthermia, 2018. 35(1): p. 658-666., https://www.ncbi.nlm.nih.gov/pubmed/30295115
339. Nathenson, M. J., Sausville, E., Looking for answers: the current status of neoadjuvant treatment in localized soft tissue sarcomas, Cancer Chemother Pharmacol, 2016. 78(5): p. 895-919., https://www.ncbi.nlm.nih.gov/pubmed/27206640
340. Unsoeld, M., Lamprecht, U., Traub, F., Hermes, B., Scharpf, M., Potkrajcic, V., et.al. MR Thermometry Data Correlate with Pathological Response for Soft Tissue Sarcoma of the Lower Extremity in a Single Center Analysis of Prospectively Registered Patients, Cancers (Basel), 2020. 12(4):, https://www.ncbi.nlm.nih.gov/pubmed/32295076
341. Schmitt, T., Lehner, B., Kasper, B., Bischof, M., Roeder, F., Dietrich, S., et.al. A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma, BMC Cancer, 2011. 11: p. 510., https://www.ncbi.nlm.nih.gov/pubmed/22152120
342. Nakano, H., Higaki, S., Tateishi, A., The efficacy of hyperthermia combined with radiation therapy for high-grade soft tissue sarcoma, Anticancer Res, 1998. 18(2B): p. 1319-23., https://www.ncbi.nlm.nih.gov/pubmed/9615809
343. Makihata, E., Kuroda, M., Kawai, A., Ozaki, T., Sugihara, S., Inoue, H., et.al. Preoperative multidisciplinary treatment with hyperthermia for soft tissue sarcoma, Acta Med Okayama, 1997. 51(2): p. 93-9., https://www.ncbi.nlm.nih.gov/pubmed/9142346
344. Uno, T., Itami, J., Kato, H., Combined chemo-radiation and hyperthermia for locally advanced soft tissue sarcoma: response and toxicity, Anticancer Res, 1995. 15(6B): p. 2655-7., https://www.ncbi.nlm.nih.gov/pubmed/8669842
345. Oertel, S., Treiber, M., Zahlten-Hinguranage, A., Eichin, S., Roeder, F., Funk, A., et.al. Intraoperative electron boost radiation followed by moderate doses of external beam radiotherapy in limb-sparing treatment of patients with extremity soft-tissue sarcoma, Int J Radiat Oncol Biol Phys, 2006. 64(5): p. 1416-23., https://www.ncbi.nlm.nih.gov/pubmed/16413697
346. Sindelar, W. F., Kinsella, T. J., Chen, P. W., DeLaney, T. F., Tepper, J. E., Rosenberg, S. A., et.al. Intraoperative radiotherapy in retroperitoneal sarcomas. Final results of a prospective, randomized, clinical trial, Arch Surg, 1993. 128(4): p. 402-10., https://www.ncbi.nlm.nih.gov/pubmed/8457152
347. Sampath, S., Hitchcock, Y. J., Shrieve, D. C., Randall, R. L., Schultheiss, T. E., Wong, J. Y., Radiotherapy and extent of surgical resection in retroperitoneal soft-tissue sarcoma: multi-institutional analysis of 261 patients, J Surg Oncol, 2010. 101(5): p. 345-50., https://www.ncbi.nlm.nih.gov/pubmed/20119974
348. Pisters, P. W., O'Sullivan, B., Retroperitoneal sarcomas: combined modality treatment approaches, Curr Opin Oncol, 2002. 14(4): p. 400-5., https://www.ncbi.nlm.nih.gov/pubmed/12130924
349. Ballo, M. T., Zagars, G. K., Pollock, R. E., Benjamin, R. S., Feig, B. W., Cormier, J. N., et.al. Retroperitoneal soft tissue sarcoma: an analysis of radiation and surgical treatment, Int J Radiat Oncol Biol Phys, 2007. 67(1): p. 158-63., https://www.ncbi.nlm.nih.gov/pubmed/17084545
350. Sourrouille, I., Macovei, R., Faron, M., Le Pechoux, C., Mir, O., Adam, J., et.al. Long-Term Outcome After Surgery for a Localized Retroperitoneal Soft Tissue Sarcoma in Elderly Patients: Results from a Retrospective, Single-Center Study, Ann Surg Oncol, 2018. 25(8): p. 2201-2208., https://www.ncbi.nlm.nih.gov/pubmed/29797115
351. Gronchi, A., De Paoli, A., Dani, C., Merlo, D. F., Quagliuolo, V., Grignani, G., et.al. Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma Group, Eur J Cancer, 2014. 50(4): p. 784-92., https://www.ncbi.nlm.nih.gov/pubmed/24316063
352. Wang, D., Bosch, W., Roberge, D., Finkelstein, S. E., Petersen, I., Haddock, M., et.al. RTOG sarcoma radiation oncologists reach consensus on gross tumor volume and clinical target volume on computed tomographic images for preoperative radiotherapy of primary soft tissue sarcoma of extremity in Radiation Therapy Oncology Group studies, Int J Radiat Oncol Biol Phys, 2011. 81(4): p. e525-8., https://www.ncbi.nlm.nih.gov/pubmed/21676552
353. Wang, D., Zhang, Q., Eisenberg, B. L., Kane, J. M., Li, X. A., Lucas, D., et.al. Significant Reduction of Late Toxicities in Patients With Extremity Sarcoma Treated With Image-Guided Radiation Therapy to a Reduced Target Volume: Results of Radiation Therapy Oncology Group RTOG-0630 Trial, J Clin Oncol, 2015. 33(20): p. 2231-8., https://www.ncbi.nlm.nih.gov/pubmed/25667281
354. Issels, R., Kampmann, E., Kanaar, R., Lindner, L. H., Hallmarks of hyperthermia in driving the future of clinical hyperthermia as targeted therapy: translation into clinical application, Int J Hyperthermia, 2016. 32(1): p. 89-95., https://www.ncbi.nlm.nih.gov/pubmed/26803991
355. Issels, R. D., Lindner, L. H., Verweij, J., Wust, P., Reichardt, P., Schem, B. C., et.al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study, Lancet Oncol, 2010. 11(6): p. 561-70., https://www.ncbi.nlm.nih.gov/pubmed/20434400
356. Jakob, J., Hohenberger, P., Role of isolated limb perfusion with recombinant human tumor necrosis factor alpha and melphalan in locally advanced extremity soft tissue sarcoma, Cancer, 2016. 122(17): p. 2624-32., https://www.ncbi.nlm.nih.gov/pubmed/27197621
357. Krementz, E. T., Lucy Wortham James lecture. Regional perfusion. Current sophistication, what next?, Cancer, 1986. 57(3): p. 416-32., https://www.ncbi.nlm.nih.gov/pubmed/3080216
358. Hohenberger, P., Haier, J., Schlag, P. M., Rhabdomyolysis and renal function impairment after isolated limb perfusion--comparison between the effects of perfusion with rhTNF alpha and a 'triple-drug' regimen, Eur J Cancer, 1997. 33(4): p. 596-601., https://www.ncbi.nlm.nih.gov/pubmed/9274441
359. Wieberdink, J., Benckhuysen, C., Braat, R. P., van Slooten, E. A., Olthuis, G. A., Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions, Eur J Cancer Clin Oncol, 1982. 18(10): p. 905-10., https://www.ncbi.nlm.nih.gov/pubmed/6891640
360. Locksley, R. M., Killeen, N., Lenardo, M. J., The TNF and TNF receptor superfamilies: integrating mammalian biology, Cell, 2001. 104(4): p. 487-501., https://www.ncbi.nlm.nih.gov/pubmed/11239407
361. Lenk, H., Tanneberger, S., Muller, U., Ebert, J., Shiga, T., Phase II clinical trial of high-dose recombinant human tumor necrosis factor, Cancer Chemother Pharmacol, 1989. 24(6): p. 391-2., https://www.ncbi.nlm.nih.gov/pubmed/2791193
362. Hohenberger, P., Latz, E., Kettelhack, C., Rezaei, A. H., Schumann, R., Schlag, P. M., Pentoxifyllin attenuates the systemic inflammatory response induced during isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan, Ann Surg Oncol, 2003. 10(5): p. 562-8., https://www.ncbi.nlm.nih.gov/pubmed/12794024
363. Lienard, D., Ewalenko, P., Delmotte, J. J., Renard, N., Lejeune, F. J., High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma, J Clin Oncol, 1992. 10(1): p. 52-60., https://www.ncbi.nlm.nih.gov/pubmed/1727926
364. Lejeune, F. J., Ruegg, C., Recombinant human tumor necrosis factor: an efficient agent for cancer treatment, Bull Cancer, 2006. 93(8): p. E90-100., https://www.ncbi.nlm.nih.gov/pubmed/16935777
365. Rastrelli, M., Campana, L. G., Valpione, S., Tropea, S., Zanon, A., Rossi, C. R., Hyperthermic isolated limb perfusion in locally advanced limb soft tissue sarcoma: A 24-year single-centre experience, Int J Hyperthermia, 2016. 32(2): p. 165-72., https://www.ncbi.nlm.nih.gov/pubmed/26608883
366. Schwarzbach, M., Lehnert, T., Willeke, F., Hinz, U., Herfarth, C., [Results of isolated hyperthermic extremity perfusion in soft tissue sarcomas within the scope of a multimodality treatment concept], Chirurg, 1996. 67(12): p. 1237-43., https://www.ncbi.nlm.nih.gov/pubmed/9081786
367. Eggermont, A. M., Schraffordt Koops, H., Klausner, J. M., Kroon, B. B., Schlag, P. M., Lienard, D., et.al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience, Ann Surg, 1996. 224(6): p. 756-64; discussion 764-5., https://www.ncbi.nlm.nih.gov/pubmed/8968230
368. Bonvalot, S., Laplanche, A., Lejeune, F., Stoeckle, E., Le Pechoux, C., Vanel, D., et.al. Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better?, Ann Oncol, 2005. 16(7): p. 1061-8., https://www.ncbi.nlm.nih.gov/pubmed/15930042
369. Pennacchioli, E., Deraco, M., Mariani, L., Fiore, M., Mussi, C., Collini, P., et.al. Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution, Ann Surg Oncol, 2007. 14(2): p. 553-9., https://www.ncbi.nlm.nih.gov/pubmed/17122991
370. Cherix, S., Speiser, M., Matter, M., Raffoul, W., Lienard, D., Theumann, N., et.al. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients, J Surg Oncol, 2008. 98(3): p. 148-55., https://www.ncbi.nlm.nih.gov/pubmed/18668638
371. Grabellus, F., Kraft, C., Sheu-Grabellus, S. Y., Bauer, S., Podleska, L. E., Lauenstein, T. C., et.al. Tumor vascularization and histopathologic regression of soft tissue sarcomas treated with isolated limb perfusion with TNF-alpha and melphalan, J Surg Oncol, 2011. 103(5): p. 371-9., https://www.ncbi.nlm.nih.gov/pubmed/21400518
372. Hoven-Gondrie, M. L., Bastiaannet, E., van Ginkel, R. J., Suurmeijer, A. J., Hoekstra, H. J., TNF dose reduction and shortening of duration of isolated limb perfusion for locally advanced soft tissue sarcoma of the extremities is safe and effective in terms of long-term patient outcome, J Surg Oncol, 2011. 103(7): p. 648-55., https://www.ncbi.nlm.nih.gov/pubmed/21337343
373. Jakob, J., Tunn, P. U., Hayes, A. J., Pilz, L. R., Nowak, K., Hohenberger, P., Oncological outcome of primary non-metastatic soft tissue sarcoma treated by neoadjuvant isolated limb perfusion and tumor resection, J Surg Oncol, 2014. 109(8): p. 786-90., https://www.ncbi.nlm.nih.gov/pubmed/24619722
374. Jakob, J., Smith, H. G., Wilkinson, M. J., Pencavel, T., Miah, A. B., Thomas, J. M., et.al. Regional chemotherapy by isolated limb perfusion prior to surgery compared with surgery and post-operative radiotherapy for primary, locally advanced extremity sarcoma: a comparison of matched cohorts, Clin Sarcoma Res, 2018. 8: p. 12., https://www.ncbi.nlm.nih.gov/pubmed/29988594
375. Gronchi, A., Ferrari, S., Quagliuolo, V., Broto, J. M., Pousa, A. L., Grignani, G., et.al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial, Lancet Oncol, 2017. 18(6): p. 812-822., https://www.ncbi.nlm.nih.gov/pubmed/28499583
376. Callegaro, D., Miceli, R., Mariani, L., Raut, C. P., Gronchi, A., Soft tissue sarcoma nomograms and their incorporation into practice, Cancer, 2017. 123(15): p. 2802-2820., https://www.ncbi.nlm.nih.gov/pubmed/28493287
377. Meric, F., Hess, K. R., Varma, D. G., Hunt, K. K., Pisters, P. W., Milas, K. M., et.al. Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas, Cancer, 2002. 95(5): p. 1120-6., https://www.ncbi.nlm.nih.gov/pubmed/12209699
378. Kraybill, W. G., Harris, J., Spiro, I. J., Ettinger, D. S., DeLaney, T. F., Blum, R. H., et.al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514, J Clin Oncol, 2006. 24(4): p. 619-25., https://www.ncbi.nlm.nih.gov/pubmed/16446334
379. Frustaci, S., Gherlinzoni, F., De Paoli, A., Bonetti, M., Azzarelli, A., Comandone, A., et.al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial, J Clin Oncol, 2001. 19(5): p. 1238-47., https://www.ncbi.nlm.nih.gov/pubmed/11230464
380. Gronchi, A., Frustaci, S., Mercuri, M., Martin, J., Lopez-Pousa, A., Verderio, P., et.al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group, J Clin Oncol, 2012. 30(8): p. 850-6., https://www.ncbi.nlm.nih.gov/pubmed/22312103
381. Gronchi, A., Stacchiotti, S., Verderio, P., Ferrari, S., Martin Broto, J., Lopez-Pousa, A., et.al. Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group, Ann Oncol, 2016. 27(12): p. 2283-2288., https://www.ncbi.nlm.nih.gov/pubmed/27733375
382. Antman, K., Suit, H., Amato, D., Corson, J., Wood, W., Proppe, K., et.al. Preliminary results of a randomized trial of adjuvant doxorubicin for sarcomas: lack of apparent difference between treatment groups, J Clin Oncol, 1984. 2(6): p. 601-8., https://www.ncbi.nlm.nih.gov/pubmed/6374055
383. Brodowicz, T., Schwameis, E., Widder, J., Amann, G., Wiltschke, C., Dominkus, M., et.al. Intensified Adjuvant IFADIC Chemotherapy for Adult Soft Tissue Sarcoma: A Prospective Randomized Feasibility Trial, Sarcoma, 2000. 4(4): p. 151-60., https://www.ncbi.nlm.nih.gov/pubmed/18521295
384. Chang, A. E., Kinsella, T., Glatstein, E., Baker, A. R., Sindelar, W. F., Lotze, M. T., et.al. Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremity, J Clin Oncol, 1988. 6(9): p. 1491-500., https://www.ncbi.nlm.nih.gov/pubmed/3047339
385. Eilber, F. R., Giuliano, A. E., Huth, J. F., Morton, D. L., A randomized prospective trial using postoperative adjuvant chemotherapy (adriamycin) in high-grade extremity soft-tissue sarcoma, Am J Clin Oncol, 1988. 11(1): p. 39-45., https://www.ncbi.nlm.nih.gov/pubmed/3341273
386. Gherlinzoni, F., Bacci, G., Picci, P., Capanna, R., Calderoni, P., Lorenzi, E. G., et.al. A randomized trial for the treatment of high-grade soft-tissue sarcomas of the extremities: preliminary observations, J Clin Oncol, 1986. 4(4): p. 552-8., https://www.ncbi.nlm.nih.gov/pubmed/3514804
387. Glenn, J., Kinsella, T., Glatstein, E., Tepper, J., Baker, A., Sugarbaker, P., et.al. A randomized, prospective trial of adjuvant chemotherapy in adults with soft tissue sarcomas of the head and neck, breast, and trunk, Cancer, 1985. 55(6): p. 1206-14., https://www.ncbi.nlm.nih.gov/pubmed/3882217
388. Lerner, H. J., Amato, D. A., Savlov, E. D., DeWys, W. D., Mittleman, A., Urtasun, R. C., et.al. Eastern Cooperative Oncology Group: a comparison of adjuvant doxorubicin and observation for patients with localized soft tissue sarcoma, J Clin Oncol, 1987. 5(4): p. 613-7., https://www.ncbi.nlm.nih.gov/pubmed/3549990
389. Omura, G. A., Blessing, J. A., Major, F., Lifshitz, S., Ehrlich, C. E., Mangan, C., et.al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study, J Clin Oncol, 1985. 3(9): p. 1240-5., https://www.ncbi.nlm.nih.gov/pubmed/3897471
390. Pautier, P., Floquet, A., Gladieff, L., Bompas, E., Ray-Coquard, I., Piperno-Neumann, S., et.al. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group, Ann Oncol, 2013. 24(4): p. 1099-104., https://www.ncbi.nlm.nih.gov/pubmed/23139262
391. Woll, P. J., Reichardt, P., Le Cesne, A., Bonvalot, S., Azzarelli, A., Hoekstra, H. J., et.al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial, Lancet Oncol, 2012. 13(10): p. 1045-54., https://www.ncbi.nlm.nih.gov/pubmed/22954508
392. Alvegard, T. A., Sigurdsson, H., Mouridsen, H., Solheim, O., Unsgaard, B., Ringborg, U., et.al. Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group, J Clin Oncol, 1989. 7(10): p. 1504-13., https://www.ncbi.nlm.nih.gov/pubmed/2674336
393. Rosenberg, S. A., Tepper, J., Glatstein, E., Costa, J., Young, R., Baker, A., et.al. Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities, Cancer, 1983. 52(3): p. 424-34., https://www.ncbi.nlm.nih.gov/pubmed/6344981
394. Bramwell, V., Rouesse, J., Steward, W., Santoro, A., Schraffordt-Koops, H., Buesa, J., et.al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, J Clin Oncol, 1994. 12(6): p. 1137-49., https://www.ncbi.nlm.nih.gov/pubmed/8201375
395. Edmonson, J. H., Fleming, T. R., Ivins, J. C., Burgert, E. O., Jr., Soule, E. H., O'Connell, M. J., et.al. Randomized study of systemic chemotherapy following complete excision of nonosseous sarcomas, J Clin Oncol, 1984. 2(12): p. 1390-6., https://www.ncbi.nlm.nih.gov/pubmed/6512582
396. Sarcoma Meta-analysis, Collaboration, Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults, Cochrane Database Syst Rev, 2000. p. CD001419., https://www.ncbi.nlm.nih.gov/pubmed/11034717
397. Frustaci, S., De Paoli, A., Bidoli, E., La Mura, N., Berretta, M., Buonadonna, A., et.al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas, Oncology, 2003. 65 Suppl 2: p. 80-4., https://www.ncbi.nlm.nih.gov/pubmed/14586155
398. Italiano, A., Delva, F., Mathoulin-Pelissier, S., Le Cesne, A., Bonvalot, S., Terrier, P., et.al. Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database, Ann Oncol, 2010. 21(12): p. 2436-2441., https://www.ncbi.nlm.nih.gov/pubmed/20439343
399. Group, E. SMO/European Sarcoma Network Working, Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 2014. 25 Suppl 3: p. iii102-12., https://www.ncbi.nlm.nih.gov/pubmed/25210080
400. Novais, E. N., Demiralp, B., Alderete, J., Larson, M. C., Rose, P. S., Sim, F. H., Do surgical margin and local recurrence influence survival in soft tissue sarcomas?, Clin Orthop Relat Res, 2010. 468(11): p. 3003-11., https://www.ncbi.nlm.nih.gov/pubmed/20645035
401. Arvinius, C., Torrecilla, E., Beano-Collado, J., Garcia-Coiradas, J., Garcia-Maroto, R., Puerto-Vazquez, M., et.al. A clinical review of 11 cases of large-sized well-differentiated liposarcomas, Eur J Orthop Surg Traumatol, 2017. 27(6): p. 837-841., https://www.ncbi.nlm.nih.gov/pubmed/28536819
402. Mussi, C. E., Daolio, P., Cimino, M., Giardina, F., De Sanctis, R., Morenghi, E., et.al. Atypical lipomatous tumors: should they be treated like other sarcoma or not? Surgical consideration from a bi-institutional experience, Ann Surg Oncol, 2014. 21(13): p. 4090-7., https://www.ncbi.nlm.nih.gov/pubmed/24962938
403. Kito, M., Yoshimura, Y., Isobe, K., Aoki, K., Momose, T., Suzuki, S., et.al. Clinical outcome of deep-seated atypical lipomatous tumor of the extremities with median-term follow-up study, Eur J Surg Oncol, 2015. 41(3): p. 400-6., https://www.ncbi.nlm.nih.gov/pubmed/25498358
404. Mavrogenis, A. F., Lesensky, J., Romagnoli, C., Alberghini, M., Letson, G. D., Ruggieri, P., Atypical lipomatous tumors/well-differentiated liposarcomas: clinical outcome of 67 patients, Orthopedics, 2011. 34(12): p. e893-8., https://www.ncbi.nlm.nih.gov/pubmed/22146207
405. Grabellus, F., Podleska, L. E., Sheu, S. Y., Bauer, S., Pottgen, C., Kloeters, C., et.al. Neoadjuvant treatment improves capsular integrity and the width of the fibrous capsule of high-grade soft-tissue sarcomas, Eur J Surg Oncol, 2013. 39(1): p. 61-7., https://www.ncbi.nlm.nih.gov/pubmed/23103117
406. White, L. M., Wunder, J. S., Bell, R. S., O'Sullivan, B., Catton, C., Ferguson, P., et.al. Histologic assessment of peritumoral edema in soft tissue sarcoma, Int J Radiat Oncol Biol Phys, 2005. 61(5): p. 1439-45., https://www.ncbi.nlm.nih.gov/pubmed/15817348
407. Grabellus, F., Kraft, C., Sheu, S. Y., Ebeling, P., Bauer, S., Lendemans, S., et.al. Evaluation of 47 soft tissue sarcoma resection specimens after isolated limb perfusion with TNF-alpha and melphalan: histologically characterized improved margins correlate with absence of recurrences, Ann Surg Oncol, 2009. 16(3): p. 676-86., https://www.ncbi.nlm.nih.gov/pubmed/19130134
408. Pasquali, S., Pizzamiglio, S., Touati, N., Litiere, S., Marreaud, S., Kasper, B., et.al. The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial, Eur J Cancer, 2019. 109: p. 51-60., https://www.ncbi.nlm.nih.gov/pubmed/30690293
409. Judson, I., Verweij, J., Gelderblom, H., Hartmann, J. T., Schoffski, P., Blay, J. Y., et.al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial, Lancet Oncol, 2014. 15(4): p. 415-23., https://www.ncbi.nlm.nih.gov/pubmed/24618336
410. Gronchi, A., Bui, B. N., Bonvalot, S., Pilotti, S., Ferrari, S., Hohenberger, P., et.al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma, Ann Oncol, 2012. 23(3): p. 771-776., https://www.ncbi.nlm.nih.gov/pubmed/21642514
411. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren, Langversion 4.0, 2020, AWMF-Registernummer: 032/035OL, 2020., https://www.leitlinienprogramm-onkologie.de/leitlinien/ovarialkarzinom/, [abgerufen, am, 09.11.2020]
412. Gysels, M., Higginson, I. J., Interactive technologies and videotapes for patient education in cancer care: systematic review and meta-analysis of randomised trials, Support Care Cancer, 2007. 15(1): p. 7-20., https://www.ncbi.nlm.nih.gov/pubmed/17024500
413. Wofford, J. L., Smith, E. D., Miller, D. P., The multimedia computer for office-based patient education: a systematic review, Patient Educ Couns, 2005. 59(2): p. 148-57., https://www.ncbi.nlm.nih.gov/pubmed/16257619
414. Beauchamp, Tom L, Childress, James F, Principles of biomedical ethicsOxford University Press, USA, 2001.
415. NHS Centre for Reviews and Disseminations, Effective Health Care - Informing, communicating and sharing decisions with people who have cancer, 2000. 6(6): p. 1-8.
416. Wright, E. B., Holcombe, C., Salmon, P., Doctors' communication of trust, care, and respect in breast cancer: qualitative study, BMJ, 2004. 328(7444): p. 864., https://www.ncbi.nlm.nih.gov/pubmed/15054034
417. Weis, J., Giesler, J. M., Subjective dimensions of patient competence: relationships with selected healthcare usage behaviors and general features of self-rated competence, Patient Educ Couns, 2008. 73(3): p. 511-8., https://www.ncbi.nlm.nih.gov/pubmed/18952394
418. Jansen, S. J., Otten, W., Baas-Thijssen, M. C., van de Velde, C. J., Nortier, J. W., Stiggelbout, A. M., Explaining differences in attitude toward adjuvant chemotherapy between experienced and inexperienced breast cancer patients, J Clin Oncol, 2005. 23(27): p. 6623-30., https://www.ncbi.nlm.nih.gov/pubmed/16170169
419. Katz, S. J., Lantz, P. M., Janz, N. K., Fagerlin, A., Schwartz, K., Liu, L., et.al. Patient involvement in surgery treatment decisions for breast cancer, J Clin Oncol, 2005. 23(24): p. 5526-33., https://www.ncbi.nlm.nih.gov/pubmed/16110013
420. Wagner, K., Koller, M., Keil, A., Trott, D., Engenhart-Cabillic, R., Pfab, R., et.al. [Radiotherapy in surgical and nonsurgical patients. Therapy expectations, quality of life and physician assessment], Chirurg, 1998. 69(3): p. 252-8., https://www.ncbi.nlm.nih.gov/pubmed/9576035
421. Bruera, E., Willey, J. S., Palmer, J. L., Rosales, M., Treatment decisions for breast carcinoma: patient preferences and physician perceptions, Cancer, 2002. 94(7): p. 2076-80., https://www.ncbi.nlm.nih.gov/pubmed/11932912
422. Butow, P., Harrison, J. D., Choy, E. T., Young, J. M., Spillane, A., Evans, A., Health professional and consumer views on involving breast cancer patients in the multidisciplinary discussion of their disease and treatment plan, Cancer, 2007. 110(9): p. 1937-44., https://www.ncbi.nlm.nih.gov/pubmed/17823912
423. Elkin, E. B., Kim, S. H., Casper, E. S., Kissane, D. W., Schrag, D., Desire for information and involvement in treatment decisions: elderly cancer patients' preferences and their physicians' perceptions, J Clin Oncol, 2007. 25(33): p. 5275-80., https://www.ncbi.nlm.nih.gov/pubmed/18024875
424. Ford, S., Schofield, T., Hope, T., Observing decision-making in the general practice consultation: who makes which decisions?, Health Expect, 2006. 9(2): p. 130-7., https://www.ncbi.nlm.nih.gov/pubmed/16677192
425. Politi, M. C., Han, P. K., Col, N. F., Communicating the uncertainty of harms and benefits of medical interventions, Med Decis Making, 2007. 27(5): p. 681-95., https://www.ncbi.nlm.nih.gov/pubmed/17873256
426. Albert, U. S., Koller, M., Wagner, U., Schulz, K. D., Survival chances and psychological aspects of quality of life in patients with localized early stage breast cancer, Inflamm Res, 2004. 53 Suppl 2: p. S136-41., https://www.ncbi.nlm.nih.gov/pubmed/15338065
427. Chouliara, Z., Kearney, N., Stott, D., Molassiotis, A., Miller, M., Perceptions of older people with cancer of information, decision making and treatment: a systematic review of selected literature, Ann Oncol, 2004. 15(11): p. 1596-602., https://www.ncbi.nlm.nih.gov/pubmed/15520059
428. Hagerty, R. G., Butow, P. N., Ellis, P. M., Dimitry, S., Tattersall, M. H., Communicating prognosis in cancer care: a systematic review of the literature, Ann Oncol, 2005. 16(7): p. 1005-53., https://www.ncbi.nlm.nih.gov/pubmed/15939716
429. Kinnersley, P., Edwards, A., Hood, K., Ryan, R., Prout, H., Cadbury, N., et.al. Interventions before consultations to help patients address their information needs by encouraging question asking: systematic review, BMJ, 2008. 337: p. a485., https://www.ncbi.nlm.nih.gov/pubmed/18632672
430. Thomas, R., Richardson, A., The NICE guidance on supportive and palliative care--implications for oncology teams, Clin Oncol (R Coll Radiol), 2004. 16(6): p. 420-4., https://www.ncbi.nlm.nih.gov/pubmed/15487134
431. Cancer Society of New Zealand, A national stocktake and review of a selection of consumer cancer information resources, 2006.
432. Eilber, F. C., Brennan, M. F., Riedel, E., Alektiar, K. M., Antonescu, C. R., Singer, S., Prognostic factors for survival in patients with locally recurrent extremity soft tissue sarcomas, Ann Surg Oncol, 2005. 12(3): p. 228-36., https://www.ncbi.nlm.nih.gov/pubmed/15827815
433. Gronchi, A., Casali, P. G., Mariani, L., Miceli, R., Fiore, M., Lo Vullo, S., et.al. Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: a series of patients treated at a single institution, J Clin Oncol, 2005. 23(1): p. 96-104., https://www.ncbi.nlm.nih.gov/pubmed/15625364
434. Sugiura, H., Tsukushi, S., Yoshida, M., Nishida, Y., What Is the Success of Repeat Surgical Treatment of a Local Recurrence After Initial Wide Resection of Soft Tissue Sarcomas?, Clin Orthop Relat Res, 2018. 476(9): p. 1791-1800., https://www.ncbi.nlm.nih.gov/pubmed/30794216
435. Torres, M. A., Ballo, M. T., Butler, C. E., Feig, B. W., Cormier, J. N., Lewis, V. O., et.al. Management of locally recurrent soft-tissue sarcoma after prior surgery and radiation therapy, Int J Radiat Oncol Biol Phys, 2007. 67(4): p. 1124-9., https://www.ncbi.nlm.nih.gov/pubmed/17208389
436. Deroose, J. P., Eggermont, A. M., van Geel, A. N., Burger, J. W., den Bakker, M. A., de Wilt, J. H., et.al. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas, J Clin Oncol, 2011. 29(30): p. 4036-44., https://www.ncbi.nlm.nih.gov/pubmed/21931039
437. Bhangu, A., Broom, L., Nepogodiev, D., Gourevitch, D., Desai, A., Outcomes of isolated limb perfusion in the treatment of extremity soft tissue sarcoma: a systematic review, Eur J Surg Oncol, 2013. 39(4): p. 311-9., https://www.ncbi.nlm.nih.gov/pubmed/23351681
438. Lans, T. E., Grunhagen, D. J., de Wilt, J. H., van Geel, A. N., Eggermont, A. M., Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs, Ann Surg Oncol, 2005. 12(5): p. 406-11., https://www.ncbi.nlm.nih.gov/pubmed/15915375
439. Cambeiro, M., Aristu, J. J., Moreno Jimenez, M., Arbea, L., Ramos, L., San Julian, M., et.al. Salvage wide resection with intraoperative electron beam therapy or HDR brachytherapy in the management of isolated local recurrences of soft tissue sarcomas of the extremities and the superficial trunk, Brachytherapy, 2015. 14(1): p. 62-70., https://www.ncbi.nlm.nih.gov/pubmed/25443530
440. Classen, J., Hehr, T., Lamprecht, U., Zumbragel, A., Bamberg, M., Budach, W., Hyperfractionated 192Ir brachytherapy for recurrent retroperitoneal sarcoma: a technique for delivery of local tumor boost dose, Strahlenther Onkol, 2003. 179(2): p. 118-22., https://www.ncbi.nlm.nih.gov/pubmed/12590323
441. Daigeler, A., Zmarsly, I., Hirsch, T., Goertz, O., Steinau, H. U., Lehnhardt, M., et.al. Long-term outcome after local recurrence of soft tissue sarcoma: a retrospective analysis of factors predictive of survival in 135 patients with locally recurrent soft tissue sarcoma, Br J Cancer, 2014. 110(6): p. 1456-64., https://www.ncbi.nlm.nih.gov/pubmed/24481401
442. Calvo, F. A., Sole, C. V., Cambeiro, M., Montero, A., Polo, A., Gonzalez, C., et.al. Prognostic value of external beam radiation therapy in patients treated with surgical resection and intraoperative electron beam radiation therapy for locally recurrent soft tissue sarcoma: a multicentric long-term outcome analysis, Int J Radiat Oncol Biol Phys, 2014. 88(1): p. 143-50., https://www.ncbi.nlm.nih.gov/pubmed/24331661
443. Essner, R., Selch, M., Eilber, F. R., Reirradiation for extremity soft tissue sarcomas. Local control and complications, Cancer, 1991. 67(11): p. 2813-7., https://www.ncbi.nlm.nih.gov/pubmed/2025846
444. Indelicato, D. J., Meadows, K., Gibbs, C. P., Jr., Morris, C. G., Scarborough, M. T., Zlotecki, R. A., Effectiveness and morbidity associated with reirradiation in conservative salvage management of recurrent soft-tissue sarcoma, Int J Radiat Oncol Biol Phys, 2009. 73(1): p. 267-72., https://www.ncbi.nlm.nih.gov/pubmed/18707824
445. Pearlstone, D. B., Janjan, N. A., Feig, B. W., Yasko, A. W., Hunt, K. K., Pollock, R. E., et.al. Re-resection with brachytherapy for locally recurrent soft tissue sarcoma arising in a previously radiated field, Cancer J Sci Am, 1999. 5(1): p. 26-33., https://www.ncbi.nlm.nih.gov/pubmed/10188058
446. Janjan, N., Crane, C., Delclos, M., Ballo, M., Brachytherapy for locally recurrent soft-tissue sarcoma, Am J Clin Oncol, 2002. 25(1): p. 9-15., https://www.ncbi.nlm.nih.gov/pubmed/11823688
447. Lehnert, T., Schwarzbach, M., Willeke, F., Treiber, M., Hinz, U., Wannenmacher, M. M., et.al. Intraoperative radiotherapy for primary and locally recurrent soft tissue sarcoma: morbidity and long-term prognosis, Eur J Surg Oncol, 2000. 26 Suppl A: p. S21-4., https://www.ncbi.nlm.nih.gov/pubmed/11130875
448. Midis, G. P., Pollock, R. E., Chen, N. P., Feig, B. W., Murphy, A., Pollack, A., et.al. Locally recurrent soft tissue sarcoma of the extremities, Surgery, 1998. 123(6): p. 666-71., https://www.ncbi.nlm.nih.gov/pubmed/9626317
449. Ikoma, N., Torres, K. E., Lin, H. Y., Ravi, V., Roland, C. L., Mann, G. N., et.al. Recurrence patterns of retroperitoneal leiomyosarcoma and impact of salvage surgery, J Surg Oncol, 2017. 116(3): p. 313-319., https://www.ncbi.nlm.nih.gov/pubmed/28557016
450. Sugiura, H., Nishida, Y., Nakashima, H., Yamada, Y., Tsukushi, S., Yamada, K., Surgical procedures and prognostic factors for local recurrence of soft tissue sarcomas, J Orthop Sci, 2014. 19(1): p. 141-9., https://www.ncbi.nlm.nih.gov/pubmed/24081391
451. Guerrero, W. M., Deneve, J. L., Local Recurrence of Extremity Soft Tissue Sarcoma, Surg Clin North Am, 2016. 96(5): p. 1157-74., https://www.ncbi.nlm.nih.gov/pubmed/27542648
452. Dorr, W., Gabrys, D., The Principles and Practice of Re-irradiation in Clinical Oncology: An Overview, Clin Oncol (R Coll Radiol), 2018. 30(2): p. 67-72., https://www.ncbi.nlm.nih.gov/pubmed/29233574
453. Wendtner, C., Abdel-Rahman, S., Baumert, J., Falk, M. H., Krych, M., Santl, M., et.al. Treatment of primary, recurrent or inadequately resected high-risk soft-tissue sarcomas (STS) of adults: results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia, Eur J Cancer, 2001. 37(13): p. 1609-16., https://www.ncbi.nlm.nih.gov/pubmed/11527685
454. Issels, R. D., Abdel-Rahman, S., Wendtner, C., Falk, M. H., Kurze, V., Sauer, H., et.al. Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study, Eur J Cancer, 2001. 37(13): p. 1599-608., https://www.ncbi.nlm.nih.gov/pubmed/11527684
455. Linthorst, M., van Geel, A. N., Baartman, E. A., Oei, S. B., Ghidey, W., van Rhoon, G. C., et.al. Effect of a combined surgery, re-irradiation and hyperthermia therapy on local control rate in radio-induced angiosarcoma of the chest wall, Strahlenther Onkol, 2013. 189(5): p. 387-93., https://www.ncbi.nlm.nih.gov/pubmed/23549781
456. Digesu, C. S., Wiesel, O., Vaporciyan, A. A., Colson, Y. L., Management of Sarcoma Metastases to the Lung, Surg Oncol Clin N Am, 2016. 25(4): p. 721-33., https://www.ncbi.nlm.nih.gov/pubmed/27591495
457. Gustafson, P., Dreinhofer, K. E., Rydholm, A., Metastasis-free survival after local recurrence of soft-tissue sarcoma, J Bone Joint Surg Br, 1993. 75(4): p. 658-60., https://www.ncbi.nlm.nih.gov/pubmed/8331127
458. Sabolch, A., Feng, M., Griffith, K., Rzasa, C., Gadzala, L., Feng, F., et.al. Risk factors for local recurrence and metastasis in soft tissue sarcomas of the extremity, Am J Clin Oncol, 2012. 35(2): p. 151-7., https://www.ncbi.nlm.nih.gov/pubmed/21336091
459. Bundesausschuss, Gemeinsamer, Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII - Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V – Eribulin (neues Anwendungsgebiet), 2016., https://www.g-ba.de/beschluesse/2775/, [abgerufen, am, 23.06.2021]
460. Bundesausschuss, Gemeinsamer, Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V Entrectinib (solide Tumore; Histologie-unabhängig), 2021., https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/588/#beschluesse, [abgerufen, am, 23.06.2021]
461. Bundesausschuss, Gemeinsamer, Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V Larotrectinib (solide Tumore, Histologieunabhängig), 2020., https://www.g-ba.de/beschluesse/4242/, [abgerufen, am, 23.06.2021]
462. Borden, E. C., Amato, D. A., Edmonson, J. H., Ritch, P. S., Shiraki, M., Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas, Cancer, 1990. 66(5): p. 862-7., https://www.ncbi.nlm.nih.gov/pubmed/2201431
463. Demetri, G. D., Le Cesne, A., Chawla, S. P., Brodowicz, T., Maki, R. G., Bach, B. A., et.al. First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study, Eur J Cancer, 2012. 48(4): p. 547-63., https://www.ncbi.nlm.nih.gov/pubmed/22240283
464. Edmonson, J. H., Ryan, L. M., Blum, R. H., Brooks, J. S., Shiraki, M., Frytak, S., et.al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas, J Clin Oncol, 1993. 11(7): p. 1269-75., https://www.ncbi.nlm.nih.gov/pubmed/8315424
465. Martin-Broto, J., Pousa, A. L., de Las Penas, R., Garcia Del Muro, X., Gutierrez, A., Martinez-Trufero, J., et.al. Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study, J Clin Oncol, 2016. 34(19): p. 2294-302., https://www.ncbi.nlm.nih.gov/pubmed/27185843
466. Maurel, J., Lopez-Pousa, A., de Las Penas, R., Fra, J., Martin, J., Cruz, J., et.al. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas, J Clin Oncol, 2009. 27(11): p. 1893-8., https://www.ncbi.nlm.nih.gov/pubmed/19273704
467. Ryan, C. W., Merimsky, O., Agulnik, M., Blay, J. Y., Schuetze, S. M., Van Tine, B. A., et.al. PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma, J Clin Oncol, 2016. 34(32): p. 3898-3905., https://www.ncbi.nlm.nih.gov/pubmed/27621408
468. Santoro, A., Tursz, T., Mouridsen, H., Verweij, J., Steward, W., Somers, R., et.al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, J Clin Oncol, 1995. 13(7): p. 1537-45., https://www.ncbi.nlm.nih.gov/pubmed/7602342
469. Tap, W. D., Papai, Z., Van Tine, B. A., Attia, S., Ganjoo, K. N., Jones, R. L., et.al. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial, Lancet Oncol, 2017. 18(8): p. 1089-1103., https://www.ncbi.nlm.nih.gov/pubmed/28651927
470. Bramwell, V. H., Mouridsen, H. T., Mulder, J. H., Somers, R., Van Oosterom, A. T., Santoro, A., et.al. Carminomycin vs adriamycin in advanced soft tissue sarcomas: an EORTC randomised phase II study, Eur J Cancer Clin Oncol, 1983. 19(8): p. 1097-104., https://www.ncbi.nlm.nih.gov/pubmed/6352280
471. Blay, J. Y., Leahy, M. G., Nguyen, B. B., Patel, S. R., Hohenberger, P., Santoro, A., et.al. Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas, Eur J Cancer, 2014. 50(6): p. 1137-47., https://www.ncbi.nlm.nih.gov/pubmed/24512981
472. Bui-Nguyen, B., Butrynski, J. E., Penel, N., Blay, J. Y., Isambert, N., Milhem, M., et.al. A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial, Eur J Cancer, 2015. 51(10): p. 1312-20., https://www.ncbi.nlm.nih.gov/pubmed/25912752
473. Gelderblom, H., Blay, J. Y., Seddon, B. M., Leahy, M., Ray-Coquard, I., Sleijfer, S., et.al. Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study, Eur J Cancer, 2014. 50(2): p. 388-96., https://www.ncbi.nlm.nih.gov/pubmed/24215845
474. Lorigan, P., Verweij, J., Papai, Z., Rodenhuis, S., Le Cesne, A., Leahy, M. G., et.al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study, J Clin Oncol, 2007. 25(21): p. 3144-50., https://www.ncbi.nlm.nih.gov/pubmed/17634494
475. Seddon, B., Strauss, S. J., Whelan, J., Leahy, M., Woll, P. J., Cowie, F., et.al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial, Lancet Oncol, 2017. 18(10): p. 1397-1410., https://www.ncbi.nlm.nih.gov/pubmed/28882536
476. Judson, I., Radford, J. A., Harris, M., Blay, J. Y., van Hoesel, Q., le Cesne, A., et.al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group, Eur J Cancer, 2001. 37(7): p. 870-7., https://www.ncbi.nlm.nih.gov/pubmed/11313175
477. Mouridsen, H. T., Bastholt, L., Somers, R., Santoro, A., Bramwell, V., Mulder, J. H., et.al. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group, Eur J Cancer Clin Oncol, 1987. 23(10): p. 1477-83., https://www.ncbi.nlm.nih.gov/pubmed/3479329
478. Nielsen, O. S., Dombernowsky, P., Mouridsen, H., Crowther, D., Verweij, J., Buesa, J., et.al. High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group, Br J Cancer, 1998. 78(12): p. 1634-9., https://www.ncbi.nlm.nih.gov/pubmed/9862576
479. Chawla, S. P., Papai, Z., Mukhametshina, G., Sankhala, K., Vasylyev, L., Fedenko, A., et.al. First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial, JAMA Oncol, 2015. 1(9): p. 1272-80., https://www.ncbi.nlm.nih.gov/pubmed/26378637
480. Chawla, Sant P., Ganjoo, Kristen N., Schuetze, Scott, Papai, Zsuzsanna, Van Tine, Brian Andrew, Choy, Edwin, et.al. Phase III study of aldoxorubicin vs investigators' choice as treatment for relapsed/refractory soft tissue sarcomas, Journal of Clinical Oncology, 2017. 35(15_suppl): p. 11000-11000., https://doi.org/10.1200/JCO.2017.35.15_suppl.11000
481. Tap, William D., Wagner, Andrew J., Papai, Zsuzsanna, Ganjoo, Kristen N., Yen, Chueh-Chuan, Schoffski, Patrick, et.al. ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS), Journal of Clinical Oncology, 2019. 37(18_suppl): p. LBA3-LBA3., https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.18_suppl.LBA3
482. Tap, W. D., Jones, R. L., Van Tine, B. A., Chmielowski, B., Elias, A. D., Adkins, D., et.al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial, Lancet, 2016. 388(10043): p. 488-97., https://www.ncbi.nlm.nih.gov/pubmed/27291997
483. Tap, W. D., Wagner, A. J., Schoffski, P., Martin-Broto, J., Krarup-Hansen, A., Ganjoo, K. N., et.al. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial, JAMA, 2020. 323(13): p. 1266-1276., https://www.ncbi.nlm.nih.gov/pubmed/32259228
484. Young, R. J., Litiere, S., Lia, M., Hogendoorn, P. C. W., Fisher, C., Mechtersheimer, G., et.al. Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study, Acta Oncol, 2017. 56(7): p. 1013-1020., https://www.ncbi.nlm.nih.gov/pubmed/28431480
485. Borden, E. C., Amato, D. A., Rosenbaum, C., Enterline, H. T., Shiraki, M. J., Creech, R. H., et.al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas, J Clin Oncol, 1987. 5(6): p. 840-50., https://www.ncbi.nlm.nih.gov/pubmed/3585441
486. Bitz, U., Pink, D., Busemann, C., Reichardt, P., Doxorubicin (Doxo) and dacarbacin (DTIC) as first-line therapy for patients (pts) with locally advanced or metastatic leiomyosarcoma (LMS) and liposarcoma (LPS), Journal of Clinical Oncology, 2011. 29(15_suppl): p. 10094-10094., https://doi.org/10.1200/jco.2011.29.15_suppl.10094
487. Sleijfer, S., Ouali, M., van Glabbeke, M., Krarup-Hansen, A., Rodenhuis, S., Le Cesne, A., et.al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG), Eur J Cancer, 2010. 46(1): p. 72-83., https://www.ncbi.nlm.nih.gov/pubmed/19853437
488. Hudgens, S., Forsythe, A., Kontoudis, I., D'Adamo, D., Bird, A., Gelderblom, H., Evaluation of Quality of Life at Progression in Patients with Soft Tissue Sarcoma, Sarcoma, 2017. 2017: p. 2372135., https://www.ncbi.nlm.nih.gov/pubmed/28512389
489. Schoffski, P., Chawla, S., Maki, R. G., Italiano, A., Gelderblom, H., Choy, E., et.al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial, Lancet, 2016. 387(10028): p. 1629-37., https://www.ncbi.nlm.nih.gov/pubmed/26874885
490. Kawai, A., Araki, N., Sugiura, H., Ueda, T., Yonemoto, T., Takahashi, M., et.al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study, Lancet Oncol, 2015. 16(4): p. 406-16., https://www.ncbi.nlm.nih.gov/pubmed/25795406
491. Coens, C., van der Graaf, W. T., Blay, J. Y., Chawla, S. P., Judson, I., Sanfilippo, R., et.al. Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072), Cancer, 2015. 121(17): p. 2933-41., https://www.ncbi.nlm.nih.gov/pubmed/26033286
492. van der Graaf, W. T., Blay, J. Y., Chawla, S. P., Kim, D. W., Bui-Nguyen, B., Casali, P. G., et.al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial, Lancet, 2012. 379(9829): p. 1879-86., https://www.ncbi.nlm.nih.gov/pubmed/22595799
493. Demetri, G. D., von Mehren, M., Jones, R. L., Hensley, M. L., Schuetze, S. M., Staddon, A., et.al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial, J Clin Oncol, 2016. 34(8): p. 786-93., https://www.ncbi.nlm.nih.gov/pubmed/26371143
494. Pautier, P., Floquet, A., Penel, N., Piperno-Neumann, S., Isambert, N., Rey, A., et.al. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study), Oncologist, 2012. 17(9): p. 1213-20., https://www.ncbi.nlm.nih.gov/pubmed/22907974
495. Maki, R. G., Wathen, J. K., Patel, S. R., Priebat, D. A., Okuno, S. H., Samuels, B., et.al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected], J Clin Oncol, 2007. 25(19): p. 2755-63., https://www.ncbi.nlm.nih.gov/pubmed/17602081
496. Hensley, M. L., Miller, A., O'Malley, D. M., Mannel, R. S., Behbakht, K., Bakkum-Gamez, J. N., et.al. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study, J Clin Oncol, 2015. 33(10): p. 1180-5., https://www.ncbi.nlm.nih.gov/pubmed/25713428
497. Demetri, G. D., Chawla, S. P., von Mehren, M., Ritch, P., Baker, L. H., Blay, J. Y., et.al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules, J Clin Oncol, 2009. 27(25): p. 4188-96., https://www.ncbi.nlm.nih.gov/pubmed/19652065
498. Garcia-Del-Muro, X., Lopez-Pousa, A., Maurel, J., Martin, J., Martinez-Trufero, J., Casado, A., et.al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study, J Clin Oncol, 2011. 29(18): p. 2528-33., https://www.ncbi.nlm.nih.gov/pubmed/21606430
499. Potter, D. A., Glenn, J., Kinsella, T., Glatstein, E., Lack, E. E., Restrepo, C., et.al. Patterns of recurrence in patients with high-grade soft-tissue sarcomas, J Clin Oncol, 1985. 3(3): p. 353-66., https://www.ncbi.nlm.nih.gov/pubmed/3973646
500. Kang, S., Kim, H. S., Kim, S., Kim, W., Han, I., Post-metastasis survival in extremity soft tissue sarcoma: a recursive partitioning analysis of prognostic factors, Eur J Cancer, 2014. 50(9): p. 1649-56., https://www.ncbi.nlm.nih.gov/pubmed/24703898
501. Savina, M., Le Cesne, A., Blay, J. Y., Ray-Coquard, I., Mir, O., Toulmonde, M., et.al. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study, BMC Med, 2017. 15(1): p. 78., https://www.ncbi.nlm.nih.gov/pubmed/28391775
502. Pastorino, U., Buyse, M., Friedel, G., Ginsberg, R. J., Girard, P., Goldstraw, P., et.al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases, J Thorac Cardiovasc Surg, 1997. 113(1): p. 37-49., https://www.ncbi.nlm.nih.gov/pubmed/9011700
503. Toussi, M. S., Bagheri, R., Dayani, M., Anvari, K., Sheibani, S., Pulmonary metastasectomy and repeat metastasectomy for soft-tissue sarcoma, Asian Cardiovasc Thorac Ann, 2013. 21(4): p. 437-42., https://www.ncbi.nlm.nih.gov/pubmed/24570526
504. Stanelle, E. J., Christison-Lagay, E. R., Wolden, S. L., Meyers, P. A., La Quaglia, M. P., Pulmonary metastasectomy in pediatric/adolescent patients with synovial sarcoma: an institutional review, J Pediatr Surg, 2013. 48(4): p. 757-63., https://www.ncbi.nlm.nih.gov/pubmed/23583130
505. Smith, R., Pak, Y., Kraybill, W., Kane, J. M., 3rd, Factors associated with actual long-term survival following soft tissue sarcoma pulmonary metastasectomy, Eur J Surg Oncol, 2009. 35(4): p. 356-61., https://www.ncbi.nlm.nih.gov/pubmed/18294807
506. Pfannschmidt, J., Klode, J., Muley, T., Dienemann, H., Hoffmann, H., Pulmonary metastasectomy in patients with soft tissue sarcomas: experiences in 50 patients, Thorac Cardiovasc Surg, 2006. 54(7): p. 489-92., https://www.ncbi.nlm.nih.gov/pubmed/17089318
507. Kim, S., Ott, H. C., Wright, C. D., Wain, J. C., Morse, C., Gaissert, H. A., et.al. Pulmonary resection of metastatic sarcoma: prognostic factors associated with improved outcomes, Ann Thorac Surg, 2011. 92(5): p. 1780-6; discussion 1786-7., https://www.ncbi.nlm.nih.gov/pubmed/22051274
508. Giuliano, K., Sachs, T., Montgomery, E., Guzzetta, A., Brock, M., Pawlik, T. M., et.al. Survival Following Lung Metastasectomy in Soft Tissue Sarcomas, Thorac Cardiovasc Surg, 2016. 64(2): p. 150-8., https://www.ncbi.nlm.nih.gov/pubmed/26339728
509. Dossett, L. A., Toloza, E. M., Fontaine, J., Robinson, L. A., Reed, D., Druta, M., et.al. Outcomes and clinical predictors of improved survival in a patients undergoing pulmonary metastasectomy for sarcoma, J Surg Oncol, 2015. 112(1): p. 103-6., https://www.ncbi.nlm.nih.gov/pubmed/26179670
510. Dear, R. F., Kelly, P. J., Wright, G. M., Stalley, P., McCaughan, B. C., Tattersall, M. H., Pulmonary metastasectomy for bone and soft tissue sarcoma in Australia: 114 patients from 1978 to 2008, Asia Pac J Clin Oncol, 2012. 8(3): p. 292-302., https://www.ncbi.nlm.nih.gov/pubmed/22897801
511. Chen, F., Fujinaga, T., Sato, K., Sonobe, M., Shoji, T., Sakai, H., et.al. Significance of tumor recurrence before pulmonary metastasis in pulmonary metastasectomy for soft tissue sarcoma, Eur J Surg Oncol, 2009. 35(6): p. 660-5., https://www.ncbi.nlm.nih.gov/pubmed/18774675
512. Burt, B. M., Ocejo, S., Mery, C. M., Dasilva, M., Bueno, R., Sugarbaker, D. J., et.al. Repeated and aggressive pulmonary resections for leiomyosarcoma metastases extends survival, Ann Thorac Surg, 2011. 92(4): p. 1202-7., https://www.ncbi.nlm.nih.gov/pubmed/21867989
513. Blackmon, S. H., Shah, N., Roth, J. A., Correa, A. M., Vaporciyan, A. A., Rice, D. C., et.al. Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival, Ann Thorac Surg, 2009. 88(3): p. 877-84; discussion 884-5., https://www.ncbi.nlm.nih.gov/pubmed/19699915
514. Abdelnour-Berchtold, E., Perentes, J. Y., Ris, H. B., Beigelman, C., Lovis, A., Peters, S., et.al. Survival and Local Recurrence After Video-Assisted Thoracoscopic Lung Metastasectomy, World J Surg, 2016. 40(2): p. 373-9., https://www.ncbi.nlm.nih.gov/pubmed/26464153
515. Guerrini, G. P., Lo Faso, F., Vagliasindi, A., Lembo, R., Solaini, L., Soliani, P., et.al. The Role of Minimally Invasive Surgery in the Treatment of Lung Metastases, J Invest Surg, 2017. 30(2): p. 110-115., https://www.ncbi.nlm.nih.gov/pubmed/27690700
516. Schmid, S., Le, U. T., Zeisel, C., Haager, B., Passlick, B., Pulmonary metastasectomy in sarcoma-experiences with laser-assisted resection, J Thorac Dis, 2018. 10(1): p. 314-320., https://www.ncbi.nlm.nih.gov/pubmed/29600062
517. Reza, J., Sammann, A., Jin, C., Horvai, A., Hudnall, M., Jablons, D. M., et.al. Aggressive and minimally invasive surgery for pulmonary metastasis of sarcoma, J Thorac Cardiovasc Surg, 2014. 147(4): p. 1193-200; discussion 1200-1., https://www.ncbi.nlm.nih.gov/pubmed/24507991
518. Falk, A. T., Moureau-Zabotto, L., Ouali, M., Penel, N., Italiano, A., Bay, J. O., et.al. Effect on survival of local ablative treatment of metastases from sarcomas: a study of the French sarcoma group, Clin Oncol (R Coll Radiol), 2015. 27(1): p. 48-55., https://www.ncbi.nlm.nih.gov/pubmed/25300878
519. Choong, P. F., Pritchard, D. J., Rock, M. G., Sim, F. H., Frassica, F. J., Survival after pulmonary metastasectomy in soft tissue sarcoma. Prognostic factors in 214 patients, Acta Orthop Scand, 1995. 66(6): p. 561-8., https://www.ncbi.nlm.nih.gov/pubmed/8553829
520. Predina, J. D., Puc, M. M., Bergey, M. R., Sonnad, S. S., Kucharczuk, J. C., Staddon, A., et.al. Improved survival after pulmonary metastasectomy for soft tissue sarcoma, J Thorac Oncol, 2011. 6(5): p. 913-9., https://www.ncbi.nlm.nih.gov/pubmed/21750417
521. Canter, R. J., Qin, L. X., Downey, R. J., Brennan, M. F., Singer, S., Maki, R. G., Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity : a retrospective analysis, Cancer, 2007. 110(9): p. 2050-60., https://www.ncbi.nlm.nih.gov/pubmed/17828771
522. Brudvik, K. W., Patel, S. H., Roland, C. L., Conrad, C., Torres, K. E., Hunt, K. K., et.al. Survival After Resection of Gastrointestinal Stromal Tumor and Sarcoma Liver Metastases in 146 Patients, J Gastrointest Surg, 2015. 19(8): p. 1476-83., https://www.ncbi.nlm.nih.gov/pubmed/26001368
523. Pawlik, T. M., Vauthey, J. N., Abdalla, E. K., Pollock, R. E., Ellis, L. M., Curley, S. A., Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver, Arch Surg, 2006. 141(6): p. 537-43; discussion 543-4., https://www.ncbi.nlm.nih.gov/pubmed/16785353
524. Marudanayagam, R., Sandhu, B., Perera, M. T., Bramhall, S. R., Mayer, D., Buckels, J. A., et.al. Liver resection for metastatic soft tissue sarcoma: an analysis of prognostic factors, Eur J Surg Oncol, 2011. 37(1): p. 87-92., https://www.ncbi.nlm.nih.gov/pubmed/21163386
525. Rehders, A., Peiper, M., Stoecklein, N. H., Alexander, A., Boelke, E., Knoefel, W. T., et.al. Hepatic metastasectomy for soft-tissue sarcomas: is it justified?, World J Surg, 2009. 33(1): p. 111-7., https://www.ncbi.nlm.nih.gov/pubmed/18949511
526. DeMatteo, R. P., Shah, A., Fong, Y., Jarnagin, W. R., Blumgart, L. H., Brennan, M. F., Results of hepatic resection for sarcoma metastatic to liver, Ann Surg, 2001. 234(4): p. 540-7; discussion 547-8., https://www.ncbi.nlm.nih.gov/pubmed/11573047
527. Gronchi, A., Guadagnolo, B. A., Erinjeri, J. P., Local Ablative Therapies to Metastatic Soft Tissue Sarcoma, Am Soc Clin Oncol Educ Book, 2016. 35: p. e566-75., https://www.ncbi.nlm.nih.gov/pubmed/27249769
528. Koelblinger, C., Strauss, S., Gillams, A., Outcome after radiofrequency ablation of sarcoma lung metastases, Cardiovasc Intervent Radiol, 2014. 37(1): p. 147-53., https://www.ncbi.nlm.nih.gov/pubmed/23670570
529. Sato, T., Iguchi, T., Hiraki, T., Gobara, H., Fujiwara, H., Sakurai, J., et.al. Radiofrequency ablation of pulmonary metastases from sarcoma: single-center retrospective evaluation of 46 patients, Jpn J Radiol, 2017. 35(2): p. 61-67., https://www.ncbi.nlm.nih.gov/pubmed/27864664
530. Frakulli, R., Salvi, F., Balestrini, D., Parisi, A., Palombarini, M., Cammelli, S., et.al. Stereotactic Radiotherapy in the Treatment of Lung Metastases from Bone and Soft-tissue Sarcomas, Anticancer Res, 2015. 35(10): p. 5581-6., https://www.ncbi.nlm.nih.gov/pubmed/26408729
531. Navarria, P., Ascolese, A. M., Cozzi, L., Tomatis, S., D'Agostino, G. R., De Rose, F., et.al. Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma, Eur J Cancer, 2015. 51(5): p. 668-74., https://www.ncbi.nlm.nih.gov/pubmed/25686482
532. Folkert, M. R., Bilsky, M. H., Tom, A. K., Oh, J. H., Alektiar, K. M., Laufer, I., et.al. Outcomes and toxicity for hypofractionated and single-fraction image-guided stereotactic radiosurgery for sarcomas metastasizing to the spine, Int J Radiat Oncol Biol Phys, 2014. 88(5): p. 1085-91., https://www.ncbi.nlm.nih.gov/pubmed/24661662
533. Yaeh, A., Nanda, T., Jani, A., Rozenblat, T., Qureshi, Y., Saad, S., et.al. Control of brain metastases from radioresistant tumors treated by stereotactic radiosurgery, J Neurooncol, 2015. 124(3): p. 507-14., https://www.ncbi.nlm.nih.gov/pubmed/26233247
534. Ahmed, K. A., Freilich, J. M., Abuodeh, Y., Figura, N., Patel, N., Sarangkasiri, S., et.al. Fractionated stereotactic radiotherapy to the post-operative cavity for radioresistant and radiosensitive brain metastases, J Neurooncol, 2014. 118(1): p. 179-86., https://www.ncbi.nlm.nih.gov/pubmed/24604750
535. Miller, M. D., Sze, D. Y., Padia, S. A., Lewandowski, R. J., Salem, R., Mpofu, P., et.al. Response and Overall Survival for Yttrium-90 Radioembolization of Hepatic Sarcoma: A Multicenter Retrospective Study, J Vasc Interv Radiol, 2018. 29(6): p. 867-873., https://www.ncbi.nlm.nih.gov/pubmed/29724518
536. Rathmann, N., Diehl, S. J., Dinter, D., Schutte, J., Pink, D., Schoenberg, S. O., et.al. Radioembolization in patients with progressive gastrointestinal stromal tumor liver metastases undergoing treatment with tyrosine kinase inhibitors, J Vasc Interv Radiol, 2015. 26(2): p. 231-8., https://www.ncbi.nlm.nih.gov/pubmed/25434477
537. Chapiro, J., Duran, R., Lin, M., Mungo, B., Schlachter, T., Schernthaner, R., et.al. Transarterial chemoembolization in soft-tissue sarcoma metastases to the liver - the use of imaging biomarkers as predictors of patient survival, Eur J Radiol, 2015. 84(3): p. 424-430., https://www.ncbi.nlm.nih.gov/pubmed/25542065
538. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), S3-Leitlinie Supportive Therapie bei onkologischen PatientInnen, Langversion 1.3, 2020, AWMF-Registernummer: 032/054OL, 2020., https://www.leitlinienprogramm-onkologie.de/leitlinien/supportive-therapie/, [abgerufen, am:, 09.11.2020]
539. Hesketh, P. J., Schnadig, I. D., Schwartzberg, L. S., Modiano, M. R., Jordan, K., Arora, S., et.al. Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy, Cancer, 2016. 122(15): p. 2418-25., https://www.ncbi.nlm.nih.gov/pubmed/27176138
540. Tanioka, M., Kitao, A., Matsumoto, K., Shibata, N., Yamaguchi, S., Fujiwara, K., et.al. A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy, Br J Cancer, 2013. 109(4): p. 859-65., https://www.ncbi.nlm.nih.gov/pubmed/23860530
541. Yahata, H., Kobayashi, H., Sonoda, K., Shimokawa, M., Ohgami, T., Saito, T., et.al. Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin, Int J Clin Oncol, 2016. 21(3): p. 491-7., https://www.ncbi.nlm.nih.gov/pubmed/26662632
542. Roila, F., Molassiotis, A., Herrstedt, J., Aapro, M., Gralla, R. J., Bruera, E., et.al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients, Ann Oncol, 2016. 27(suppl 5): p. v119-v133., https://www.ncbi.nlm.nih.gov/pubmed/27664248
543. Beumer, J. H., Schellens, J. H., Beijnen, J. H., Hepatotoxicity and metabolism of trabectedin: a literature review, Pharmacol Res, 2005. 51(5): p. 391-8., https://www.ncbi.nlm.nih.gov/pubmed/15749453
544. Leporini, C., Patane, M., Saullo, F., Rende, P., Gallelli, L., Di Paola, E. D., et.al. A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations, BioDrugs, 2014. 28(6): p. 499-511., https://www.ncbi.nlm.nih.gov/pubmed/25209722
545. Thariat, J., Etienne-Grimaldi, M. C., Launay-Vacher, V., Soto-Matos, A., Fernandez-Teruel, C., Ghafari, T., et.al. Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease, Cancer Chemother Pharmacol, 2011. 68(5): p. 1363-7., https://www.ncbi.nlm.nih.gov/pubmed/21850465
546. Jordan, K., Jahn, F., Jordan, B., Kegel, T., Muller-Tidow, C., Russel, J., Trabectedin: Supportive care strategies and safety profile, Crit Rev Oncol Hematol, 2015. 94(3): p. 279-90., https://www.ncbi.nlm.nih.gov/pubmed/25794812
547. Le Cesne, A., Blay, J. Y., Judson, I., Van Oosterom, A., Verweij, J., Radford, J., et.al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial, J Clin Oncol, 2005. 23(3): p. 576-84., https://www.ncbi.nlm.nih.gov/pubmed/15659504
548. Garcia-Carbonero, R., Supko, J. G., Maki, R. G., Manola, J., Ryan, D. P., Harmon, D., et.al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study, J Clin Oncol, 2005. 23(24): p. 5484-92., https://www.ncbi.nlm.nih.gov/pubmed/16110008
549. Paz-Ares, L., Lopez-Pousa, A., Poveda, A., Balana, C., Ciruelos, E., Bellmunt, J., et.al. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone, Invest New Drugs, 2012. 30(2): p. 729-40., https://www.ncbi.nlm.nih.gov/pubmed/20960029
550. Grosso, F., Dileo, P., Sanfilippo, R., Stacchiotti, S., Bertulli, R., Piovesan, C., et.al. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma, Eur J Cancer, 2006. 42(10): p. 1484-90., https://www.ncbi.nlm.nih.gov/pubmed/16737808
551. European Medicines Agency (EMA), Yondelis: EPAR - Product information, 2018., https://www.ema.europa.eu/en/documents/product-information/yondelis-epar-product-information_en.pdf, [abgerufen, am, 01.10.2020]
552. Janssen Pharmaceutical Companies, YONDELIS (trabectedin) for injection - package leaflet, 2015., http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/YONDELIS-pi.pdf, [abgerufen, am, 25.04.2019]
553. Hing, J., Perez-Ruixo, J. J., Stuyckens, K., Soto-Matos, A., Lopez-Lazaro, L., Zannikos, P., Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia, Clin Pharmacol Ther, 2008. 83(1): p. 130-43., https://www.ncbi.nlm.nih.gov/pubmed/17597713
554. Vehreschild, J. J., Bohme, A., Cornely, O. A., Kahl, C., Karthaus, M., Kreuzer, K. A., et.al. Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO), Ann Oncol, 2014. 25(9): p. 1709-1718., https://www.ncbi.nlm.nih.gov/pubmed/24631945
555. Olver, I., Clark-Snow, R. A., Ballatori, E., Espersen, B. T., Bria, E., Jordan, K., Guidelines for the control of nausea and vomiting with chemotherapy of low or minimal emetic potential, Support Care Cancer, 2011. 19 Suppl 1: p. S33-6., https://www.ncbi.nlm.nih.gov/pubmed/20803222
556. Basch, E., Prestrud, A. A., Hesketh, P. J., Kris, M. G., Feyer, P. C., Somerfield, M. R., et.al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update, J Clin Oncol, 2011. 29(31): p. 4189-98., https://www.ncbi.nlm.nih.gov/pubmed/21947834
557. Shadle, C. R., Lee, Y., Majumdar, A. K., Petty, K. J., Gargano, C., Bradstreet, T. E., et.al. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity, J Clin Pharmacol, 2004. 44(3): p. 215-23., https://www.ncbi.nlm.nih.gov/pubmed/14973304
558. de Wit, M., Ortner, P., Lipp, H. P., Sehouli, J., Untch, M., Ruhnke, M., et.al. Management of cytotoxic extravasation - ASORS expert opinion for diagnosis, prevention and treatment, Onkologie, 2013. 36(3): p. 127-35., https://www.ncbi.nlm.nih.gov/pubmed/23486002
559. Meanwell, C. A., Blake, A. E., Latief, T. N., Blackledge, G., Mould, J. J., Blake, D. R., et.al. Encephalopathy associated with ifosphamide/mesna therapy, Lancet, 1985. 1(8425): p. 406-7., https://www.ncbi.nlm.nih.gov/pubmed/2857462
560. Simonian, N. A., Gilliam, F. G., Chiappa, K. H., Ifosfamide causes a diazepam-sensitive encephalopathy, Neurology, 1993. 43(12): p. 2700-2., https://www.ncbi.nlm.nih.gov/pubmed/8255482
561. Kupfer, A., Aeschlimann, C., Wermuth, B., Cerny, T., Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue, Lancet, 1994. 343(8900): p. 763-4., https://www.ncbi.nlm.nih.gov/pubmed/7510815
562. Kasper, B., Harter, C., Meissner, J., Bellos, F., Krasniqi, F., Ho, A. D., et.al. Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with high-dose ifosfamide?, Support Care Cancer, 2004. 12(3): p. 205-7., https://www.ncbi.nlm.nih.gov/pubmed/14727169
563. Kellner, O., Dempke, W., Schmoll, H. J., [Glucose infusions--a possible effective therapeutic option in ifosfamide-induced encephalopathy], Dtsch Med Wochenschr, 1999. 124(37): p. 1086-7., https://www.ncbi.nlm.nih.gov/pubmed/10520310
564. Gerrand, C. H., Billingham, L. J., Woll, P. J., Grimer, R. J., Follow up after Primary Treatment of Soft Tissue Sarcoma: A Survey of Current Practice in the United Kingdom, Sarcoma, 2007. 2007: p. 34128., https://www.ncbi.nlm.nih.gov/pubmed/18270541
565. Greenberg, D. D., Crawford, B., Surveillance Strategies for Sarcoma: Results of a Survey of Members of the Musculoskeletal Tumor Society, Sarcoma, 2016. 2016: p. 8289509., https://www.ncbi.nlm.nih.gov/pubmed/27478404
566. Rothermundt, C., Whelan, J. S., Dileo, P., Strauss, S. J., Coleman, J., Briggs, T. W., et.al. What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients, Br J Cancer, 2014. 110(10): p. 2420-6., https://www.ncbi.nlm.nih.gov/pubmed/24736584
567. Rutkowski, P., Lugowska, I., Follow-up in soft tissue sarcomas, Memo, 2014. 7(2): p. 92-96., https://www.ncbi.nlm.nih.gov/pubmed/25089160
568. Whooley, B. P., Gibbs, J. F., Mooney, M. M., McGrath, B. E., Kraybill, W. G., Primary extremity sarcoma: what is the appropriate follow-up?, Ann Surg Oncol, 2000. 7(1): p. 9-14., https://www.ncbi.nlm.nih.gov/pubmed/10674442
569. Coindre, J. M., Terrier, P., Guillou, L., Le Doussal, V., Collin, F., Ranchere, D., et.al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group, Cancer, 2001. 91(10): p. 1914-26., https://www.ncbi.nlm.nih.gov/pubmed/11346874
570. Krieg, A. H., Hefti, F., Speth, B. M., Jundt, G., Guillou, L., Exner, U. G., et.al. Synovial sarcomas usually metastasize after >5 years: a multicenter retrospective analysis with minimum follow-up of 10 years for survivors, Ann Oncol, 2011. 22(2): p. 458-67., https://www.ncbi.nlm.nih.gov/pubmed/20716627
571. Sawamura, C., Matsumoto, S., Shimoji, T., Okawa, A., Ae, K., How long should we follow patients with soft tissue sarcomas?, Clin Orthop Relat Res, 2014. 472(3): p. 842-8., https://www.ncbi.nlm.nih.gov/pubmed/23716116
572. Durr, H. R., Rauh, J., Baur-Melnyk, A., Knosel, T., Lindner, L., Roeder, F., et.al. Myxoid liposarcoma: local relapse and metastatic pattern in 43 patients, BMC Cancer, 2018. 18(1): p. 304., https://www.ncbi.nlm.nih.gov/pubmed/29558901
573. Puri, A., Gulia, A., Hawaldar, R., Ranganathan, P., Badwe, R. A., Does intensity of surveillance affect survival after surgery for sarcomas? Results of a randomized noninferiority trial, Clin Orthop Relat Res, 2014. 472(5): p. 1568-75., https://www.ncbi.nlm.nih.gov/pubmed/24249538
574. Knapp, E. L., Kransdorf, M. J., Letson, G. D., Diagnostic imaging update: soft tissue sarcomas, Cancer Control, 2005. 12(1): p. 22-6., https://www.ncbi.nlm.nih.gov/pubmed/15668649
575. Tzeng, C. W., Smith, J. K., Heslin, M. J., Soft tissue sarcoma: preoperative and postoperative imaging for staging, Surg Oncol Clin N Am, 2007. 16(2): p. 389-402., https://www.ncbi.nlm.nih.gov/pubmed/17560519
576. Del Grande, F., Subhawong, T., Weber, K., Aro, M., Mugera, C., Fayad, L. M., Detection of soft-tissue sarcoma recurrence: added value of functional MR imaging techniques at 3.0 T, Radiology, 2014. 271(2): p. 499-511., https://www.ncbi.nlm.nih.gov/pubmed/24495264
577. ElDaly, M. M., Moustafa, A. F. I., Abdel-Meguid, S. M. S., Shokry, A. M., El Wahab, N. A., Can MRI diffusion-weighted imaging identify postoperative residual/recurrent soft-tissue sarcomas?, Indian J Radiol Imaging, 2018. 28(1): p. 70-77., https://www.ncbi.nlm.nih.gov/pubmed/29692531
578. Richardson, K., Potter, M., Damron, T. A., Image intensive soft tissue sarcoma surveillance uncovers pathology earlier than patient complaints but with frequent initially indeterminate lesions, J Surg Oncol, 2016. 113(7): p. 818-22., https://www.ncbi.nlm.nih.gov/pubmed/27060189
579. Cho, H. S., Park, I. H., Jeong, W. J., Han, I., Kim, H. S., Prognostic value of computed tomography for monitoring pulmonary metastases in soft tissue sarcoma patients after surgical management: a retrospective cohort study, Ann Surg Oncol, 2011. 18(12): p. 3392-8., https://www.ncbi.nlm.nih.gov/pubmed/21537873
580. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Erweiterte S3-Leitlinie Palliativmedizin für Patienten mit einer nicht heilbaren Krebserkrankung, Langversion 2.2, 2020, AWMF-Registernummer: 128/001OL, 2020., https://www.leitlinienprogramm-onkologie.de/leitlinien/palliativmedizin/, [abgerufen, am:, 09.11.2020]
581. Bundesministerium der Justiz und für Verbraucherschutz, Sozialgesetzbuch Neuntes Buch - Rehabilitation und Teilhabe von Menschen mit Behinderungen - (Neuntes Buch Sozialgesetzbuch - SGB IX), Zuletzt geändert durch Art. 6 Abs. 3 G v. 28.11.2018 l 2016.
582. Deutsche Rentenversicherung (DRV), Indikationskatalog für Anschlussrehabilitation (AHB), 2017.
583. Bundesarbeitsgemeinschaft für Rehabilitation (BAR), Rahmenempfehlungen zur ambulanten onkologischen Rehabilitation, 2004.
584. Deutsche Rentenversicherung (DRV), Strukturqualität von Reha-Einrichtungen - Anforderungen der Deutschen Rentenversicherung, 2. überarbeitete und erweiterte Auflage, 2014.
585. Deutsche Rentenversicherung (DRV), Anforderungsprofil für eine stationäre Einrichtung zur onkologischen Rehabilitation Erwachsener, 2018.
586. Stoeckle, E., Michot, A., Rigal, L., Babre, F., Sargos, P., Henriques de Figueiredo, B., et.al. The risk of postoperative complications and functional impairment after multimodality treatment for limb and trunk wall soft-tissue sarcoma: Long term results from a monocentric series, Eur J Surg Oncol, 2017. 43(6): p. 1117-1125., https://www.ncbi.nlm.nih.gov/pubmed/28202211
587. Deutsches Institut für Medizinishe Dokumentation und Information (DIMDI), Internationale Klassifikation der Funktionsfähigkeit, Behinderung und Gesundheit (ICF), 2005., https://www.dimdi.de/dynamic/de/klassifikationen/downloads/
588. Kwong, T. N., Furtado, S., Gerrand, C., What do we know about survivorship after treatment for extremity sarcoma? A systematic review, Eur J Surg Oncol, 2014. 40(9): p. 1109-24., https://www.ncbi.nlm.nih.gov/pubmed/24767804
589. Wampler, M. A., Galantino, M. L., Huang, S., Gilchrist, L. S., Marchese, V. G., Morris, G. S., et.al. Physical activity among adult survivors of childhood lower-extremity sarcoma, J Cancer Surviv, 2012. 6(1): p. 45-53., https://www.ncbi.nlm.nih.gov/pubmed/21681405
590. Gerrand, C., Furtado, S., Issues of Survivorship and Rehabilitation in Soft Tissue Sarcoma, Clin Oncol (R Coll Radiol), 2017. 29(8): p. 538-545., https://www.ncbi.nlm.nih.gov/pubmed/28442210
591. Michot, A., Stoeckle, E., Bannel, J. D., Colombani, S., Sargos, P., Brouste, V., et.al. The introduction of early patient rehabilitation in surgery of soft tissue sarcoma and its impact on post-operative outcome, Eur J Surg Oncol, 2015. 41(12): p. 1678-84., https://www.ncbi.nlm.nih.gov/pubmed/26442684
592. Mishra, S. I., Scherer, R. W., Snyder, C., Geigle, P. M., Berlanstein, D. R., Topaloglu, O., Exercise interventions on health-related quality of life for people with cancer during active treatment, Cochrane Database Syst Rev, 2012. p. CD008465., https://www.ncbi.nlm.nih.gov/pubmed/22895974
593. Fong, D. Y., Ho, J. W., Hui, B. P., Lee, A. M., Macfarlane, D. J., Leung, S. S., et.al. Physical activity for cancer survivors: meta-analysis of randomised controlled trials, BMJ, 2012. 344: p. e70., https://www.ncbi.nlm.nih.gov/pubmed/22294757
594. Scott, D. A., Mills, M., Black, A., Cantwell, M., Campbell, A., Cardwell, C. R., et.al. Multidimensional rehabilitation programmes for adult cancer survivors, Cochrane Database Syst Rev, 2013. p. CD007730., https://www.ncbi.nlm.nih.gov/pubmed/23543556
595. Robert, R. S., Ottaviani, G., Huh, W. W., Palla, S., Jaffe, N., Psychosocial and functional outcomes in long-term survivors of osteosarcoma: a comparison of limb-salvage surgery and amputation, Pediatr Blood Cancer, 2010. 54(7): p. 990-9., https://www.ncbi.nlm.nih.gov/pubmed/20135700
596. Punzalan, M., Hyden, G., The role of physical therapy and occupational therapy in the rehabilitation of pediatric and adolescent patients with osteosarcoma, Cancer Treat Res, 2009. 152: p. 367-84., https://www.ncbi.nlm.nih.gov/pubmed/20213402
597. Kauzlaric, N., Kauzlaric, K. S., Kolundzic, R., Prosthetic rehabilitation of persons with lower limb amputations due to tumour, Eur J Cancer Care (Engl), 2007. 16(3): p. 238-43., https://www.ncbi.nlm.nih.gov/pubmed/17508943
598. Shehadeh, A., El Dahleh, M., Salem, A., Sarhan, Y., Sultan, I., Henshaw, R. M., et.al. Standardization of rehabilitation after limb salvage surgery for sarcomas improves patients' outcome, Hematol Oncol Stem Cell Ther, 2013. 6(3-4): p. 105-11., https://www.ncbi.nlm.nih.gov/pubmed/24161605
599. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), S3-Leitlinie Psychoonkologische Diagnostik, Beratung und Behandlung von erwachsenen Krebspatienten, Langversion 1.1, 2014, AWMF-Registernummer: 032/051OL, 2014., https://www.leitlinienprogramm-onkologie.de/leitlinien/psychoonkologie/, [abgerufen, am:, 09.11.2020]
600. Herschbach, P, Weis, J., Screeningverfahren in der Psychoonkologie: Testinstrumente zur Identifikation betreuungsbedürftiger KrebspatientenDeutsche Krebsgesellschaft, 2010., https://www.dapo-ev.de/wp-content/uploads/2017/04/pso_broschuere2.pdf
601. Vodicka, E., Kim, K., Devine, E. B., Gnanasakthy, A., Scoggins, J. F., Patrick, D. L., Inclusion of patient-reported outcome measures in registered clinical trials: Evidence from ClinicalTrials.gov (2007-2013), Contemp Clin Trials, 2015. 43: p. 1-9., https://www.ncbi.nlm.nih.gov/pubmed/25896116
602. Health, U. S. Department of, Human Services, F. D. A. Center for Drug Evaluation, Research, Health, U. S. Department of, Human Services, F. D. A. Center for Biologics Evaluation, Research, et.al. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance, Health Qual Life Outcomes, 2006. 4: p. 79., https://www.ncbi.nlm.nih.gov/pubmed/17034633
603. European Medicines Agency (EMA), The use of patient-reported outcome (PRO) measures in oncology studies, 2016., https://www.ema.europa.eu/en/documents/other/appendix-2-guideline-evaluation-anticancer-medicinal-products-man_en.pdf, [abgerufen, am, 09.12.2019]
604. Groenvold, M., Aaronson, N. K., Darlington, A. E., Fitzsimmons, D., Greimel, E., Holzner, B., et.al. Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials-Letter, Clin Cancer Res, 2016. 22(22): p. 5617., https://www.ncbi.nlm.nih.gov/pubmed/28151714
605. Kulis, D., Bottomley, A., Whittaker, C., van de Poll-Franse, L. V., Darlington, A., Holzner, B., et.al. The Use of The Eortc Item Library To Supplement Eortc Quality of Life Instruments, Value in Health, 2017. 20(9): p. A775., https://doi.org/10.1016/j.jval.2017.08.2236, https://www.valueinhealthjournal.com/article/S1098-3015(17)32570-6/pdf
606. Deutsche Krebsgesellschaft e.V., Erhebungsbogen Sarkomzentren - Modul im Onkologischen Zentrum der Deutschen Krebsgesellschaft, 2018., https://www.krebsgesellschaft.de/zertdokumente.html, (Vers., B2;, 20.07.2018), [abgerufen, am, 15.04.2019]
607. Dettmers, Stephan, Voigt, Mona, Uhrig, Annika, Blankenburg, Katrin, Zwischenstand Expertenstandard psychosoziale Erstberatung onkologischer Patient* innen durch Soziale Arbeit in der stationären Versorgung (PEOPSA)Springer, FORUM Deutsche Krebsgesellschaft DKG (6), 2017.
608. Weis, Ilse, Die Onkologische Erstberatung: Vorschlag für einen Standard zur Erstberatung onkologischer Patienten durch Soziale Arbeit, FORUM, 2015. 30(3): p. 194-196.
609. Nationales Zertifizierungsprogramm Krebs, Erhebungsbogen für Onkologische Spitzenzentren und Onkologische Zentren, 2018., https://www.krebsgesellschaft.de/zertdokumente.html, [abgerufen, am, 15.04.2019]
610. Tang, M. H., Castle, D. J., Choong, P. F., Identifying the prevalence, trajectory, and determinants of psychological distress in extremity sarcoma, Sarcoma, 2015. 2015: p. 745163., https://www.ncbi.nlm.nih.gov/pubmed/25767410
611. Kain, J., Carlson, A., Kahler, J., Bemboom, J., McDonald, K., Miller, B., Lessons and Advice From Our Patients: A Focus Group of Sarcoma Survivors, Iowa Orthop J, 2017. 37: p. 139-146., https://www.ncbi.nlm.nih.gov/pubmed/28852348
612. Paredes, T., Canavarro, M. C., Simoes, M. R., Anxiety and depression in sarcoma patients: emotional adjustment and its determinants in the different phases of disease, Eur J Oncol Nurs, 2011. 15(1): p. 73-9., https://www.ncbi.nlm.nih.gov/pubmed/20667777
613. Paredes, T., Pereira, M., Moreira, H., Simoes, M. R., Canavarro, M. C., Quality of life of sarcoma patients from diagnosis to treatments: predictors and longitudinal trajectories, Eur J Oncol Nurs, 2011. 15(5): p. 492-9., https://www.ncbi.nlm.nih.gov/pubmed/21306951
614. Paredes, T., Pereira, M., Simoes, M. R., Canavarro, M. C., A longitudinal study on emotional adjustment of sarcoma patients: the determinant role of demographic, clinical and coping variables, Eur J Cancer Care (Engl), 2012. 21(1): p. 41-51., https://www.ncbi.nlm.nih.gov/pubmed/21812845
615. Furtado, S., Briggs, T., Fulton, J., Russell, L., Grimer, R., Wren, V., et.al. Patient experience after lower extremity amputation for sarcoma in England: a national survey, Disabil Rehabil, 2017. 39(12): p. 1171-1190., https://www.ncbi.nlm.nih.gov/pubmed/27384383
616. Schreiber, D., Bell, R. S., Wunder, J. S., O'Sullivan, B., Turcotte, R., Masri, B. A., et.al. Evaluating function and health related quality of life in patients treated for extremity soft tissue sarcoma, Qual Life Res, 2006. 15(9): p. 1439-46., https://www.ncbi.nlm.nih.gov/pubmed/16732468
617. Paredes, T. F., Canavarro, M. C., Simoes, M. R., Social support and adjustment in patients with sarcoma: the moderator effect of the disease phase, J Psychosoc Oncol, 2012. 30(4): p. 402-25., https://www.ncbi.nlm.nih.gov/pubmed/22747105
618. Taylor, M. F., Pooley, J. A., Sarcoma survivors' perspectives on their body image and functional quality of life post-resection/limb salvage surgery, Eur J Cancer Care (Engl), 2017. 26(6):, https://www.ncbi.nlm.nih.gov/pubmed/28220660
619. Haun, M. W., Estel, S., Rucker, G., Friederich, H. C., Villalobos, M., Thomas, M., et.al. Early palliative care for adults with advanced cancer, Cochrane Database Syst Rev, 2017. 6: p. CD011129., https://www.ncbi.nlm.nih.gov/pubmed/28603881
620. Adler, K., Schlieper, D., Kindgen-Milles, D., Meier, S., Schwartz, J., van Caster, P., et.al. [Integration of palliative care into intensive care : Systematic review], Anaesthesist, 2017. 66(9): p. 660-666., https://www.ncbi.nlm.nih.gov/pubmed/28589374
621. Dalgaard, K. M., Bergenholtz, H., Nielsen, M. E., Timm, H., Early integration of palliative care in hospitals: A systematic review on methods, barriers, and outcome, Palliat Support Care, 2014. 12(6): p. 495-513., https://www.ncbi.nlm.nih.gov/pubmed/24621947
622. Davis, M. P., Temel, J. S., Balboni, T., Glare, P., A review of the trials which examine early integration of outpatient and home palliative care for patients with serious illnesses, Ann Palliat Med, 2015. 4(3): p. 99-121., https://www.ncbi.nlm.nih.gov/pubmed/26231807
623. Gaertner, J., Siemens, W., Meerpohl, J. J., Antes, G., Meffert, C., Xander, C., et.al. Effect of specialist palliative care services on quality of life in adults with advanced incurable illness in hospital, hospice, or community settings: systematic review and meta-analysis, BMJ, 2017. 357: p. j2925., https://www.ncbi.nlm.nih.gov/pubmed/28676557
624. Hui, D., Kim, Y. J., Park, J. C., Zhang, Y., Strasser, F., Cherny, N., et.al. Integration of oncology and palliative care: a systematic review, Oncologist, 2015. 20(1): p. 77-83., https://www.ncbi.nlm.nih.gov/pubmed/25480826
625. Hui, D., Meng, Y. C., Bruera, S., Geng, Y., Hutchins, R., Mori, M., et.al. Referral Criteria for Outpatient Palliative Cancer Care: A Systematic Review, Oncologist, 2016. 21(7): p. 895-901., https://www.ncbi.nlm.nih.gov/pubmed/27185614
626. Tassinari, D., Drudi, F., Monterubbianesi, M. C., Stocchi, L., Ferioli, I., Marzaloni, A., et.al. Early Palliative Care in Advanced Oncologic and Non-Oncologic Chronic Diseases: A Systematic Review of Literature, Rev Recent Clin Trials, 2016. 11(1): p. 63-71., https://www.ncbi.nlm.nih.gov/pubmed/26464077
627. Casali, P. G., Abecassis, N., Aro, H. T., Bauer, S., Biagini, R., Bielack, S., et.al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 2018. 29(Suppl 4): p. iv68-iv78., https://www.ncbi.nlm.nih.gov/pubmed/29846513
628. Dumont, A. G., Rink, L., Godwin, A. K., Miettinen, M., Joensuu, H., Strosberg, J. R., et.al. A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients, Ann Oncol, 2012. 23(5): p. 1335-1340., https://www.ncbi.nlm.nih.gov/pubmed/21994214
629. Eriksson, M., Reichardt, P., Sundby Hall, K., Schutte, J., Cameron, S., Hohenberger, P., et.al. Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour - Does it increase the risk for tumour cell seeding and recurrence?, Eur J Cancer, 2016. 59: p. 128-133., https://www.ncbi.nlm.nih.gov/pubmed/27033260
630. Landi, B., Blay, J. Y., Bonvalot, S., Brasseur, M., Coindre, J. M., Emile, J. F., et.al. Gastrointestinal stromal tumours (GISTs): French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO), Dig Liver Dis, 2019. 51(9): p. 1223-1231., https://www.ncbi.nlm.nih.gov/pubmed/31387778
631. Stroobants, S., Goeminne, J., Seegers, M., Dimitrijevic, S., Dupont, P., Nuyts, J., et.al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec), Eur J Cancer, 2003. 39(14): p. 2012-20., https://www.ncbi.nlm.nih.gov/pubmed/12957455
632. Demetri, G. D., Wang, Y., Wehrle, E., Racine, A., Nikolova, Z., Blanke, C. D., et.al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors, J Clin Oncol, 2009. 27(19): p. 3141-7., https://www.ncbi.nlm.nih.gov/pubmed/19451435
633. Wang, D., Zhang, Q., Blanke, C. D., Demetri, G. D., Heinrich, M. C., Watson, J. C., et.al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132, Ann Surg Oncol, 2012. 19(4): p. 1074-80., https://www.ncbi.nlm.nih.gov/pubmed/22203182
634. Hohenberger, P., Eisenberg, B., Role of surgery combined with kinase inhibition in the management of gastrointestinal stromal tumor (GIST), Ann Surg Oncol, 2010. 17(10): p. 2585-600., https://www.ncbi.nlm.nih.gov/pubmed/20407930
635. Jakob, J., Hohenberger, P., Neoadjuvant Therapy to Downstage the Extent of Resection of Gastrointestinal Stromal Tumors, Visc Med, 2018. 34(5): p. 359-365., https://www.ncbi.nlm.nih.gov/pubmed/30498703
636. Cavnar, M. J., Wang, L., Balachandran, V. P., Antonescu, C. R., Tap, W. D., Keohan, M., et.al. Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome, Ann Surg Oncol, 2017. 24(13): p. 3972-3980., https://www.ncbi.nlm.nih.gov/pubmed/29058144
637. Jakob, J., Mussi, C., Ronellenfitsch, U., Wardelmann, E., Negri, T., Gronchi, A., et.al. Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib, Ann Surg Oncol, 2013. 20(2): p. 586-92., https://www.ncbi.nlm.nih.gov/pubmed/22965573
638. Ronellenfitsch, U., Hohenberger, P., Surgery for Gastrointestinal Stromal Tumors: State of the Art of Laparoscopic Resection and Surgery for M1 Tumors, Visc Med, 2018. 34(5): p. 367-374., https://www.ncbi.nlm.nih.gov/pubmed/30498704
639. Ronellenfitsch, U., Staiger, W., Kahler, G., Strobel, P., Schwarzbach, M., Hohenberger, P., Perioperative and oncological outcome of laparoscopic resection of gastrointestinal stromal tumour (GIST) of the stomach, Diagn Ther Endosc, 2009. 2009: p. 286138., https://www.ncbi.nlm.nih.gov/pubmed/19343179
640. Bachet, J. B., Landi, B., Laurent-Puig, P., Italiano, A., Le Cesne, A., Levy, P., et.al. Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13, Eur J Cancer, 2013. 49(11): p. 2531-41., https://www.ncbi.nlm.nih.gov/pubmed/23648119
641. Holmebakk, T., Bjerkehagen, B., Hompland, I., Stoldt, S., Boye, K., Relationship between R1 resection, tumour rupture and recurrence in resected gastrointestinal stromal tumour, Br J Surg, 2019. 106(4): p. 419-426., https://www.ncbi.nlm.nih.gov/pubmed/30507040
642. Rutkowski, P., Nowecki, Z. I., Michej, W., Debiec-Rychter, M., Wozniak, A., Limon, J., et.al. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor, Ann Surg Oncol, 2007. 14(7): p. 2018-27., https://www.ncbi.nlm.nih.gov/pubmed/17473953
643. Hohenberger, P., Ronellenfitsch, U., Oladeji, O., Pink, D., Strobel, P., Wardelmann, E., et.al. Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour, Br J Surg, 2010. 97(12): p. 1854-9., https://www.ncbi.nlm.nih.gov/pubmed/20730857
644. Dematteo, R. P., Ballman, K. V., Antonescu, C. R., Maki, R. G., Pisters, P. W., Demetri, G. D., et.al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial, Lancet, 2009. 373(9669): p. 1097-104., https://www.ncbi.nlm.nih.gov/pubmed/19303137
645. Hohenberger, P., Bonvalot, S., van Coevorden, F., Rutkowski, P., Stoeckle, E., Olungu, C., et.al. Quality of surgery and surgical reporting for patients with primary gastrointestinal stromal tumours participating in the EORTC STBSG 62024 adjuvant imatinib study, Eur J Cancer, 2019. 120: p. 47-53., https://www.ncbi.nlm.nih.gov/pubmed/31479947
646. Joensuu, H., Eriksson, M., Sundby Hall, K., Hartmann, J. T., Pink, D., Schutte, J., et.al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial, JAMA, 2012. 307(12): p. 1265-72., https://www.ncbi.nlm.nih.gov/pubmed/22453568
647. McCarter, M. D., Antonescu, C. R., Ballman, K. V., Maki, R. G., Pisters, P. W., Demetri, G. D., et.al. Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence, J Am Coll Surg, 2012. 215(1): p. 53-9; discussion 59-60., https://www.ncbi.nlm.nih.gov/pubmed/22726733
648. Zhi, X., Jiang, B., Yu, J., Roe, O. D., Qin, J., Ni, Q., et.al. Prognostic role of microscopically positive margins for primary gastrointestinal stromal tumors: a systematic review and meta-analysis, Sci Rep, 2016. 6: p. 21541., https://www.ncbi.nlm.nih.gov/pubmed/26891953
649. Nishida, T., Blay, J. Y., Hirota, S., Kitagawa, Y., Kang, Y. K., The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines, Gastric Cancer, 2016. 19(1): p. 3-14., https://www.ncbi.nlm.nih.gov/pubmed/26276366
650. Fletcher, C.D., Berman, J.J., Corless, C., Gorstein, F., Lasota, J., Longley, B.J., et.al. Diagnosis of gastrointestinal stromal tumors: a consensus approach, Int. J. Surg. Pathol, 2002. 10(2): p. 81-89., http://www.ncbi.nlm.nih.gov/pubmed/12075401
651. Zhang, L., Smyrk, T. C., Young, W. F., Jr., Stratakis, C. A., Carney, J. A., Gastric stromal tumors in Carney triad are different clinically, pathologically, and behaviorally from sporadic gastric gastrointestinal stromal tumors: findings in 104 cases, Am J Surg Pathol, 2010. 34(1): p. 53-64., https://www.ncbi.nlm.nih.gov/pubmed/19935059
652. Novelli, M., Rossi, S., Rodriguez-Justo, M., Taniere, P., Seddon, B., Toffolatti, L., et.al. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours, Histopathology, 2010. 57(2): p. 259-70., https://www.ncbi.nlm.nih.gov/pubmed/20716168
653. Miettinen, M., Majidi, M., Lasota, J., Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review, Eur J Cancer, 2002. 38 Suppl 5: p. S39-51., https://www.ncbi.nlm.nih.gov/pubmed/12528772
654. Casali, P. G., Abecassis, N., Aro, H. T., Bauer, S., Biagini, R., Bielack, S., et.al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 2018. 29(Suppl 4): p. iv68-iv78., https://www.ncbi.nlm.nih.gov/pubmed/29846513
655. Gastrointestinal Stromal Tumor Meta-Analysis, Group, Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients, J Clin Oncol, 2010. 28(7): p. 1247-53., https://www.ncbi.nlm.nih.gov/pubmed/20124181
656. Cassier, P. A., Fumagalli, E., Rutkowski, P., Schoffski, P., Van Glabbeke, M., Debiec-Rychter, M., et.al. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era, Clin Cancer Res, 2012. 18(16): p. 4458-64., https://www.ncbi.nlm.nih.gov/pubmed/22718859
657. Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., von Mehren, M., Joensuu, H., et.al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor, J Clin Oncol, 2003. 21(23): p. 4342-9., https://www.ncbi.nlm.nih.gov/pubmed/14645423
658. Debiec-Rychter, M., Sciot, R., Le Cesne, A., Schlemmer, M., Hohenberger, P., van Oosterom, A. T., et.al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours, Eur J Cancer, 2006. 42(8): p. 1093-103., https://www.ncbi.nlm.nih.gov/pubmed/16624552
659. Muhlenberg, T., Ketzer, J., Heinrich, M. C., Grunewald, S., Marino-Enriquez, A., Trautmann, M., et.al. KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage Strategy, Mol Cancer Ther, 2019. 18(11): p. 1985-1996., https://www.ncbi.nlm.nih.gov/pubmed/31308077
660. Nannini, M., Urbini, M., Astolfi, A., Biasco, G., Pantaleo, M. A., The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST), J Transl Med, 2017. 15(1): p. 113., https://www.ncbi.nlm.nih.gov/pubmed/28535771
661. Rednam, S. P., Erez, A., Druker, H., Janeway, K. A., Kamihara, J., Kohlmann, W. K., et.al. Von Hippel-Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood, Clin Cancer Res, 2017. 23(12): p. e68-e75., https://www.ncbi.nlm.nih.gov/pubmed/28620007
662. Miettinen, M., Lasota, J., Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis, Arch Pathol Lab Med, 2006. 130(10): p. 1466-78., https://www.ncbi.nlm.nih.gov/pubmed/17090188
663. Joensuu, H., Wardelmann, E., Sihto, H., Eriksson, M., Sundby Hall, K., Reichardt, A., et.al. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial, JAMA Oncol, 2017. 3(5): p. 602-609., https://www.ncbi.nlm.nih.gov/pubmed/28334365
664. Wozniak, A., Rutkowski, P., Schoffski, P., Ray-Coquard, I., Hostein, I., Schildhaus, H. U., et.al. Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGIST, Clin Cancer Res, 2014. 20(23): p. 6105-16., https://www.ncbi.nlm.nih.gov/pubmed/25294914
665. Martin-Broto, J., Gutierrez, A., Garcia-Del-Muro, X., Lopez-Guerrero, J. A., Martinez-Trufero, J., de Sande, L. M., et.al. Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study, Ann Oncol, 2010. 21(7): p. 1552-1557., https://www.ncbi.nlm.nih.gov/pubmed/20231303
666. Joensuu, H., Eriksson, M., Sundby Hall, K., Reichardt, A., Hartmann, J. T., Pink, D., et.al. Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial, J Clin Oncol, 2016. 34(3): p. 244-50., https://www.ncbi.nlm.nih.gov/pubmed/26527782
667. Casali, P. G., Le Cesne, A., Poveda Velasco, A., Kotasek, D., Rutkowski, P., Hohenberger, P., et.al. Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas, J Clin Oncol, 2015. 33(36): p. 4276-83., https://www.ncbi.nlm.nih.gov/pubmed/26573069
668. Cohen, M. H., Cortazar, P., Justice, R., Pazdur, R., Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors, Oncologist, 2010. 15(3): p. 300-7., https://www.ncbi.nlm.nih.gov/pubmed/20200041
669. Corless, C. L., Ballman, K. V., Antonescu, C. R., Kolesnikova, V., Maki, R. G., Pisters, P. W., et.al. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial, J Clin Oncol, 2014. 32(15): p. 1563-70., https://www.ncbi.nlm.nih.gov/pubmed/24638003
670. Joensuu, H., Eriksson, M., Sundby Hall, K., Reichardt, A., Hermes, B., Schutte, J., et.al. Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up, JAMA Oncol, 2020. 6(8): p. 1241-1246., https://www.ncbi.nlm.nih.gov/pubmed/32469385
671. Blay, J. Y., Shen, L., Kang, Y. K., Rutkowski, P., Qin, S., Nosov, D., et.al. Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial, Lancet Oncol, 2015. 16(5): p. 550-60., https://www.ncbi.nlm.nih.gov/pubmed/25882987
672. Muler, J. H., Baker, L., Zalupski, M. M., Gastrointestinal stromal tumors: chemotherapy and imatinib, Curr Oncol Rep, 2002. 4(6): p. 499-503., https://www.ncbi.nlm.nih.gov/pubmed/12354362
673. DeMatteo, R. P., Lewis, J. J., Leung, D., Mudan, S. S., Woodruff, J. M., Brennan, M. F., Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival, Ann Surg, 2000. 231(1): p. 51-8., https://www.ncbi.nlm.nih.gov/pubmed/10636102
674. Verweij, J., Casali, P. G., Zalcberg, J., LeCesne, A., Reichardt, P., Blay, J. Y., et.al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial, Lancet, 2004. 364(9440): p. 1127-34., https://www.ncbi.nlm.nih.gov/pubmed/15451219
675. Blanke, C.D., Rankin, C., Demetri, G.D., Ryan, C.W., Von Mehren, M., Benjamin, R.S., et.al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033, J. Clin. Oncol, 2008. 26(4): p. 626-632., http://www.ncbi.nlm.nih.gov/pubmed/18235122
676. Heinrich, M. C., Corless, C. L., Duensing, A., McGreevey, L., Chen, C. J., Joseph, N., et.al. PDGFRA activating mutations in gastrointestinal stromal tumors, Science, 2003. 299(5607): p. 708-10., https://www.ncbi.nlm.nih.gov/pubmed/12522257
677. Heinrich, M. C., Jones, R. L., von Mehren, M., Schoffski, P., Serrano, C., Kang, Y. K., et.al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial, Lancet Oncol, 2020. 21(7): p. 935-946., https://www.ncbi.nlm.nih.gov/pubmed/32615108
678. European Medicines Agency (EMA), Ayvakyt (avapritinib): An overview of Ayvakyt and why it is authorised in the EU, 2020., https://www.ema.europa.eu/en/documents/overview/ayvakyt-epar-medicine-overview_en.pdf, [abgerufen, am, 01.10.2020]
679. Janeway, K. A., Liegl, B., Harlow, A., Le, C., Perez-Atayde, A., Kozakewich, H., et.al. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors, Cancer Res, 2007. 67(19): p. 9084-8., https://www.ncbi.nlm.nih.gov/pubmed/17909012
680. Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., et.al. Improved overall survival in melanoma with combined dabrafenib and trametinib, N Engl J Med, 2015. 372(1): p. 30-9., https://www.ncbi.nlm.nih.gov/pubmed/25399551
681. Falchook, G. S., Trent, J. C., Heinrich, M. C., Beadling, C., Patterson, J., Bastida, C. C., et.al. BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance, Oncotarget, 2013. 4(2): p. 310-5., https://www.ncbi.nlm.nih.gov/pubmed/23470635
682. Cocco, E., Scaltriti, M., Drilon, A., NTRK fusion-positive cancers and TRK inhibitor therapy, Nat Rev Clin Oncol, 2018. 15(12): p. 731-747., https://www.ncbi.nlm.nih.gov/pubmed/30333516
683. Antoch, G., Kanja, J., Bauer, S., Kuehl, H., Renzing-Koehler, K., Schuette, J., et.al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors, J Nucl Med, 2004. 45(3): p. 357-65., https://www.ncbi.nlm.nih.gov/pubmed/15001674
684. Antoch, G., Kanja, J., Bauer, S., Kuehl, H., Renzing-Koehler, K., Schuette, J., et.al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors, J Nucl Med, 2004. 45(3): p. 357-65., https://www.ncbi.nlm.nih.gov/pubmed/15001674
685. Le Cesne, A., Ray-Coquard, I., Bui, B. N., Adenis, A., Rios, M., Bertucci, F., et.al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial, Lancet Oncol, 2010. 11(10): p. 942-9., https://www.ncbi.nlm.nih.gov/pubmed/20864406
686. Patrikidou, A., Chabaud, S., Ray-Coquard, I., Bui, B. N., Adenis, A., Rios, M., et.al. Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial, Ann Oncol, 2013. 24(4): p. 1087-93., https://www.ncbi.nlm.nih.gov/pubmed/23175622
687. Bauer, S., Rutkowski, P., Hohenberger, P., Miceli, R., Fumagalli, E., Siedlecki, J. A., et.al. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study), Eur J Surg Oncol, 2014. 40(4): p. 412-9., https://www.ncbi.nlm.nih.gov/pubmed/24491288
688. Mussi, C., Ronellenfitsch, U., Jakob, J., Tamborini, E., Reichardt, P., Casali, P. G., et.al. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?, Ann Oncol, 2010. 21(2): p. 403-408., https://www.ncbi.nlm.nih.gov/pubmed/19628568
689. Raut, C. P., Posner, M., Desai, J., Morgan, J. A., George, S., Zahrieh, D., et.al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors, J Clin Oncol, 2006. 24(15): p. 2325-31., https://www.ncbi.nlm.nih.gov/pubmed/16710031
690. Sato, S., Tsujinaka, T., Masuzawa, T., Yamamoto, K., Takahashi, T., Yamashita, Y., et.al. Role of metastasectomy for recurrent/metastatic gastrointestinal stromal tumors based on an analysis of the Kinki GIST registry, Surg Today, 2017. 47(1): p. 58-64., https://www.ncbi.nlm.nih.gov/pubmed/27194124
691. Ford, S. J., Gronchi, A., Indications for surgery in advanced/metastatic GIST, Eur J Cancer, 2016. 63: p. 154-67., https://www.ncbi.nlm.nih.gov/pubmed/27318456
692. Van Glabbeke, M., Verweij, J., Casali, P. G., Le Cesne, A., Hohenberger, P., Ray-Coquard, I., et.al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study, J Clin Oncol, 2005. 23(24): p. 5795-804., https://www.ncbi.nlm.nih.gov/pubmed/16110036
693. Keung, E. Z., Fairweather, M., Raut, C. P., The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors, Curr Treat Options Oncol, 2016. 17(2): p. 8., https://www.ncbi.nlm.nih.gov/pubmed/26820287
694. Du, C. Y., Zhou, Y., Song, C., Wang, Y. P., Jie, Z. G., He, Y. L., et.al. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China, Eur J Cancer, 2014. 50(10): p. 1772-1778., https://www.ncbi.nlm.nih.gov/pubmed/24768330
695. von Mehren, M., Joensuu, H., Gastrointestinal Stromal Tumors, J Clin Oncol, 2018. 36(2): p. 136-143., https://www.ncbi.nlm.nih.gov/pubmed/29220298
696. Demetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., et.al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial, Lancet, 2006. 368(9544): p. 1329-38., https://www.ncbi.nlm.nih.gov/pubmed/17046465
697. Demetri, G. D., Garrett, C. R., Schoffski, P., Shah, M. H., Verweij, J., Leyvraz, S., et.al. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure, Clin Cancer Res, 2012. 18(11): p. 3170-9., https://www.ncbi.nlm.nih.gov/pubmed/22661587
698. George, S., Blay, J. Y., Casali, P. G., Le Cesne, A., Stephenson, P., Deprimo, S. E., et.al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure, Eur J Cancer, 2009. 45(11): p. 1959-68., https://www.ncbi.nlm.nih.gov/pubmed/19282169
699. Heinrich, M. C., Corless, C. L., Liegl, B., Fletcher, C. D., Raut, C. P., Donsky, R., et.al. Mechanisms of sunitinib malate (SU) resistance in gastrointestinal stromal tumors (GISTs), Journal of Clinical Oncology, 2007. 25(18_suppl): p. 10006-10006., https://ascopubs.org/doi/abs/10.1200/jco.2007.25.18_suppl.10006
700. Gramza, A. W., Corless, C. L., Heinrich, M. C., Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors, Clin Cancer Res, 2009. 15(24): p. 7510-7518., https://www.ncbi.nlm.nih.gov/pubmed/20008851
701. Corless, C. L., Barnett, C. M., Heinrich, M. C., Gastrointestinal stromal tumours: origin and molecular oncology, Nat Rev Cancer, 2011. 11(12): p. 865-78., https://www.ncbi.nlm.nih.gov/pubmed/22089421
702. Demetri, G. D., Reichardt, P., Kang, Y. K., Blay, J. Y., Rutkowski, P., Gelderblom, H., et.al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial, Lancet, 2013. 381(9863): p. 295-302., https://www.ncbi.nlm.nih.gov/pubmed/23177515
703. Poole, C. D., Connolly, M. P., Chang, J., Currie, C. J., Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo, Gastric Cancer, 2015. 18(3): p. 627-34., https://www.ncbi.nlm.nih.gov/pubmed/24957256
704. Blay, JY, Serrano, C, Heinrich, MC, Zalcberg, J, Bauer, S, Gelderblom, H, et.al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial., Lancet Oncol, 2020. 21 (7)(7): p. 923-934., https://pubmed.ncbi.nlm.nih.gov/32511981/
705. Bauer, S, Heinrich, MC, George, S, Zalcberg, JR, Serrano, C, Gelderblom, H, et.al. Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous , Clin Cancer Res, 2021. 27 (23)(23): p. 6333-6342., https://pubmed.ncbi.nlm.nih.gov/34503977/
706. Bauer, S., Rutkowski, P., Hohenberger, P., Miceli, R., Fumagalli, E., Siedlecki, J. A., et.al. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study), Eur J Surg Oncol, 2014. 40(4): p. 412-9., https://www.ncbi.nlm.nih.gov/pubmed/24491288
707. Shankar, S., vanSonnenberg, E., Desai, J., Dipiro, P. J., Van Den Abbeele, A., Demetri, G. D., Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate, Radiology, 2005. 235(3): p. 892-8., https://www.ncbi.nlm.nih.gov/pubmed/15833985
708. Yamanaka, T., Takaki, H., Nakatsuka, A., Uraki, J., Fujimori, M., Hasegawa, T., et.al. Radiofrequency ablation for liver metastasis from gastrointestinal stromal tumor, J Vasc Interv Radiol, 2013. 24(3): p. 341-6., https://www.ncbi.nlm.nih.gov/pubmed/23352855
709. Hakime, A., Le Cesne, A., Deschamps, F., Farouil, G., Boudabous, S., Auperin, A., et.al. A role for adjuvant RFA in managing hepatic metastases from gastrointestinal stromal tumors (GIST) after treatment with targeted systemic therapy using kinase inhibitors, Cardiovasc Intervent Radiol, 2014. 37(1): p. 132-9., https://www.ncbi.nlm.nih.gov/pubmed/23589213
710. Jung, J. H., Won, H. J., Shin, Y. M., Kim, P. N., Safety and Efficacy of Radiofrequency Ablation for Hepatic Metastases from Gastrointestinal Stromal Tumor, J Vasc Interv Radiol, 2015. 26(12): p. 1797-1802., https://www.ncbi.nlm.nih.gov/pubmed/26603498
711. Ronellenfitsch, U., Henzler, T., Menge, F., Dimitrakopoulou-Strauss, A., Hohenberger, P., [Advanced gastrointestinal stromal tumors : What role does surgery currently play in multimodal concepts?], Chirurg, 2016. 87(5): p. 389-97., https://www.ncbi.nlm.nih.gov/pubmed/27080051
712. Yoon, I. S., Shin, J. H., Han, K., Kim, P. N., Kim, K. H., Kang, Y. K., et.al. Ultrasound-Guided Intraoperative Radiofrequency Ablation and Surgical Resection for Liver Metastasis from Malignant Gastrointestinal Stromal Tumors, Korean J Radiol, 2018. 19(1): p. 54-62., https://www.ncbi.nlm.nih.gov/pubmed/29354000
713. Pierce, D. B., Johnson, G. E., Monroe, E., Loggers, E. T., Jones, R. L., Pollack, S. M., et.al. Safety and Efficacy Outcomes of Embolization in Hepatic Sarcomas, AJR Am J Roentgenol, 2018. 210(1): p. 175-182., https://www.ncbi.nlm.nih.gov/pubmed/29090997
714. Kang, Y. K., Ryu, M. H., Yoo, C., Ryoo, B. Y., Kim, H. J., Lee, J. J., et.al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial, Lancet Oncol, 2013. 14(12): p. 1175-82., https://www.ncbi.nlm.nih.gov/pubmed/24140183
715. Yoo, C., Ryu, M. H., Nam, B. H., Ryoo, B. Y., Demetri, G. D., Kang, Y. K., Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT), Eur J Cancer, 2016. 52: p. 201-8., https://www.ncbi.nlm.nih.gov/pubmed/26699729
716. Desai, J., Shankar, S., Heinrich, M. C., Fletcher, J. A., Fletcher, C. D., Manola, J., et.al. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors, Clin Cancer Res, 2007. 13(18 Pt 1): p. 5398-405., https://www.ncbi.nlm.nih.gov/pubmed/17875769
717. Garner, A. P., Gozgit, J. M., Anjum, R., Vodala, S., Schrock, A., Zhou, T., et.al. Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients, Clin Cancer Res, 2014. 20(22): p. 5745-5755., https://www.ncbi.nlm.nih.gov/pubmed/25239608
718. Wardelmann, E., Thomas, N., Merkelbach-Bruse, S., Pauls, K., Speidel, N., Buttner, R., et.al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations, Lancet Oncol, 2005. 6(4): p. 249-51., https://www.ncbi.nlm.nih.gov/pubmed/15811621
719. Mir, O., Cropet, C., Toulmonde, M., Cesne, A. L., Molimard, M., Bompas, E., et.al. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial, Lancet Oncol, 2016. 17(5): p. 632-41., https://www.ncbi.nlm.nih.gov/pubmed/27068858
720. Reichardt, P., Blay, J. Y., Gelderblom, H., Schlemmer, M., Demetri, G. D., Bui-Nguyen, B., et.al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib, Ann Oncol, 2012. 23(7): p. 1680-7., https://www.ncbi.nlm.nih.gov/pubmed/22357255
721. Joensuu, H., Eriksson, M., Sundby Hall, K., Hartmann, J. T., Pink, D., Schutte, J., et.al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial, JAMA, 2012. 307(12): p. 1265-72., https://www.ncbi.nlm.nih.gov/pubmed/22453568
722. Joensuu, H., Reichardt, P., Eriksson, M., Sundby Hall, K., Vehtari, A., Gastrointestinal stromal tumor: a method for optimizing the timing of CT scans in the follow-up of cancer patients, Radiology, 2014. 271(1): p. 96-103., https://www.ncbi.nlm.nih.gov/pubmed/24475826
723. Czarnecka, A. M., Sobczuk, P., Kostrzanowski, M., Spalek, M., Chojnacka, M., Szumera-Cieckiewicz, A., et.al. Epithelioid Sarcoma-From Genetics to Clinical Practice, Cancers (Basel), 2020. 12(8):, https://www.ncbi.nlm.nih.gov/pubmed/32751241
724. Hornick, J. L., Dal Cin, P., Fletcher, C. D., Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma, Am J Surg Pathol, 2009. 33(4): p. 542-50., https://www.ncbi.nlm.nih.gov/pubmed/19033866
725. Frezza, A. M., Jones, R. L., Lo Vullo, S., Asano, N., Lucibello, F., Ben-Ami, E., et.al. Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series, JAMA Oncol, 2018. 4(9): p. e180219., https://www.ncbi.nlm.nih.gov/pubmed/29800950
726. Stacchiotti, Silvia, Schoffski, Patrick, Jones, Robin, Agulnik, Mark, Villalobos, Victor Manuel, Jahan, Thierry Marie, et.al. Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950), Journal of Clinical Oncology, 2019. 37(15_suppl): p. 11003-11003., https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.11003
727. Robinson, D. R., Wu, Y. M., Kalyana-Sundaram, S., Cao, X., Lonigro, R. J., Sung, Y. S., et.al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing, Nat Genet, 2013. 45(2): p. 180-5., https://www.ncbi.nlm.nih.gov/pubmed/23313952
728. Demicco, E. G., Wagner, M. J., Maki, R. G., Gupta, V., Iofin, I., Lazar, A. J., et.al. Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model, Mod Pathol, 2017. 30(10): p. 1433-1442., https://www.ncbi.nlm.nih.gov/pubmed/28731041
729. Stacchiotti, S., Negri, T., Libertini, M., Palassini, E., Marrari, A., De Troia, B., et.al. Sunitinib malate in solitary fibrous tumor (SFT), Ann Oncol, 2012. 23(12): p. 3171-3179., https://www.ncbi.nlm.nih.gov/pubmed/22711763
730. Park, M. S., Patel, S. R., Ludwig, J. A., Trent, J. C., Conrad, C. A., Lazar, A. J., et.al. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor, Cancer, 2011. 117(21): p. 4939-47., https://www.ncbi.nlm.nih.gov/pubmed/21480200
731. Kacker, C., Marx, A., Mossinger, K., Svehla, F., Schneider, U., Hogendoorn, P. C., et.al. High frequency of MYC gene amplification is a common feature of radiation-induced sarcomas. Further results from EORTC STBSG TL 01/01, Genes Chromosomes Cancer, 2013. 52(1): p. 93-8., https://www.ncbi.nlm.nih.gov/pubmed/23012233
732. Fury, M. G., Antonescu, C. R., Van Zee, K. J., Brennan, M. F., Maki, R. G., A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy, Cancer J, 2005. 11(3): p. 241-7., https://www.ncbi.nlm.nih.gov/pubmed/16053668
733. Penel, N., Bui, B. N., Bay, J. O., Cupissol, D., Ray-Coquard, I., Piperno-Neumann, S., et.al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study, J Clin Oncol, 2008. 26(32): p. 5269-74., https://www.ncbi.nlm.nih.gov/pubmed/18809609
734. Schlemmer, M., Reichardt, P., Verweij, J., Hartmann, J. T., Judson, I., Thyss, A., et.al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group, Eur J Cancer, 2008. 44(16): p. 2433-6., https://www.ncbi.nlm.nih.gov/pubmed/18771914
735. Young, R. J., Natukunda, A., Litiere, S., Woll, P. J., Wardelmann, E., van der Graaf, W. T., First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials, Eur J Cancer, 2014. 50(18): p. 3178-86., https://www.ncbi.nlm.nih.gov/pubmed/25459395
736. Kollar, A., Jones, R. L., Stacchiotti, S., Gelderblom, H., Guida, M., Grignani, G., et.al. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis, Acta Oncol, 2017. 56(1): p. 88-92., https://www.ncbi.nlm.nih.gov/pubmed/27838944
737. Pink, Daniel, Bauer, Sebastian, Brodowicz, Thomas, Reichardt, Peter, Kasper, Bernd, Richter, Stephan, et.al. Treatment of angiosarcoma with pazopanib and paclitaxel: Results of the phase II trial of the German Interdisciplinary Sarcoma Group (GISG-06 EVA) study, Journal of Clinical Oncology, 2018. 36(15_suppl): p. 11570-11570., https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.11570
738. Hamacher, Rainer, Kämpfe, Dietrich, Reuter-Jessen, Kirsten, Pöttgen, Christoph, Podleska, Lars E., Farzaliyev, Farhad, et.al. Dramatic Response of a PD-L1–Positive Advanced Angiosarcoma of the Scalp to Pembrolizumab, JCO Precision Oncology, 2018. p. 1-7., https://ascopubs.org/doi/abs/10.1200/PO.17.00107
739. Cornillie, J., van Cann, T., Wozniak, A., Hompes, D., Schoffski, P., Biology and management of clear cell sarcoma: state of the art and future perspectives, Expert Rev Anticancer Ther, 2016. 16(8): p. 839-45., https://www.ncbi.nlm.nih.gov/pubmed/27253849
740. Schoffski, P., Wozniak, A., Stacchiotti, S., Rutkowski, P., Blay, J. Y., Lindner, L. H., et.al. Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE', Ann Oncol, 2017. 28(12): p. 3000-3008., https://www.ncbi.nlm.nih.gov/pubmed/28950372
741. Judson, I., Morden, J. P., Kilburn, L., Leahy, M., Benson, C., Bhadri, V., et.al. Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial, Lancet Oncol, 2019. 20(7): p. 1023-1034., https://www.ncbi.nlm.nih.gov/pubmed/31160249
742. Stacchiotti, S., Tamborini, E., Marrari, A., Brich, S., Rota, S. A., Orsenigo, M., et.al. Response to sunitinib malate in advanced alveolar soft part sarcoma, Clin Cancer Res, 2009. 15(3): p. 1096-104., https://www.ncbi.nlm.nih.gov/pubmed/19188185
743. Wilky, B. A., Trucco, M. M., Subhawong, T. K., Florou, V., Park, W., Kwon, D., et.al. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial, Lancet Oncol, 2019. 20(6): p. 837-848., https://www.ncbi.nlm.nih.gov/pubmed/31078463
744. Martin-Broto, J, Hindi, N, Grignani, G, Martinez-Trufero, J, Redondo, A, Valverde, C, et.al. Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial., J Immunother Cancer, 2020. 8 (2)(2):, https://pubmed.ncbi.nlm.nih.gov/33203665/
745. Baldi, G. G., Brahmi, M., Lo Vullo, S., Cojocaru, E., Mir, O., Casanova, M., et.al. The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis, Oncologist, 2020. 25(11): p. e1777-e1784., https://www.ncbi.nlm.nih.gov/pubmed/32584482
746. Kube, S., Vokuhl, C., Dantonello, T., Scheer, M., Hallmen, E., Feuchtgruber, S., et.al. Inflammatory myofibroblastic tumors-A retrospective analysis of the Cooperative Weichteilsarkom Studiengruppe, Pediatr Blood Cancer, 2018. 65(6): p. e27012., https://www.ncbi.nlm.nih.gov/pubmed/29480552
747. Schoffski, P., Sufliarsky, J., Gelderblom, H., Blay, J. Y., Strauss, S. J., Stacchiotti, S., et.al. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial, Lancet Respir Med, 2018. 6(6): p. 431-441., https://www.ncbi.nlm.nih.gov/pubmed/29669701
748. Kenerson, H., Folpe, A. L., Takayama, T. K., Yeung, R. S., Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms, Hum Pathol, 2007. 38(9): p. 1361-71., https://www.ncbi.nlm.nih.gov/pubmed/17521703
749. Wagner, A. J., Malinowska-Kolodziej, I., Morgan, J. A., Qin, W., Fletcher, C. D., Vena, N., et.al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors, J Clin Oncol, 2010. 28(5): p. 835-40., https://www.ncbi.nlm.nih.gov/pubmed/20048174
750. Bissler, J. J., Kingswood, J. C., Radzikowska, E., Zonnenberg, B. A., Frost, M., Belousova, E., et.al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial, Lancet, 2013. 381(9869): p. 817-24., https://www.ncbi.nlm.nih.gov/pubmed/23312829
751. Mehrabi, A., Kashfi, A., Fonouni, H., Schemmer, P., Schmied, B. M., Hallscheidt, P., et.al. Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy, Cancer, 2006. 107(9): p. 2108-21., https://www.ncbi.nlm.nih.gov/pubmed/17019735
752. Angelini, A., Mavrogenis, A. F., Gambarotti, M., Merlino, B., Picci, P., Ruggieri, P., Surgical treatment and results of 62 patients with epithelioid hemangioendothelioma of bone, J Surg Oncol, 2014. 109(8): p. 791-7., https://www.ncbi.nlm.nih.gov/pubmed/24643837
753. Rosenbaum, E., Jadeja, B., Xu, B., Zhang, L., Agaram, N. P., Travis, W., et.al. Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets, Mod Pathol, 2020. 33(4): p. 591-602., https://www.ncbi.nlm.nih.gov/pubmed/31537895
754. Kitaichi, M., Nagai, S., Nishimura, K., Itoh, H., Asamoto, H., Izumi, T., et.al. Pulmonary epithelioid haemangioendothelioma in 21 patients, including three with partial spontaneous regression, Eur Respir J, 1998. 12(1): p. 89-96., https://www.ncbi.nlm.nih.gov/pubmed/9701420
755. Tanas, M. R., Sboner, A., Oliveira, A. M., Erickson-Johnson, M. R., Hespelt, J., Hanwright, P. J., et.al. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma, Sci Transl Med, 2011. 3(98): p. 98ra82., https://www.ncbi.nlm.nih.gov/pubmed/21885404
756. Grotz, T. E., Nagorney, D., Donohue, J., Que, F., Kendrick, M., Farnell, M., et.al. Hepatic epithelioid haemangioendothelioma: is transplantation the only treatment option?, HPB (Oxford), 2010. 12(8): p. 546-53., https://www.ncbi.nlm.nih.gov/pubmed/20887322
757. Deyrup, A. T., Tighiouart, M., Montag, A. G., Weiss, S. W., Epithelioid hemangioendothelioma of soft tissue: a proposal for risk stratification based on 49 cases, Am J Surg Pathol, 2008. 32(6): p. 924-7., https://www.ncbi.nlm.nih.gov/pubmed/18551749
758. Weitz, J., Klimstra, D. S., Cymes, K., Jarnagin, W. R., D'Angelica, M., La Quaglia, M. P., et.al. Management of primary liver sarcomas, Cancer, 2007. 109(7): p. 1391-6., https://www.ncbi.nlm.nih.gov/pubmed/17315167
759. Nudo, C. G., Yoshida, E. M., Bain, V. G., Marleau, D., Wong, P., Marotta, P. J., et.al. Liver transplantation for hepatic epithelioid hemangioendothelioma: the Canadian multicentre experience, Can J Gastroenterol, 2008. 22(10): p. 821-4., https://www.ncbi.nlm.nih.gov/pubmed/18925305
760. Lai, Q., Feys, E., Karam, V., Adam, R., Klempnauer, J., Oliverius, M., et.al. Hepatic Epithelioid Hemangioendothelioma and Adult Liver Transplantation: Proposal for a Prognostic Score Based on the Analysis of the ELTR-ELITA Registry, Transplantation, 2017. 101(3): p. 555-564., https://www.ncbi.nlm.nih.gov/pubmed/28212256
761. Sardaro, A., Bardoscia, L., Petruzzelli, M. F., Portaluri, M., Epithelioid hemangioendothelioma: an overview and update on a rare vascular tumor, Oncol Rev, 2014. 8(2): p. 259., https://www.ncbi.nlm.nih.gov/pubmed/25992243
762. Sybert, D. R., Steffee, A. D., Keppler, L., Biscup, R. S., Enker, P., Seven-year follow-up of vertebral excision and reconstruction for malignant hemangioendothelioma of bone, Spine (Phila Pa 1976), 1995. 20(7): p. 841-4., https://www.ncbi.nlm.nih.gov/pubmed/7701400
763. Albakr, A., Schell, M., Drew, B., Cenic, A., Epithelioid hemangioendothelioma of the spine: case report and review of the literature, J Spine Surg, 2017. 3(2): p. 250-259., https://www.ncbi.nlm.nih.gov/pubmed/28744509
764. Chevreau, C., Le Cesne, A., Ray-Coquard, I., Italiano, A., Cioffi, A., Isambert, N., et.al. Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO), Cancer, 2013. 119(14): p. 2639-44., https://www.ncbi.nlm.nih.gov/pubmed/23589078
765. Stacchiotti, S., Simeone, N., Lo Vullo, S., Baldi, G. G., Brunello, A., Vincenzi, B., et.al. Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A case-series analysis within the Italian Rare Cancer Network, Cancer, 2021. 127(4): p. 569-576., https://www.ncbi.nlm.nih.gov/pubmed/33107985
766. Stacchiotti, S., Miah, A. B., Frezza, A. M., Messiou, C., Morosi, C., Caraceni, A., et.al. Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts, ESMO Open, 2021. 6(3): p. 100170., https://www.ncbi.nlm.nih.gov/pubmed/34090171
767. Shek, T. W., Ho, F. C., Ng, I. O., Chan, A. C., Ma, L., Srivastava, G., Follicular dendritic cell tumor of the liver. Evidence for an Epstein-Barr virus-related clonal proliferation of follicular dendritic cells, Am J Surg Pathol, 1996. 20(3): p. 313-24., https://www.ncbi.nlm.nih.gov/pubmed/8772785
768. Shinagare, A. B., Ramaiya, N. H., Jagannathan, J. P., Hornick, J. L., Swanson, R. S., Primary follicular dendritic cell sarcoma of liver treated with cyclophosphamide, doxorubicin, vincristine, and prednisone regimen and surgery, J Clin Oncol, 2011. 29(35): p. e849-51., https://www.ncbi.nlm.nih.gov/pubmed/22042944
769. Shinde, R. S., Gupta, A., Goel, M., Patkar, S., Solitary fibrous tumor of the liver - An unusual entity: A case report and review of literature, Ann Hepatobiliary Pancreat Surg, 2018. 22(2): p. 156-158., https://www.ncbi.nlm.nih.gov/pubmed/29896577
770. Tokarskaya, Z. B., Zhuntova, G. V., Scott, B. R., Khokhryakov, V. F., Belyaeva, Z. D., Vasilenko, E. K., et.al. Influence of alpha and gamma radiations and non-radiation risk factors on the incidence of malignant liver tumors among Mayak PA workers, Health Phys, 2006. 91(4): p. 296-310., https://www.ncbi.nlm.nih.gov/pubmed/16966873
771. Sharp, G. B., The relationship between internally deposited alpha-particle radiation and subsite-specific liver cancer and liver cirrhosis: an analysis of published data, J Radiat Res, 2002. 43(4): p. 371-80., https://www.ncbi.nlm.nih.gov/pubmed/12674201
772. Baker, K. S., Leisenring, W. M., Goodman, P. J., Ermoian, R. P., Flowers, M. E., Schoch, G., et.al. Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation, Blood, 2019. 133(26): p. 2790-2799., https://www.ncbi.nlm.nih.gov/pubmed/30992266
773. Tripke, V., Heinrich, S., Huber, T., Mittler, J., Hoppe-Lotichius, M., Straub, B. K., et.al. Surgical therapy of primary hepatic angiosarcoma, BMC Surg, 2019. 19(1): p. 5., https://www.ncbi.nlm.nih.gov/pubmed/30630447
774. Putra, J., Ornvold, K., Undifferentiated embryonal sarcoma of the liver: a concise review, Arch Pathol Lab Med, 2015. 139(2): p. 269-73., https://www.ncbi.nlm.nih.gov/pubmed/25611111
775. Lenze, F., Birkfellner, T., Lenz, P., Hussein, K., Langer, F., Kreipe, H., et.al. Undifferentiated embryonal sarcoma of the liver in adults, Cancer, 2008. 112(10): p. 2274-82., https://www.ncbi.nlm.nih.gov/pubmed/18361435
776. Kirkham, J. C., Nero, C. J., Tambouret, R. H., Yoon, S. S., Leiomyoma and leiomyosarcoma arising from the round ligament of the uterus, J Am Coll Surg, 2008. 207(3): p. 452., https://www.ncbi.nlm.nih.gov/pubmed/18722953
777. Thomas, K. L., Gonzalez, R. J., Henderson-Jackson, E., Caracciolo, J. T., Paratesticular Liposarcoma Masquerading as an Inguinal Hernia, Urology, 2018. 113: p. e5-e6., https://www.ncbi.nlm.nih.gov/pubmed/29203187
778. Keenan, R. A., Nic An Riogh, A. U., Stroiescu, A., Fuentes, A., Heneghan, J., Cullen, I. M., et.al. Paratesticular sarcomas: a case series and literature review, Ther Adv Urol, 2019. 11: p. 1756287218818029., https://www.ncbi.nlm.nih.gov/pubmed/30671140
779. Rodriguez, D., Barrisford, G. W., Sanchez, A., Preston, M. A., Kreydin, E. I., Olumi, A. F., Primary spermatic cord tumors: disease characteristics, prognostic factors, and treatment outcomes, Urol Oncol, 2014. 32(1): p. 52 e19-25., https://www.ncbi.nlm.nih.gov/pubmed/24239475
780. Priemer, D. S., Trevino, K., Chen, S., Ulbright, T. M., Idrees, M. T., Paratesticular Soft-Tissue Masses in Orchiectomy Specimens: A 17-Year Survey of Primary and Incidental Cases From One Institution, Int J Surg Pathol, 2017. 25(6): p. 480-487., https://www.ncbi.nlm.nih.gov/pubmed/28459169
781. Kryvenko, O. N., Rosenberg, A. E., Jorda, M., Epstein, J. I., Dedifferentiated liposarcoma of the spermatic cord: a series of 42 cases, Am J Surg Pathol, 2015. 39(9): p. 1219-25., https://www.ncbi.nlm.nih.gov/pubmed/25828386
782. Ballo, M. T., Zagars, G. K., Pisters, P. W., Feig, B. W., Patel, S. R., von Eschenbach, A. C., Spermatic cord sarcoma: outcome, patterns of failure and management, J Urol, 2001. 166(4): p. 1306-10., https://www.ncbi.nlm.nih.gov/pubmed/11547063
783. Catton, C., Jewett, M., O'Sullivan, B., Kandel, R., Paratesticular sarcoma: failure patterns after definitive local therapy, J Urol, 1999. 161(6): p. 1844-7., https://www.ncbi.nlm.nih.gov/pubmed/10332450
784. Radaelli, S., Desai, A., Hodson, J., Colombo, C., Roberts, K., Gourevitch, D., et.al. Prognostic factors and outcome of spermatic cord sarcoma, Ann Surg Oncol, 2014. 21(11): p. 3557-63., https://www.ncbi.nlm.nih.gov/pubmed/24802908
785. Coleman, J., Brennan, M. F., Alektiar, K., Russo, P., Adult spermatic cord sarcomas: management and results, Ann Surg Oncol, 2003. 10(6): p. 669-75., https://www.ncbi.nlm.nih.gov/pubmed/12839852
786. Murray, K. S., Vertosick, E. A., Spaliviero, M., Mashni, J. W., Jr., Sjoberg, D. D., Alektiar, K. M., et.al. Importance of wide re-resection in adult spermatic cord sarcomas: Report on oncologic outcomes at a single institution, J Surg Oncol, 2018. 117(7): p. 1464-1468., https://www.ncbi.nlm.nih.gov/pubmed/29473967
787. Khandekar, M. J., Raut, C. P., Hornick, J. L., Wang, Q., Alexander, B. M., Baldini, E. H., Paratesticular liposarcoma: unusual patterns of recurrence and importance of margins, Ann Surg Oncol, 2013. 20(7): p. 2148-55., https://www.ncbi.nlm.nih.gov/pubmed/23591942
788. Rodriguez, D., Olumi, A. F., Management of spermatic cord tumors: a rare urologic malignancy, Ther Adv Urol, 2012. 4(6): p. 325-34., https://www.ncbi.nlm.nih.gov/pubmed/23205059
789. Fagundes, M. A., Zietman, A. L., Althausen, A. F., Coen, J. J., Shipley, W. U., The management of spermatic cord sarcoma, Cancer, 1996. 77(9): p. 1873-6., https://www.ncbi.nlm.nih.gov/pubmed/8646687
790. Bozzini, G., Albersen, M., Romero Otero, J., Margreiter, M., Garcia Cruz, E., Mueller, A., et.al. Feasibility and safety of conservative surgery for the treatment of spermatic cord leiomyosarcoma, Int J Surg, 2015. 24(Pt A): p. 81-4., https://www.ncbi.nlm.nih.gov/pubmed/26578108
791. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Entwicklung von leitlinienbasierten Qualitätsindikatoren. Methodenpapier für das Leitlinienprogramm Onkologie, Version 2.1, 2017., http://www.leitlinienprogramm-onkologie.de/methodik/informationen-zur-methodik/
792. Sarcoma National Managed Clinical Network, South East and West of Scotland Cancer Networks Audit Report Sarcoma Quality Performance Indicators. Clinical Audit Data: 01 April 2014 to 31 March 2015, 2016., https://www.ssn.scot.nhs.uk/wp-content/uploads/2017/04/Final_Published_National_Sarcoma_QPI_Audit_Report_v1_0_160516.pdf